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Cancer is one of the most life-threatening health problems in the world. 
However, conventional therapies including chemotherapy and radiotherapy are 
non-specific to normal body cells and have many adverse effects. Therefore, 
investigation on novel approaches for cancer treatment is needed. Searching natural 
products with apoptosis and differentiation-inducing properties on cancer cells is one 
of the main directions nowadays. 
Cytokinins are a group of plant hormones that can promote plant cell division 
and differentiation. Working in conjunction with other plant hormones such as auxin, 
cytokinins have important roles in the regulation of plant growth and development. 
The chemical structure of cytokinins is an adenine base with various side chain 
substitutions on the N^ position. Recent reports indicated that cytokinins and their 
derivatives have potent effect in suppressing leukemia cell growth. Due to the 
abundance of cytokinins in nature, there has been an increasing interest in studying 
the cancer therapeutic potential of cytokinins. Nevertheless, the mechanisms by 
which cytokinins and their derivatives exhibit their anti-tumor activities remain 
poorly understood. 
In the present study, the anti-proliferative effect of various cytokinins and their 
riboside derivatives on the murine myeloid leukemia WEHI-3B JCS cells was 
investigated. In addition, the apoptosis-inducing activity and differentiation-inducing 
activities of cytokinins on the myeloid leukemia WEHI-3B JCS cells were also 
examined. In vitro studies showed that cytokinins and their riboside derivatives 
inhibited the growth of myeloid leukemia cells in a time- and dose-dependent manner, 
and cytokinin ribosides were found to be much more potent than their corresponding 
parental cytokinin counterparts. Kinetin, a cytokinin with well-defined chemical 
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properties and biological effects, and its riboside were selected for further studies. 
Kinetin and its riboside had found to have little, if any, cytotoxicity on the WEHI-3B 
JCS cells and were effective in suppressing the proliferation of various leukemia cell 
lines of mouse and human origins. Moreover, the cytokinins exerted only low levels 
of cytotoxic effect on the normal cell lines. In vivo studies showed that both kinetin 
and its riboside could reduce the tumorigenicity of WEHI-3B JCS cells and inhibit 
the in vivo growth of WEHI-3B JCS cells in syngeneic BALB/c mice. 
The anti-leukemia effect of kinetin and kinetin riboside may be a result of cell 
cycle arrest at the GQ/GI phase and the induction of apoptosis. Results showed that 
cytokinin-treated WEHI-3B JCS cells were arrested at the GQ/GI phase of cell cycle 
and the expression of cyclin E was down-regulated. Moreover, kinetin riboside 
increased the expression of cyclin dependent kinase inhibitor gene p27. On the other 
hand, DNA fragmentation was induced in both kinetin-treated and kinetin 
riboside-treated WEHI-3B JCS cells. Caspase activation analysis showed that kinetin 
induced significant activation of caspases 3 and 9, while kinetin riboside induced 
significant activation of caspases 3, 8 and 9 on WEHI-3B JCS cells. The expression 
of the pro-apoptotic gene Box was upregulated in the cytokinin-treated WEHI-3B 
JCS cells. Interestingly, FasL expression was also upregulated. Interestingly enough, 
the differentiation-inducing activity of kinetin and kinetin riboside on WEHI-3B JCS 
cells was not significant, in terms of morphological, phenotypic and biochemical 
changes. 
Collectively, our findings demonstrated that cytokinins in general, and kinetin 
and its riboside in particular, could inhibit the growth of myeloid leukemia cells 
effectively. The anti-leukemia effect may probably a result of cell cycle arrest and 
apoptosis-induction exhibited by cytokinins. Further investigation is required to 
elucidate the molecular basis and the signaling pathways by which cytokinins can 
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exert their anti-tumor effects, both in vitro and in vivo. 
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胞週期素E (cyclin E)基因的表達°另外，凱因庭核糖核苷更可誘發WEHI-3B JCS 
血癌細胞增加細胞週期調整基因p27�另一方面，經凯因庭處理以及經凱因庭核 
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Chapter 1: General Introduction 
1.1 Hematopoiesis and Leukemia 
1.1.1 An Overview on Hematopoiesis • 
Every day the human body produces 2 - 2.5 x erythrocytes, 1.5 - 2 x lO'^  
platelets and 1 - 1.5 x neutrophils to replace normal cell turnover and the blood 
cell lost due to trauma (Van Zant et al, 1997). The production of blood cells is a 
highly regulated process called hematopoiesis and the multipotent hematopoietic 
stem cells (HSCs) are the progenitors of the blood cells. Deregulation of 
hematopoiesis would result in hematologic malignancy such as leukemia (Smith, 
2003). 
During human embryogenesis，hematopoiesis first takes place in yolk sac to 
produce mainly nucleated erythrocytes (Tavian et al” 2001). Afterwards, 
colonization of hematopoietic stem cells takes place on the dorsal aorta and vitelline 
artery of the embryo (Peault et al., 2002). These cells generate multipotent lymphoid 
and myeloid progenitor cells. Later, fetal liver and spleen are the sites of 
hematopoiesis. In the human adult, bone marrow is the major site for the production 
and development of hematopoietic cells (Savino et al, 2005). HSCs are very rare and 
it is estimated that there is only one stem cell per 100,000 marrow cells (Metcalf, 
1995). Long term-HSC (LT-HSC) is self-renewal and has large capacity to generate 
large numbers of cells throughout life. In addition, LT-HSC will generate short-term 
• HSC (ST-HSC) which is responsible for the differentiating into committed 
hematopoietic progenitor cells (Kondo et al,，2003). Interaction of HSC with 
microenvironment is important in regulation of hematopoiesis. Interleukin (IL)-l, 
IL-3，stem cell factor, colony stimulating factors for granulocytes (G-CSF) and 
granulocytes/macrophages (GM-CSF) and chemokine CXCL12, together with other 
cytokines and chemokines produced by microenvironmental cells, will regulate the ‘ 
— - ^ 
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proliferation and differentiation ofHSC (Metcalf, 1998; Kondo et al., 2003; Leung et 
al.’ 2005). HSC will differentiate into various precursors and then committed into 
distinct cell lineages under the influence of cytokines. HSC first differentiates into 
myeloid and lymphoid progenitor cells. Myeloid progenitor cells will further 
differentiate into monocytes, neutrophils, basophils, eosinophils, erythrocytes and 
platelets. Lymphoid progenitor cells will further differentiate into B-lymphocytes and 
T-lymphocytes (Savino et al.’ 2005). Figure 1.1 shows the schematic differentiation 
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Fig. 1.1: Schematic illustration of hematopoiesis. Pluripotent hematopoiesis stem 
cells give rise to various mature blood cells. The proliferative capacity of the cells 
would decreases with increasing degree of differentiation of the cells. (CFU, 
colony-forming unit; E, erythroid; Mega, megakaryocyte; Eo, eosinophil; Bas, 
basophil.) (Howard and Hamilton, 2002) 
* 
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1.1.2 An Overview of Leukemia 
Cancer cells generally result from defectives in the regulation of normal 
proliferation and homeostasis. There are six main alterations in cancer cells 
contributing to their abnormalities: self-sufficiency in growth signals, insensitivity to 
growth-inhibitory signals, evasion of apoptosis，unlimited replicative potential, 
sustained angiogenesis and tissue invasion and metastasis (Hanahan and Weinberg, 
2000). Leukemia is the result of uncoupling or imbalance of the proliferation and 
differentiation of hematopoietic stem cells. The malign叩t cells continue to 
proliferate accompanied with the loss of differentiation potential. Abnormalities of 
hematopoietic cell development at any stage may result in leukemia. For example, 
mutation of multipotent early progenitors or committed late progenitors will result in 
leukemia cells (Leung et al, 2005). Leukemia stem cells (LSC) are the major cells 
responsible for the development of leukemia. Like HSC, LSC has the ability of 
self-renewal but it can escape from apoptosis and differentiation (Warner et al.’ 2004; 
% 
Wang and Dick, 2005). Targeting the LSC is a new direction of leukemia therapy 
nowadays. 
. Leukemia cells originated from bone marrow can spread to the blood 
circulation, secondary lymphoid organs, liver, lungs, nervous system and other 
organs. The leukemia cells will replace normal hematopoietic cells in bone marrow 
due to their abnormal proliferative ability and disrupt normal blood cell turnover. 
Some common symptoms of leukemia are fatigue, lack of appetite, fever,, bleeding 
and bruising (Leung et al., 2005). One diagnostic factor of leukemia is the abnormal 
high amount of white blood cells in circulation (American Cancer Society, 2006). 
Leukemia is a complex and fatal disease and can be divided into numerous subtypes. 
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1.1.2.2 Classification and Epidemiology of Leukemia 
Based on the cell lineage, onset rate and degree of cellular maturation, 
leukemia can be classified into four types, i.e. acute myeloid leukemia (AML), a c u t e � 
lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML) and chronic 
lymphoblastic leukemia (CLL) (Hoffbrand et al, 2001). Lymphoid leukemia is 
developed from lymphoid precursor cells in the bone marrow while myeloid 
leukemia is developed from other types of precursor blood cells such as monocytes, 
» 
granulocytes, erythrocytes and megakaryotes. Generally, acute leukemia cells grow 
rapidly and are blast cells with low degree of maturation. The mortality of the disease 
is high and will be fatal if not treated. On the other hand, in chronic leukemia the 
leukemia cells are more mature but malfunctional (Hoffbrand et al.’ 2001). AML 
involves granulocytes, monocytes, red blood cells, or platelets. ALL involves T-cells 
or B-cells. About 85% of cases are B-cell type while 15% are T-cell type (American 
Cancer Society, 2006). Based on the French-American-British (FAB) classification 
scheme, AML can be divided into MO to M7 several subtypes in terms of 
, ultrastructural morphology, cytogenetics, immunophenotyping, and 
immunohistochemical markers. ALL is classified into three types (LI, L2 and L3), 
while CML and CLL are subdivided into six and seven subtypes respectively 
(Hoffbrand et al, 2001). The classification of leukemia is summarized in Table 1.1. 
Leukemia is one of the most common cancers found in children. In 2005, there 
are about 35,000 new cases of all types of leukemia in the United States. Acute 
leukemia contributes to about half of the cases. Among these, about 11,930 new 
cases are AML and about 9,000 people died from AML in the United States in 2005 
(American Cancer Society, 2006). In Hong Kong, cancer is the first leading cause of 
death among all other diseases. Each year around 120 to 150 new cases of leukemia 
Chapter 1: General Introduction 
develop in children and leukemia is the most common childhood cancer in Hong 
Kong, as it occupied around 36% of total childhood cancer cases (Children's Cancer 
Foundation, Hong Kong, 2006). Among the overall population of Hong Kong, 
around 350 to 400 new cases of leukemia are reported every year (Hong Kong 
Cancer Registry, Hospital Authority, Hong Kong, 2006). Therefore, leukemia is a 
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Table 1.1: Classification of leukemia 
Type Subtype ~ ~ Variant ： 
Acute Acute Myeloid MO: minimal differentiation 
Leukemia (AML) M1: myeloblastic (>90% myeloblasts) 
M2: myeloblastic with granulocytic maturation 
(>10% promyelocytes or later granulocytes) 
M3: promyelocytic (coarsely granular or 
microgranular promyelocytes) 




M6: erythroblastic (>50% erythroblasts) 
M7: megakaryoblastic (>50% megakaryoblasts) 
Acute LI: homogenous small blasts with little 
Lymphoblastic cytoplasm 
‘ Leukemia (CML) L2: heterogeneous larger blasts with variable 
amounts of cytoplasm 
L3: homogenous large blasts with vacuolated 
basophilic cytoplasm 
Chronic Chronic Myeloid Philadelphia-positive chronic myeloid leukemia 
Leukemia (CML) Philadelphia-negative chronic myeloid leukemia 
Juvenile chronic myeloid leukemia 
Chronic neutrophilic leukemia 
Eosinophilic leukemia 
Chronic myelomonocytic leukemia 
Chronic B-chronic lymphocytic leukemia 
Lymphoblastic B-prolymphocytic leukemia 
Leukemia (CLL) Hairy cell leukemia ‘ 
Plasma cell leukemia 
T-chronic lymphocytic leukemia 
T-prolymphocytic leukemia 
Adult T-cell leukemia / lymphoma 
(Modified from Hoffbrand et al.’ 2001) 
< 
• — — ； 
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1.1.2.3 Conventional Approaches to Leukemia Therapy 
The conventional treatments for leukemia nowadays include three different 
options, which are chemotherapy, radiotherapy and hematopoietic stem cell 
transplantation. Based on the stages of leukemia development, the most appropriate 
treatment is chosen. All the three options have their advantages but also 
disadvantages such as toxicity and other adverse side effects. 
In chemotherapy, anticancer drugs are delivered orally, by intravenous injection, 
intramuscular injection or through cerebrospinal fluid to destroy most of leukemia 
cells as well as some of the normal bone marrow cells (American Cancer Society, 
2006). Usually a combination of several anticancer drugs is used to control cancer 
cells. As these drugs are more effective to actively dividing cancer cells, normal cells « 
such as hair follicular cells which constantly divide are also affected. 
Anti-metabolites (e.g. methotrexate), alkylating agents (e.g. cyclophosphamide) and 
nucleoside analogues (e.g. fludarabine) are some examples of common anticancer 
drugs (American Cancer Society, 2006). Although chemotherapy is effective against 
leukemia, it also damages normal cells and results in lots of side effects. Some 
common side effects are hair loss, mouth sores, weakened immunity, easy bruising or 
bleeding and fatigue. A more severe side effect is tumor lysis syndrome. It is caused 
by the rapid breakdown of large numbers of leukemia cells, resulting in the release of 
cellular contents into the blood circulation and damaging organs such as heart, 
kidneys and nervous system (Locatelli and Rossi, 2005; American Cancer Society, 
2006). 
In radiotherapy, cancer cells are killed by high-energy radiation from a machine 
outside the body. It is used to treat leukemia that has spread to the brain and spinal 
fluid or the testicles. Radiotherapy is commonly used before treatment of leukemia 
- 8 -
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patients by peripheral blood stem cell transplantation (American Cancer Society, 
2006). Similar to chemotherapy, radiotherapy attacks both actively dividing cancer 
cells and normal cells non-specifically. Fatigue, weakened immunity and sunburn of 
skin are some common side effects and the functions of irradiated organs may be # 
affected. (Featherstone et al., 2005; American Cancer Society, 2006). 
In hematopoietic stem cell transplantation (HSCT), the bone marrow or 
peripheral blood stem cells are transplanted into patients' bone marrow to restore the 
blood cell producing capacity after chemotherapy or radiotherapy (American Cancer 
Society, 2006). The transplantation may be allogeneic .(the donor is another 
individual) or autologous (the donor cells are from the patient's healthy 
hematopoietic stem cells). Although HSCT is a better option among the three 
treatments, several side effects or disadvantages are still associated. Allogeneic 
transplantation has the difficulty of finding the human leukocyte antigen-compatible 
donors and graft-versus-host diseases (GVHD) may occur. Autologous 
transplantation has the difficulties of separating healthy HSC from the leukemia cells 
(Leung et al., 2005; American Cancer Society, 2006). 
1.1.2.4 Novel Approaches to Leukemia Therapy 
As described previously, conventional therapies have numerous undesirable 
side effects in spite of their therapeutic efficacy. Therefore, novel approaches to treat 
leukemia are under intensive investigations in the past decades. Leukemia results 
from deregulation of the balance between proliferation and differentiation or 
maturation of hematopoietic stem cells or progenitor cells. Restoring the normal 
mechanism of the programmed cell death or inducing the differentiation of the 
leukemia cells and combination of these events with chemotherapy are the basis of 
-9- • 
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the novel approaches (Wang, 2003). 
1.1.2.4.1 Differentiation Therapy 
Acute promyelocytic leukemia (APL) is an example of successful application 
of differentiation therapy. One factor causing APL is the chromosome translocation 
of t(15;l7)(q22;q21) which generates a fusion gene and results in the production of a 
fusion protein PML-RARa. This protein blocks differentiation of myeloid cells and 
inhibits apoptosis of the cells. Application of dX\-trans retinoic acid (ATRA) causes 
degradation of PML-RARa protein and restores normal differentiation of the 
promyeloid cells (Wang, 2003). In addition to ATRA, numerous cytokines such as 
interleukins and GM-CSF are applied to induce the differentiation of leukemia cells 
to various lineages (Leung et al, 2005). A detailed review on the recent advancement 
in the usage of cytokines for the differentiation therapy of leukemia has just been 
published (Leung et al, 2005). ‘ 
1.1.2.4.2 Induction of Apoptosis 
Inducing apoptosis of leukemia cells is another new strategy of cancer therapy. 
Numerous small molecules have been designed to target the leukemia abnormal 
molecules that can inhibit apoptosis (Fischer and Schulze-Osthoff, 2005). The 
molecular targets include death receptors, caspases and Bcl-2 family proteins as well 
as other transcription factors such as NFKB involving in apoptosis regulation (Fischer 
and Schulze-Osthoff, 2005; Reed and Pellecchia, 2005). Mitochondrion is a cellular 
organelle that has been targeted for apoptosis induction (Fleischer et al, 2006). 
-10- V 
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t 
1.1.2.4.3 Natural Products as a Source of Anti-leukemia Drug 
Searching natural products having the ability of apoptosis-induction and 
differentiation-induction on tumor cells especially leukemia cells is one of the major 
directions of drug development. Various natural products including biochanin A 
�(isoflavonoid), vitamin D3, green tea catechin, and red wine resveratrol etc. were 
reported to have a potent differentiation-inducing effect on leukemia cells (Miller 
and Waxman, 2002). Arsenic trioxide is a compound used in traditional Chinese 
medicine, it has both apoptosis- and differentiation-inducing activities on APL (Wang, 
2003). Natural products are alternative and complementary drugs for leukemia 
therapy, and the objective of this M.Phil, study is to search for potent anti-leukemia 
compounds from the naturally occurring phytochemicals. 
- 1 1 - . 
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1.2 Introduction to Cytokinins 
1.2.1 Historical Development and Occurrence of Cytokinins 
Cytokinins are a group of plant hormones which can promote cell division and 
differentiation. In 1955, the first cytokinin was discovered in coconut milk and 
autoclaved DNA extract. The cytokinin had potent effect in promoting the cell 
division of tobacco tissues, and the cytokinin was named as kinetin (Miller et al., 
1956). Since the discovery of kinetin, lots of efforts were invested in the searching of 
cytokinin-like substances in plants. Another cytokinin, zeatin, was discovered in the 
sweet com. Isopentenyladenine and benzyladenine were discovered in later 
researches. Among the naturally occurring cytokinins, zeatin is the most widely 
distributed and potent cytokinin found in plants (Shaw, 1994). ‘ 
It was believed that zeatin and isopentenyladenine were naturally occurring 
cytokinins while kinetin and benzyladenine were regarded as synthetic cytokinins. 
However, recent studies showed that kinetin and benzyladenine could be found in 
plant tissues. Benzyladenine was isolated in some plant species while kinetin was 
found in young coconut (Ge et al” 2005). As these two cytokinins are relatively 
inexpensive and stable as compared to isopentenyladenine and zeatin, they are the 
most widely used cytokinins in plant science (Srivastava, 2002). As kinetin can be 
formed during degradation of DNA, it is not surprising that it is present in animals. 
The discovery of kinetin in human urine had also been reported (Barciszewski et al.’ 
2000). 
-12 - - -
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1.2.2 Functions of Cytokinins and the Signal transduction of Cytokinins in 
Plants 
The functions of cytokinins in plants include many aspects of plant growth and 
development. They regulate the plant cell division, cell differentiation and cell cycle. 
Cytokinins stimulate seed germination, de novo shoot and adventitious bud 
formations and the release of lateral buds from apical dominance. In addition, leaf 
expansion, chloroplast development and flower development are stimulated by 
cytokinins. On the other hand, cytokinins inhibit oxidation and delay leaf senescence 
and chlorophyll degradation. Working with different concentrations of another 
phytohormone auxin, cytokinins regulate the growth ratio and development of root 
and shoot of plants (Mok, 1994; Aloni et al., 2006). The regulatory effects of 
cytokinins on plants are mainly by controlling gene expression through the 
two-component signal transduction system. 
Although many cytokinin-binding proteins were identified in plant tissues, they 
did not satisfy the requirement of being a cytokinin receptor (Brinegar, 1994). The 
two-component signal transduction or complicated multi-step phosphorelay system 
of cytokinin in plants is a widely accepted model that cytokinin exerts its function. 
Briefly, the system consists of transmembrane sensor kinase receptors, histidine 
phosphotransfer proteins and response regulators (Ferreira and Kieber, 2005). When 
the kinase receptor binds to a cytokinin, the kinase auto-phosphorylates and the 
phosphoryl group is transferred to the histidine phosphotransfer proteins. Finally, the 
phosphoryl group is transferred to the response regulator, which initiates target gene 
transcriptions (Ferreira and Kieber, 2005). Figure 1.2 is a schematic presentation of 
cytokinin signaling. 
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Fig. 1.2: Schematic presentation of cytokinin signaling. (P： phosphoryl group) 
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1.2.3 Phytochemistry and Metabolism of Cytokinins 
1.2.3.1 Chemical Structures of Cytokinins 
There are two main types of cytokinins, the adenine type and the phenylurea type. 
The adenine type cytokinins are the derivatives of adenine with different side chain 
substitutions in the N^ position (Shaw, 1994). The substitutions can be further 
divided into two types, the isoprenoid type and the aromatic type. Most of the 
naturally occurring cytokinins are isoprenoid substituted cytokinins, for example 
isopentenyladenine and trans-ZQd^ Lm. Aromatic substituted cytokinins include kinetin 
and benzyladenine. The chemical structures of adenine cytokinins used in this study 
are shown in Fig. 1.3. The side chain structure of the N^ substitution affects the 
activity of cytokinin significantly, as reported in many studies (Shaw, 1994). 
Geometric isomers of the same side chain structure also have different potency. One 
example is the active trans-ztdim and the inactive cw-zeatin (Mok and Mok, 2001). 
In addition, modifications on other positions of the adenine ring are possible in 
nature. One common modification is the addition of a riboside group to the 
adenine and forms the adenosine core structure. The chemical structures of adenine 
cytokinin ribosides used in this study are shown in Fig. 1.4. This study will focus 
on the adenine cytokinins and their riboside derivatives. Glucosylation of the adenine 
ring is common but the modified cytokinin is relatively inactive (Chen, 1997). 
On the other hand, the phenylurea type cytokinins are synthetic and are not found 
in plant tissues (Shudo, 1994). The phenylurea cytokinins are the derivatives of 
. phenylurea, whose chemical structure is different from the adenine ones. In contrast 
to the adenine cytokinins, phenylurea cytokinins are more stable but less active. 
Examples of phenylurea cytokinins are N',N'-diphenylurea, phenylpridylurea and 
thidiaurzon. The chemical structures of these cytokinins were shown in Fig. 1.5. 
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Fig. 1.3: Chemical structures of adenine-based cytokinins used in this study. (A) 
Adenine, (B) Kinetin, (C) Benzyladenine, (D) Isopentenyladenine and (E) 
trans-Zeatin. 
- 1 6 - V 
T 
• Chapter 1: General Introduction 
NH2 
• (A) I 2 
N八ZN 
HO OH ‘ 
( C ) 作 
\ o NH \ — — / NH 
、人N 、人 
HO HO 
HO OH HO OH 
CH3 HO^ 
• (D) , (E) \ 
H 3 C — 4 
NH �� 
NH 
、 入 z \ r � 
HO, OH HO \ _ / 
� HO OH 
Fig. 1.4: Chemical structures of adenine-based cytokinin ribosides used in this 
study. (A) Adenosine, (B) Kinetin riboside, (C) Benzyladenosine, (D) 
Isopentenyladenosine and (E) trans-ZQatin riboside. 
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Fig. 1.5: Chemical structures of urea-based cytokinins. (A) Diphenylurea, (B) 
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1.2.3.2 Biosynthesis of Cytokinins in Plants 
It is believed that cytokinins are synthesized in the young tissues having active 
cell division ability or meristematic tissues of plant, such as root apices, shoot buds, 
developing seeds. The synthesized cytokinins are transported to other parts of plant 
through xylem and phloem (Letham, 1994). 
Isoprenoid type cytokinins can be synthesized using various substances, ATP, 
ADP or tRNA, as starting materials. Until now, the biosynthesis of aromatic type 
cytokinins is still unknown, but is believed to be mediated through similar pathways 
as the isoprenoid ones. Although the cytokinin synthesis enzymes have not been 
totally identified, there are mainly two proposed pathways in the biosynthesis of 
isoprenoid cytokinins starting with ATP or ADP, namely, the 
isopentenyladenosine-5 ‘ -monophosphate (iPMP) dependent pathway and the iPMP 
independent pathway (Astot et al., 2000; Mok and Mok, 2001; Sakakibara and Takei, 
2002; Takei et al, 2004; Sakaibara, 2005). In the iPMP dependent pathway, ATP or 
ADP is condensed with dimethylallyl pyrophosphate (DMAPP) by adenosine 
isopentenyltransferase. DMAPP is a common metabolite present in eukaryotic cells. 
Then the intermediate products, isopentenylATP (iPTP) and isopentenylADP (iPDP) 
are serially dephosphorylated by adenosine kinase (AK) to give rise to 
isopentenylAMP (iPMP) and isopentenyladenosine (iPAR). Deriboxylation of iPAR 
gives rise to isopentenyladenine (iPA). Hydroxylation of iPMP and iPAR by 
cytokinin hydroxylase (CKH) produces zeatin monophosphate (ZMP) and zeatin 
riboside (ZR). Zeatin is fomed after removal of the ribosyl group of ZR or by direct 
hydroxylation of iPA. 
Alternatively, the biosynthesis of cytokinins can be done without iPMP. 
Hydroxylations of iPTP and iPDP give rise to zeatin triphosphate (ZTP) and zeatin 
-19- • 
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diphosphate (ZDP) respectively by zeatin hydroxylase. Dephosphorylations of ZTP 
and ZDP give rise to zeatin monophosphate (ZMP), which then further 
dephosphorylated to become zeatin riboside (ZR). rr聽-Zeatin is formed after 
removal of the ribosyl group of ZR. Recently, a new putative pathway was proposed. 
By a putative enzyme isopentenyltransferase, ATP/ADP/AMP could be condensed 
with hydroxymethylbutenyl diphosphate to give rise to ZTP/ZDP/ZMP. Figure 1.6 is 
a schematic summary for the biosynthesis of cytokinins. 
Another source of cytokinins is tRNA. During tRNA degradation, nucleotides 
are converted to cw-zeatin by tRNA-isopentenyltransferase and therefore cw-zeatin is 
the major cytokinin. By the action of cis-trans isomerases, isomerization of inactive 
cw-zeatin to active trans-zQdi^m occurs. However, the turnover rate of tRNA is not 
high enough to explain the amount of free cytokinins found in plant tissues. 
Therefore, the biosynthesis of cytokinins from tRNA is regarded as a minor source of 
cytokinins (Chan, 1997; Srivastava, 2002). 
In addition to biosynthesis, cytokinins may be synthesized chemically. For 
example, kinetin can be produced by reflnxing two compounds, 
6-methylmercaptopurine and furfurylamine overnight (Srivastava, 2002). 
Alternatively, kinetin can be formed by autoclaving adenine and deoxyribose in a 
low pH condition. Under this condition, deoxyribose is converted to furfuryl group 
and linked to the N^ position of adenine. , 
\ 
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1.2.3.3 Metabolisms of Cytokinins in Plants and Animals 
The level of cytokinins in plants is regulated by the balance between de novo 
synthesis and degradation. Degradation of cytokinins is mediated through the action 
cytokinin oxidases or dehydrogenases family. Members of the oxidase family have 
different affinity to the cytokinins. These enzymes attack the double bond of the 
isoprenoid side chain of isoprenoid type cytokinins, i.e. trans-z&atm and 
isopentenyladenine, and convert them to adenine base or nucleotides. On the other 
hand, the aromatic type cytokinins, i.e. kinetin and benzyladenine, are not the 
preferred substrates of the cytokinin oxidases. The aromatic cytokinins also do not 
inhibit the action of cytokinin oxidases (Mok and Mok, 2001). 
In addition to the degradation of cytokinins, there are several modifications on 
the adenine ring and the N^ side chain. For example trans-zeaXin can be modified into 
0-glucosylzeatin, O-xylosylzeatin and 0-acetylzeatin by different enzymes. 
O-Glycosyltransferase converts the zeatin into inactive 0-glucosylzeatin for storage. 
When there is a shortage of cytokinins, P-glucosidase restores the inactive 
0-glucosylzeatin back to active zeatin. Alternatively, zeatin may be converted into 
dihydrozeatin by zeatin reductase to preserve the endogenous cytokinins. Moreover, 
interconversion between cytokinin bases, nucleosides and nucleotides are common 
but regulated. Cytokinin bases may be converted into nucleosides by adenosine 
phosphorylase. Nucleosides may be further converted into nucleotides by adenosine 
kinase (Mok and Mok, 2001). 
Studies of cytokinin metabolism in animal are limited, so the metabolic fate of 
cytokinins in humans or mice is largely unknown. Benzyladenosine is one of the 
cytokinin derivatives being studied so far (Chheda et al., 1979). Radiolabeled 
benzyladenosine was injected into rats intravenously. After 48 hours of injection, the 
»-
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rats were sacrificed and analyzed for the radioactive substance distribution. Most of 
the radioactive substances were detected in urine, and the substances detected were 
unchanged benzyladenosine, adenine, uric acid and trace amount of benzyladenine. 
In addition to urine, liver and muscle also retained a major part of radioactivity in the 
body. However, the labeled substances were not identified. It was believed that 
benzyladenosine was first debenzylated by unknown enzymes, and then converted 
into adenine and uric acid by adenosine deaminase. Moreover, benzyladenosine 
might be converted to phosphorylated form by adenosine kinase (Chheda et al., 
1979). To elucidate the metabolic pathways of cytokinins in animals, more 
investigations should be performed in the future. 
1.2.4 Biological and Pharmacological Activities of Cytokinins in Animals 
Studies on cytokinins mainly focus on their functions in plant physiology and 
the biochemistry of trans-zcatm. Although research on the functions of cytokinins in 
animals is limited, these earlier studies could give us some insight on the activities of 
cytokinins in animals. Kinetin is the cytokinin that is most extensively studied 
(Barciszewski et al, 1999; Minorsky, 2003). Many studies showed that kinetin is a 
secondary product of DNA oxidation and has direct or indirect antioxidation effect 
. (Barciszewski et al.，2000). 
It has been reported that kinetin has potent inhibitory effect on the oxidation of 
unsaturated fatty acids in membranes (Leshem, 1988). Moreover, the 
kinetin-copper(II) complex has a superoxide dismutase-like activity and can reduce 
the level of oxygen radicals (Goldstein and Czapski, 1991). 
More recently, kinetin and benzyladenine were found to be capable of rescuing 
human mRNA splicing defect in certain mutant genes and could increase the ‘ 
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wild-type mRNA expression (Slaugenhaupt et al, 2004). However, the action 
mechanism of kinetin in regulating tissue-specific gene expression still awaits further 
investigation. 
1.2.4.1 Anti-aging Effect 
As kinetin delays the senescence of plant tissues (Leshem, 1988), scientists 
proposed that kinetin has anti-aging effect. Treating human fibroblasts (Rattan and 
Clark, 1994) or the fruitfly Zaprionus paravittiger (Sharaia et al, 1995) with kinetin 
could delay the onset of aging. Serial cultured human fibroblasts would show aging 
characteristics, including large and flattened cell shape, with increased cell debris 
such as lysosomal residual bodies and may have more than one nucleus. Co-culture 
of human fibroblasts with kinetin did not show the aging characteristics compared 
with the normal cultures. The morphology of kinetin-treated fibroblasts remained 
long and spindle shaped, and the cytoskeleton was organized as young fibroblasts. 
However, kinetin did not alter the doubling time of fibroblasts and had no effect on 
the nucleic acid and protein synthesis, and the fibroblast maximum proliferative 
capacity was unchanged (Rattan and Clark, 1994). When the fruitfly Z paravittiger 
was fed with kinetin-added diet, the lifespan of fruitfly was extended a few days and 
the death rate related with aging was reduced (Sharma et al, 1995). 
1.2.4.2 Anti-thrombosis Effect and Inhibition of Blood Platelet Aggregation 
Intravascular thrombosis is one of the causes of cardiovascular diseases. It was 
found that injection of kinetin into mice intravenously prolonged the bleeding time.m 
vzvo (Hsiao et al, 2003). Moreover, kinetin suppressed hydroxyl radical formation in 
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collagen-activated platelets. Kinetin also reduced the mortality of mice suffered from 
lethal acute pulmonary thrombosis. 
In addition, Sheu et al (2003) also found that kinetin could inhibit the platelet 
aggregation in vitro. Platelet aggregation could be induced by collagen, arachidonic 
‘ acid or ADP and the effect could be antagonized by kinetin. Analysis of biochemical 
changes of kinetin action showed that the intracellular Ca^^ mobilization was reduced 
and cyclic AMP formation increased. It was suggested that the inhibitory effect of 
kinetin on platelet aggregation might be mediated through modulation of intracellular 
Ca2+ concentration and cyclic AMP level. “ 
1.2.4.3 Anti-tumor Effect . 
It was reported that several cytokinins (isopetenyladenine, benzyladenine and 
kinetin) had growth-inhibitory effect on a number of tumor cell lines in vitro 
(Havlicek et al., 1997). Recently, a more systematic and extensive study 
investigating the anti-tumor effects of adenine analogues including cytokinins and 
cytokinin ribosides showed that both cytokinins and their riboside derivatives were 
more potent than other adenine analogues being tested, in terms of suppressing the 
proliferation of human myeloid leukemia cell line HL-60 (Ishii et aL，2002). The 
anti-tumor effects of kinetin, benzyladenine and isopentenyladenine were strong, but 
the effects of kinetin riboside, benzyladenosine and isopentenyladenosine were even 
stronger. Interestingly, the three cytokinins induced morphological changes of HL-60 
cells but induction of apoptosis was not observed. In contrast, the cytokinin ribosides 
induced apoptosis of HL-60 cells prior to the differentiation of the cells. However, 
the inhibitory effect of trans-zQatin (the most abundant cytokinin in plants) and 
trans-zQatin riboside were not potent. The action mechanisms of the anti-tumor 
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activities of the cytokinins and their riboside derivatives were still poorly understood. 
Therefore, more in depth investigations should be conducted to provide better insight 
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1.3 Aims and Scopes of This Investigation 
Cytokinins are naturally occurring phytohormones which are abundant in plants 
and these phytohormones can also be synthesized chemically. Recent reports showed 
that cytokinins could suppress tumor cell growth in vitro. However, their anti-tumor 
activities and the action mechanisms remain poorly understood. The aims of this 
project were to test for the anti-leukemia effects of cytokinins and to explore the 
apoptosis-inducing and differentiation-inducing potentials of cytokinins on myeloid 
leukemia cells. In addition, the cellular and molecular mechanisms of anti-leukemia 
activity of cytokinins would also be studied. -
In the present study, the anti-proliferative effect of four adenine-based cytokinins 
together with their riboside derivatives was studied, using a well-characterized and 
subcloned murine myelomonocytic leukemia cell line WEHI-3B JCS as an in vitro 
cell model. In addition to WEHI-3B JCS cells, various leukemia cell lines 
representing different lineages of hematopoietic development were used to 
demonstrate the specificity and efficacy of the anti-proliferative activity of cytokinins 
on leukemia. The effect of cytokinins on the cell cycle progression of WEHI-3B JCS 
cells was analyzed by flow cytometry. Moreover, the effects of cytokinins on the in 
vivo tumorigenicity of WEHI-3B JCS cells and the in vivo anti-leukemia activity of 
cytokinins were studied, using the syngeneic BALB/c mice. 
To further elucidate the anti-leukemia activities of cytokinins, the ability of 
cytokinins to induce apoptosis of the WEHI-3B JCS cells was measured by the DNA 
fragmentation assay and the ELISA kit. The role of mitochondria in the 
cytokinin-treated WEHI-3B JCS cells was analyzed by studying the mitochondrial 
membrane potential changes. Moreover, the induction of caspases in the 
cytokinin-treated WEHI-3B JCS cells was also measured to elucidate the apoptotic 
pathways being triggered. On the other hand, the differentiation-inducing ability of ‘ 
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cytokinins on WEHI-3B JCS cells was also investigated by examining the 
‘morpho logy and surface phenotype of the treated cells. Finally, the modulatory effect 
of cytokinins on the expression of a few cell cycle regulatory and apoptosis-related 
genes in the myeloid leukemia WEHI-3B JCS cells was measured by the 
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2.1 Materials 
2.1.1 Animals 
Inbred female BALB/c (haplotype H-2'') mice aged 6 to 8 weeks old were bred 
at the University Laboratory Animal Services Centre of The Chinese University of 
Hong Kong under a specific pathogen-free condition. They were fed with animal diet 
(Chow 5001, Rodent Laboratory) and tap water ad libitum. 
2.1.2 Cell lines 
Various cell lines used in this study were listed as follows: 
A) Murine Cell lines 
1) WEHI-3B 
WEHI-3B (D-) is a murine myelomonocytic leukemia cell line derived from 
the mineral oil-induced BALB/c strain mice. The cell line was originally obtained 
i 
from Dr. D. Metcalf (Walter and Eliza Hall Institute for Medical Research, 
Melbourne, Australia) and subsequently subcloned at the John Curtin School of 
Medical Research, Australian National University, Canberra, Australia. One of the 
subclones designated as WEHI-3B JCS (Leung et al., 1994) was used in this study. 
2) Ml 
Ml is a murine myeloblastic leukemia cell line established in vitro from a 
spontaneous myeloid leukemia of SL strain mice by Y. Ichikawa in the Kyoto 
University of Japan in 1969 (Ichikawa, 1969). The cell line was purchased from the 
American Type Culture Collection (ATCC). 
3) PU5-1.8 
PU5-1.8 is a murine spontaneous macrophage-like tumor cell line originated 
« 
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from BALB/c strain mice (van Furth et al., 1985). The cell line was kindly provided 
by the Department of Pathology, University of Cambridge, United Kingdom. 
4) J774A.1 
J774A.1 is a murine macrophage-like tumor cell line which arose in female 
BALB/c strain mice in 1968 (van Furth et al” 1985). The cell line was purchased 
fromATCC. 
5) MBL-2 
MBL-2 is a murine T cell lymphoma cell line established from Moloney 
leukemia virus infected C57BL/6J strain mice (Ng et al., 1978). The cell line was 
kindly provided by the Department of Pathology, University of Cambridge, United 
Kingdom. 
6) L1210 . 
L1210 is a murine lymphocytic leukemia cell line established from an 
8-month-old DBA/2 strain subline 212 female mouse # 234 that developed tumor 
after skin painting with 0.2% methylcholanthrene in ether (Law et al., 1949). The 
cell line was purchased from ATCC. 
7) BALB/c CL.7 
. BALB/c CL.7 is a murine normal fibroblast cell line established from the 
embryos of BALB/c strain mice (Patek et al, 1978). The cell line was purchased 
fromATCC. 
卷 
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B) Human Cell lines ' 
8) HL-60 
HL-60 is a human promyelocytic leukemia cell line established from a 
36-year-old Caucasian female with acute promyelocytic leukemia (Collins et al” 
1977). The cell line was purchased from ATCC. 
9) NB-4 
NB-4 is a human acute promyelocytic leukemia cell line established from the 
bone marrow of a 23-year-old female with acute promyeloid leukemia in second 
relapse (Lanotte et al” 1991). The cell line was kindly provided by Prof. K.R Fung, 




K-562 is a human chronic myelogenous leukemia cell line established from the 
- pleural effusion of a 5 3-year-old female with chronic myelogenous leukemia in 
terminal blast crises (Lozzio and Lozzio, 1975). The cell line was purchased from 
ATCC. 
11) EoL-1 
EoL-1 is a human acute eosinophilic leukemia cell line established from the 
peripheral blood of a 33-year-old male with acute eosinophilic leukemia 
(Philadelphia chromosome-negative eosinophilic leukemia) and hyper-eosinophilic 
syndrome (Saito et al, 1985). The cell line was kindly provided by Prof. C.K. Wong, 
Department of Chemical Pathology, The Chinese University of Hong Kong, Hong 
Kong, China. ‘ 
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12) U-937 
U-937 is a human histiocytic lymphoma cell line established from of a 
37-year-old Caucasian male with histiocytic lymphoma (Sundstrom and Nilsson， 
1976). The cell line was kindly provided by Prof. W.K. Liu, Department of Anatomy, 
The Chinese University of Hong Kong, Hong Kong, China. 
13) MEG-01 
MEG-01 is a human megakaryoblast-like tumor cell line established from a 
55-year-old male with chronic myelogenous leukemia (Ogura et al., 1985). The cell 
line was kindly provided by Prof. B. S. Lau, School of Pharmacy, The Chinese 
University of Hong Kong, Hong Kong, China. 
.14) WRL68 
WRL 68 is a human hepatocyte-like cell line with ftmctional properties of 
normal hepatocytes (Apostolov, 1976). The cell line was kindly provided by Prof. 
K.R Fung, Department of Biochemistry, The Chinese University of Hong Kong, 
Hong Kong, China. 
2.1.3 Cell culture medium, buffers and other reagents 
1) Cell culture medium 
The powdered form of RPMI 1640 medium (GIBCO BRL Life Technologies 
Inc.), supplemented with 25 mM N-2-hydroxy-ethyl-piperazine-N'-2-ethane-sulfonic 
acid (HEPES) and 2 mM L-glutamine was used for the preparation of culture 
medium. The powdered medium was dissolved in deionized water and was buffered 
with 2 g sodium bicarbonate (NaHCOs) (Sigma-Aldrich Co.) per litre. The medium 
was adjusted to pH 7.15 by 1 M HCl or NaOH (Sigma-Aldrich Co.). The medium ‘ � 
• — 
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was then sterilized by membrane filtration through a 0.22 |im Millipore filter and 
stored in dark at 4°C until use. 
"Plain RPMI medium" was prepared by supplementing RPMI medium with 1% 
antibiotics (PSF or PSN). "Complete RPMI medium" was prepared by 
supplementing plain RPMI medium with 10% fetal bovine serum (FBS) for the 
sub-culturing of most of the human and murine cell lines used in this study. For the 
culture of HL-60 cells, complete RPMI medium supplemented with 20% FBS was 
used. When performing assays, heat inactivated (HI)-FBS was used instead of FBS 
to supplement plain RPMI medium. . 
2) Serum supplements 
Fetal Bovine Serum (FBS) (GIBCO BRL Life Technologies Inc.) was stored as 
50 ml and 20 ml aliquots. Heat-inactivated fetal bovine serum (HI-FBS) was 
prepared by heating the FBS at 56°C for 30 minutes. Both serum aliquots (heated 
and imheated) were stored at :20�C until use. 
3) Antibiotic solutions 
Two types of antibiotic solution were used in alternate periods, the 
Antibiotic-Antimycotic (PSF) [10,000 units/ml penicillin G (sodium salt), 10,000 
l^g/ml streptomycin sulfate and 25 fig/ml amphotericin B as Fungizone in 0.85% 
saline] and Antibiotic (PSN) [5,000 ^ig/ml penicillin G sodium, 5,000 ^ig/ml 
streptomycin sulfate and 10,000 f^g/ml neomycin sulfate in 0.85% saline]. Stock 
solutions (lOOX concentration) were purchased from GIBCO BRL Life Technologies 
Inc. They were stored at -20°C as 5 ml aliquots. 
* 
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4) Phosphate-buffered saline (PBS) 
Phosphate-buffered saline was prepared by dissolving the powder of 8 g NaCl 
(137 mM)，0.2 g KCl，0.2 g KH2P04(1.4 mM) and 1.15 g NazHPO* (4.3 mM) in one 
litre of deionized water. The chemicals were purchased from Sigma-Aldrich Co. The 
pH of the solution was adjusted to 7.2 by adding 1 M HCl or NaOH and then 
sterilized by autoclaving at 121°C for 20 minutes. 
5) Methylthiazoletetrazolium (MTT) 
Methylthiazoletetrazolium (MTT) powder was purchased from USB 
Corporation. The MTT powder was dissolved in sterile PBS. The concentration of 
the stock solution was 4 mg/ml and 30 of the stock solution was added to each 
well of the 96-well flat-bottomed microplate. 
6) Thioglycollate (TG) (3%, w/v) broth 
Thioglycollate (TG) (3%, w/v) broth was prepared by adding 3 g of dehydrated 
thioglycollate powder (Difco Laboratories) to 100 ml deionized water. It was then 
heated to dissolve the powder completely and sterilized by autoclaving at 121°C for 
20 minutes. It was stored in dark at room temperature for at least one month before 
use. 
7) Trypsin-EDTA solution 
Trypsin-EDTA solution was purchased from GIBCO BRL Life Technologies 
Inc. The solution contained 0.25% trypsin and 1 mM EDTA-tetrasodium in HBSS 
without Ca2+ and Mg2+. It was stored at -20°C as 5 ml aliquots until use. 
< 
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8) Cytokinins and related compounds 
Cytokinins and related compounds used in this study were purchased from 
Sigma-Aldrich, Inc. and their estimated purity was listed in Table 2.1. The stock 
solutions were prepared by dissolving the powder in cell culture-tested, sterile 
dimethysulfoxide (DMSO). All stock solutions were stored at -20°C and used within 
2 months. 
Table 2.1. Cytokinins and related chemicals used in this study 
Cytokinin Estimated purity (%) Stock concentration (M) 
Kinetin (KI) > 99.0 0.2 
Kinetin riboside (KR) > 99.0 0.2 
Benzadenine (BA) > 99.0 0.2 
Benadenosine (BAR) > 99.0 0.2 
,Isopentenyladenine (IPA) > 98.5 0.2 
Isopentenyladenosine (IPAR) • >98.0 0.2 
Zeatin (ZE) > 97.0 0.2 
Zeatin riboside (ZR) =95.0 0.2 
Adenine > 99.0 1 
Adenosine ~ 99.0 1 
9) [Methyl-^H] thymidine ([^H]-TdR) 
The stock solution with specific activity of 2 Ci/mmol was purchased from 
Amersham Life Science Ltd. and was stored at 4°C as 500 pil aliquots. The working 
solution (25 jiCi/ml) was freshly prepared by diluting the stock solution with 
complete RPMI medium. In proliferation assays, 20 |j.1 working solution was added 
* 
to each well of the 96-well flat-bottomed microplate.   
TJT- — 
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10) Liquid scintillation cocktail 
The OptiPhase "Hisafe"2 liquid scintillation cocktail was purchased from 
Perkin-Elmer Co. The cocktail was based on biodegradable solvents with dioctyl 
sulfosuccinate, sodium salts and poly(ethyleneglycol)mono(4-nonylphenyI)-ether. It 
was ready-to-use and stored in dark at room temperature. 
11) Lactate Dehydrogenase (LDH) cytotoxicity assay kit 
The kit was purchased from Bio Vision，Inc. and was used for measuring 
cytotoxicity of cytokinins. The kit contained a lyophilized catalyst and a dye solution. 
The catalyst was reconstituted with 1 ml deionized water. For 100 assays, a working 
solution was freshly prepared by mixing 250 i^l catalyst solution with 11.25 ml dye 
solution. The whole kit was stored at -20°C and kept in dark. 
12) Dye solutions 
a) Hemacolor staining solutions 
Hemacolor staining solutions set was purchased from Merck. The solution set 
was used to stain the cells on microscopic glass slides after cytocentrifiigation. It 
consisted of three different solutions. Hemacolor solution 1 (methanol) was used for 
cell fixation, solution 2 was a buffered red color reagent and solution 3 was a 
buffered blue color reagent. The solutions were kept in dark and stored at room 
temperature. 
b) 0.4% (w/v) Trypan blue solution 
Trypan blue solution was purchased from Sigma-Aldrich Co. and contained 
0.4% (w/v) trypan blue dissolved in a solution of 0.817% (w/v) NaCl and 0.06% 
(w/v) KH2PO4. The solution was stored at room temperature. ‘ 
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d) 0.5% (w/v) Crystal Violet solution 
Crystal violet powder (mixture of crystal violet and methyl violet) was 
purchased from Sigma-Aldrich Co. The dye was prepared by dissolving 0.5 g of 
crystal violet powder, 0.9 g NaCl, 2% (v/v) formaldehyde in 50 ml ethanol and then 
added up the volume to 100 ml with deionized water. The solution was kept in dark 
and stored at room temperature. 
2.1.4 Reagents and buffers for flow cytometry 
1) Propidium iodide (PI) DNA staining buffer 
The PI DNA staining buffer was freshly prepared in PBS containing 40 [ig/m\ 
propidium iodide (Sigma-Aldrich Co.) and 8 ^ig/ml RNase A (USB Corporation). 
The PBS and PI stock solution was stored at 4°C while RNase A stock solution was 
stored at -20°C. 
2) JC-1 staining solution 
5，5'，6，6’-tetrachloro-l，r，3，3'-tetraethylbenzimidazolyl-carbocyanine iodide 
(JC-1) was purchased from Molecular Probes Inc. JC-1 is a lipophilic, cationic 
fluorescent dye which selectively accumulates in mitochondria. It can be used as a 
sensitive marker for the mitochondrial membrane potential of a cell, indicated by a 
fluorescence emission shift from green (525 rnn, monomer form) to red (590 nm, 
dimer form) upon excitation at 488 nm. The stock solution of JC-1 was prepared at a 
concentration of 5 mg/ml in DMSO and stored at -20°C. The dye was diluted to 10 
|iM (1.3 [i\ of stock) in warm PBS before use. 
( 
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3) Fluorescein diacetate 
Fluorescein diacetate (Calbiochem) was used for measuring non-specific 
esterase activity. The stock solution (20 mg/ml) was prepared by dissolving 20 mg of 
the powder per ml of DMSO and stored at -20°C. The working solution was freshly 
prepared by diluting the stock solution with warm culture medium to a concentration 
of 200 |Lig/ml and protected from light. 
4) Dihydroethidium 
Dihydroethidium purchased from Molecular Probes, Inc..was used for detecting 
free peroxide radical (O2.-). The stock solution (10 mM) was prepared by dissolving 
the powder in DMSO and stored at -20°C. The working solution was freshly 
prepared by diluting the stock solution with PBS to a concentration of 10 |iM and 
protected from light. 
5) 75% (v/v) ethanol ‘ 
Absolute ethanol (analytical grade) was purchased from Merck. The 75% (v/v) 
ethanol was prepared by mixing 75 ml absolute ethanol with 25 ml autoclaved 
deionized water. The solution was stored at 4°C. It was used for fixing cells in cell 
cycle analysis. 
6) 1% (w/v) paraformaldehyde 
Paraformaldehyde (in powdered form) was purchased from Sigma-Aldrich Co. 
One gram of paraformaldehyde was dissolved in 50 ml deionized water by heating to 
� 60�C with constant stirring in a fume hood for 1 hour. A few drops of 1 M NaOH 
were added to facilitate the dissolution of paraformaldehyde powder. After a clear 
solution was obtained，it was cooled to room temperature. 50 ml 2X PBS solution ‘ 
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was added to give a 1% (w/v) paraformaldehyde in PBS and the solution was stored 
in dark at 4°C until use. 
7) FACS medium 
The FACS medium contains 2% (v/v) HI-FCS and 0.05% (w/v) sodium azide 
in PBS. It was used for washing and resuspending cells in FACS analysis. Sodium 
azide was added to inhibit internalization of cell-bound antibodies, patching and 
capping of the cells. The FACS medium was stored at 4°C. 
8) FACS flow shealth fluid 
The shealth fluid is a ready-to-use solution purchased from Becton Dickinson. 
The fluid is a balanced electrolyte solution containing sodium chloride，potassium 
chloride, disodium EDTA, sodium fluoride and an anti-microbial agent. It was stored 
at room temperature. 
9) Antibodies for flow cytometry 
a) Rat anti-mouse macrophage differentiation antigen CDllb (Mac-1) 
monoclonal antibody (clone Ml/70, rat IgG2b isotype) 
It was obtained from the culture supernatant of the hybridoma cell line Ml/70 
(ATCC). The antibody reacts with the mouse CDllb antigen. Small volume aliquots 
of the antibody were stored at -70�C until use. Once thawed, the antibody was kept at 
4 � C 
b) Rat anti-mouse macrophage differentiation antigen F4/80 monoclonal 
antibody (clone C1.A3-1, rat IgGib isotype) 
It was obtained from the culture supernatant of the hybridoma cell line F4/80 ‘ 
^W- 
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(ATCC). The antibody reacts with the mouse F4/80 antigen. Small volume aliquots 
of the antibody were stored at -70°C until use. Once thawed, the antibody was kept at 
4�C. 
c) Rat anti-mouse myeloid differentiation antigen Gr-1 monoclonal antibody 
(clone RB6-8C5, rat IgGzb isotype) 
The antibody was purchased from BD Pharmingen. The RB6-8C5 antibody 
reacts with the mouse myeloid differentiation antigen Gr-l. Undiluted antibody was 
stored at 4�C. . 
d) Fluorescein isothiocyanate (FITC)-conjugated goat F(ab，)2 anti-rat IgG (H+L 
chain specific) antibody 
The antibody was purchased from BD Pharmingen. The F(ab’)2 fragment of 
this FITC-conjugated antibody was used as a secondary antibody to react with the 
heavy and light chains of rat IgG. The antibody has minimal cross reactivity with 
mouse immunoglobulins. Undiluted antibody was stored at 4°C. 
e) Mouse IgG and rat IgG 
Mouse IgG (10 mg/ml) and rat IgG (10 mg/ml) were purchased from 
Sigma-Aldrich Co. The antibodies were used to block the non-specific binding of 
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2.1.5 Reagents for DNA extraction 
1) IGEPAL CA-630 lysis buffer 
The lysis buffer was prepared in 50 mM Tris [hydroxylmethyl] amino methane 
(Tris)-HCl, pH 7.5 with 3% non-ionic detergent IGEPAL CA-630 ((Octylphenoxy) 
polyethoxyethanol) and 20 mM EDTA. IGEPAL CA-630 lysis buffer components 
were purchased from Sigma-Aldrich, Inc. and IGEPAL is a registered trademark of 
Phone-Poulenc, Inc. The lysis buffer was stored at room temperature. 
2) Proteinase K 
Proteinase K was purchased from USB Corporation. It is a highly active 
subtilisin type of protease. It was purified from the mold Tritirachium album Limber. 
The stock solution (20 mg/ml) was prepared by dissolving proteinase powder in 
autoclaved TioEo.i buffer. It was stored as 500 \x\ aliquots at -20°C. 
3) RNaseA 
The bovine pancreatic RNase was purchased from USB Corporation. The stock 
solution (10 mg/ml) was prepared by dissolving RNase powder in TioEo.i buffer. The 
stock solution was boiled for 15 minutes to denature any contaminated DNase. The 
stock solution was stored as 500 i^l aliquots at -20°C. 
4) 3M Sodium acetate solution (NaOAc) (pH 5.2) 
Sodium acetate powder was purchased from Sigma-Aldrich Co. The 3M stock 
solution was prepared by dissolving 24.61 g sodium acetate in 100 ml deionized 
water and adjusted the pH to 5.2 with glacial acetic acid. It was then sterilized by 
autoclaving at 121 °C for 20 minutes. The solution was stored at room temperature. 
< 
-41 - "“  
•‘ 
Chapter 2: Materials & Methods 
5) TioEo.i buffer 
The TioEo.i buffer was prepared in deionized water containing 10 mM Tris-HCl 
(pH 7.5) and 0.1 mM EDTA. It was stored at room temperature. 
2.1.6 Cellular DNA Fragmentation ELISA kit 
The ELISA kit was purchased from Roche Applied Science. The kit was stored 
at 4°C. It contained the following reagents: 
1) Anti-DNA antibody 
It is a mouse monoclonal antibody (clone MCA-33). It recognizes DNA 
components and was used for microplate coating. The lyophilized antibody was 
reconstituted in 1 ml deionized water and stored at 4°C until use. 
2) Anti-BrdU-peroxidase (POD) antibody 
It is a Fab-fragment derived from mouse monoclonal antibody (clone BMG 
6H8). The antibody recognizes the BrdU incorporated into DNA fragments and was 
conjugated with peroxidase for the enzymatic reaction with 
3,3'-5,5'-tetramethylbenzidine (TMB) substrate to give a light blue colour. The 
lyophilized antibody was reconstituted in 1 ml deionized water and stored at 4°C 
until use. 
3) lOX coating buffer 
It was used for diluting anti-DNA antibody to coat the microplate. The buffer 
was freshly prepared by adding one volume of lOX coating buffer to nine volumes of 
deionized water. The stock buffer was stored at 4°C until use. 
< 
• “  
产 Chapter 2: Materials & Methods 
4) lOOOX BrdU labeling reagent 
It is a solution containing 10 mM 5 ‘ -bromo-2‘ -deoxy-uridine (BrdU) in sterile 
PBS (pH 7.4). The reagent was further diluted with sterile PBS to give a lOOX (1 
mM) working solution, which was used for labeling cells with BrdU incorporated 
into genomic DNA. The final concentration of BrdU in cell labeling was 10 }iM (IX) 
in culture medium. The stock reagent was stored at 4°C while the working solutions 
were stored as 50 \i\ aliquots at -20�C. The working solution was then stored at 4°C 
once thawed. 
5) 2X incubation buffer 
The 2X incubation buffer contains bovine serum albumin (BSA)，EDTA ’ 
Tween 20 and a preservative. The working buffer was prepared by diluting 2X 
incubation buffer with an equal volume of deionized water. The buffer was used for 
lysing the cells and for blocking non-specific binding sites in anti-DNA antibody 
precoated microplate. Both the stock and working buffer was stored at 4°C. The 
working buffer could be stored up to a week. 
6) lOX washing buffer 
The lOX washing buffer contains EDTA, Tween 20 and a preservative. The 
working buffer was prepared by diluting one volume of lOX washing buffer with 
nine volumes of deionized water. The buffer was used for washing the microplate in 
ELISA procedure and diluting anti-BrdU-POD antibody. Both the stock and working 
buffer was stored at 4°C. The working buffer could be stored up to a week. 
7) 3,3'-5,5'-Tetramethylbenzidine (TMB) substrate solution 
3,3'-5,5'-Tetrainethylbenzidine (TMB) is a ready-to-use solution. When reacted ‘ 
. -
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with peroxidase, the substrate turned light blue. The intensity of light blue colour 
indicated the amount of anti-BrdU-POD antibodies bound to the DNA fragment, 
which correlated to the degree of apoptosis in the ELISA assay. The TMB substrate 
was stored in dark at 4°C. 
8) 5% (v/v) sulphuric acid (H2SO4) 
This solution was not included in the ELISA kit and it was used for stopping 
the enzymatic reaction of peroxidase and TMB substrate. The solution was prepared 
by mixing 560 fil of concentrated H2SO4 (95-97%) to 8 ml ice-cold deionized water 
and then made up to 10 ml with deionized water. The solution was stored at room 
temperature. ‘ 
9) PoIy-D-lysine hydrobromide 
It was in powdered form and not included in the ELISA kit. The chemical was 
purchased from Sigma-Aldrich Co. and used for coating microplate for the binding 
of suspension cells. The stock solution was prepared by dissolving 100 mg 
poly-D-lysine hydrobromide powder in 10 ml sterile deionized water and then stored 
at -20�C as 0.5 ml aliquots. The working solution was freshly prepared by diluting _ 
the stock solution with sterile deionized water to a concentration of 0.1 mg/ml. 
2.1.7 Reagents for total RNA isolation 
1) DEPC-treated deionized water 
Diethyl pyrocarbonate (DEPC，Sigma-Aldrich Co.) was added to deionized 
water in ratio 1:1,000 to give 0.1% DEPC. The solution was shaken vigorously to 
disperse DEPC thoroughly and then stood overnight. The solution was then 
autoclaved at 121°C for 40 minutes to inactivate the remaining DEPC. ‘ 
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2) Glassware and metal apparatus 
Glassware (Pasteur pipettes and beakers) and metal forceps were baked at 
‘ 150°C oven overnight and then cooled down to room temperature before use. 
3) Tris-HCI buffer (pH 7.5) 
Tris [hydroxymethyl] amino methane (Tris, Sigma-Aldrich Co.) was prepared 
as a 1 M stock solution in DEPC-treated deionized water. The buffer was adjusted to 
pH 7.5 with hydrochloric acid (HCl) and autoclaved at 121°C for 20 minutes. 
4) TRIZOL reagent 
TRIZOL reagent (Invitrogen Life Technologies Inc.) is a ready-to-use solution 
for isolating total RNA from cells and tissues. It is a mono-phasic solution of phenol 
and guanidine isothiocyanate. The reagent was stored at 4°C. 
5) Chloroform 
Chloroform was purchased from BDH Laboratory Supplies. It was stored at 
room temperature. 
6) Isopropanol 
"Isopropanol was purchased from BDH Laboratory Supplies. The solution was 
stored at room temperature. 
7) 75% (v/v) ethanol 
Absolute ethanol (analytical grade) was purchased from Merck. For RNA 
extraction, ethanol was prepared as a 75% (v/v) solution in DEPC-treated deionized 
water. The solution was stored at 4°C. ‘ 
“ - — 
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2.1.8 Reagents for Reverse Transcription-Polymerase Chain 
Reaction (RT-PCR) 
1) Moloney murine leukemia virus reverse transcriptase (M-MLV RT) 
M-MLV RT was purchased from Invitrogen Life Technologies Inc. The enzyme 
I 
was isolated from Escherichia coli expressing a portion of the pol gene of M-MLV 
on a plasmid. One unit of the M-MLV RT was defined as the amount of enzyme that 
incorporated 1 nmole of deoxythymidine triphosphate (dTTP) into acid-precipitable 
material in 10 minutes at 37°C using poly(A) and oligo-dT12-18 as template and 
primer respectively. It was stored at -20°C in the buffer containing 20 mM Tris-HCl 
(pH 7.5)，100 mM NaCl, 0.1 mM EDTA, 1 mM dithiothreitol (DTT), 0.01% (v/v) 
NP-40 and 50% (v/v) glycerol. 
2) 5X M-MLV first strand buffer 
M-MLV first strand buffer (Invitrogen Life Technologies Inc.) was supplied as 
a 5X solution containing 250'mM Tris-HCl (pH 8.3)，375 mM potassium chloride 
(KCl) and 15 mM magnesium chloride (MgCb). It was stored at -20°C until use. 
3) RNaseOUT™ recombinant ribonuclease inhibitor 
The RNaseOUT™ recombinant ribonuclease inhibitor (Invitrogen Life 
雜 
Technologies Inc.) was supplied at a concentration of 40 units/|j,l. The inhibitor is a 
recombinant protein derived from E. coli expressing a cloned porcine liver gene and 
‘ it is active against RNase A, RNase B and RNase C. The inhibitor requires a 
minimum of 1 mM DTT to maintain its activity. One unit of the RNaseOUT™ 
recombinant ribonuclease inhibitor was defined as the amount of the inhibitor 
required to inhibit the activity of 5 ng of RNase A by 50% as measured by the 
inhibition of hydrolysis of cytidine 2，. 3'-cyclic monophosphate by RNase A. The ‘ 
： • 
产 Chapter 2: Materials & Methods 
inhibitor was stored at -20°C in a buffer containing 20 mM Tris-HCl (pH 8.0)，50 
mM KCl, 0.5 mM EDTA，8 mM DTT and 50% (v/v) glycerol. 
4) 01igo(dT)12-18, sodium salt (pd(T)12-18, sodium salt) 
01igo(dT)12-18 was purchased from Amersham Pharmacia Biotech. It was 
prepared as a stock solution of 1 \igl\i\ in TioEo.i buffer and stored at -20°C. 
5) Dithiothreitol (DTT) (100 mM) 
DTT (100 mM) was purchased from Invitrogen Life Technologies, Inc. and was 
stored at -20°C until use. 
6) Ultrapure dNTP set，2'-deoxynucleoside 5'-triphosphate, sodium salt 
The deoxynucleoside triphosphate (dNTP) set was purchased from Amersham 
Pharmacia Biotech. It contains each nucleotide (dATP, dCTP，dTTP and dGTP) 
supplied as 100 mM solution in deionized water (pH 7.5). A stock solution with 10 
mM of each dNTP was prepared in 1 mM Tris-HCl (pH 7.5) and stored at -20°C. 
7) Thermoprime Plus DNA polymerase 
Thermoprime Plus DNA polymerase (Advanced Biotechnologies Ltd.) is a 
I 
thermostable DNA polymerase isolated from recombinant E. coli, which was cloned 
with a Taq polymerase gene from Thermus "icelandicusa strain of Thermus 
aquaticus. The polymerase is a single polypeptide of approximately 94 kD having 5' 
to 3，polymerization-dependent exonuclease replacement activity, but lacking the 3， 
to 5' exonuclease activity. One unit of the enzyme was defined as the amount of the 
enzyme that would incorporate 10 nmoles of dNTPs into acid insoluble material in 
30 minutes at 74�C. The polymerase was dissolved in the storage buffer contained 
« 
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100 mM KCl, 20 mM Tris-HCl (pH 8.0) 0.1 mM EDTA，1 mM DTT, 0.5% Tween 20， 
0.5% NP-40 and 50% (v/v) glycerol and was stored at -20°C until use. 
8) lOX reaction buffer IV 
The lOX reaction buffer IV was supplied with Thermoprime Plus DNA 
polymerase (Advanced Biotechnologies Ltd.) containing 200 mM (NH4)2S04，750 
mM Tris-HCl (pH 8.8)，and 0.1% (v/v) Tween-20. It was stored at -20�C until use. 
9) 25 mM magnesium chloride (MgCh) solution 
The 25 mM MgCb solution was supplied with the Thermoprime Plus DNA 
polymerase (Advanced Biotechnologies Ltd.). The solution was stored at -20°C until 
J 
use. 
10) Primer pairs 
J 
The specific oligonucleotide primer pairs used in reverse-transcription 
polymerase chain reaction (RT-PCR) were designed based on the published 
sequences of the cloned cDNA. They were designed to prime on the sense and 
antisense sequences of the corresponding cDNA respectively. The PGR primers were 
synthesized by Invitrogen Life Technologies Inc. The sequences and predicted sizes 
of the PGR products were listed in Table 2.2. The lyophilized primer pairs obtained 
from the supplier were reconstituted in DEPC-treated deionized water to a working 
concentration of 2.5 \M. The primers were stored at -20°C. 
748^ ~  
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Table 2.2. Primers used in RT-PCR and the predicted sizes of the PCR products. 
cDNA ^ ^ ⑵各,，、 Predicted size of the 
1 •於 , S t r a n d Sequence (5' to 3') 
amplified PCR product (bp) 
O A nr^ T t Scnsc TGA AGGTCG GAG TCA ACG GAT TTG GT 
GAPDH 226 
, Antisense CAT GTG GGC CAT GAG GTC CAC CAC  
n , . Sense AGG TGC ACC TGA CGC CCT T 
ocl-2 293 
Antisense CAG CCA GGA GAA ATC AAA CAG AGG  
r.,^ Sense TGC AGA GGA TGA TTG CTG A 
Bax 173 
_ _ Antisense GAT CAG CTC GGG CAC TTT A  
Bad Sense ATC CCA GAG TTT GAG TCG AGG GA 
Antisense TTC GAG CCC ACC AGG ACT GGA  
FasL Sense ACA GCA ACC AGC AAT ACA  
^ Antisense GTA TGG TTT CAC GAC TGG ^  
n^ , Sense TAG TTC CTG CAC CTG CAG CCT 
myelin A 3 99 
^ _ _ Antisense AGC ATG GAC TCC GAG CGA CT  
CV r ^ Sense CCA TTA TTG ATC GGT TCA TGC AGA 
Lyclin B 584 
^ Antisense ATG TGT ACA GTT CAG CTG TGC CAG 
Cyclin E Sense CCC AGC AGT AAG AAG GCA GAG 
Antisense CAG CTT CTG GAG CAC TCA GTG  
C W T.. Sense AAG GAG AAG CTG TCC CTG ATC 一 
myelin D2 273 
Antisense GAA CTG CTG CAG GCT GTT CAG  
Sense CTT TGA CTT CGT CAC GGA GAC ‘ 
469 
Antisense AGG CAG CGT ATA TCA GGA GAC  
P27 Sense AAG CAC TGC CGG GAT ATG GA “ 
^ I Antisense AAC CCA GCC TGA TTG TCT GAC  
" “ “   
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2.1.9 Reagents for Gel Electrophoresis for Nucleic Adds 
1) 5X Tris-borate-EDTA (TBE) buffer 
The 5X TBE buffer stock was prepared by dissolving 54 g Tris, 27.5 g boric 
acid and 20 ml 0.5 M EDTA in one litre deionized water. The pH of the buffer was 
adjusted to 8.0. The working 0.5X TBE buffer used in electrophoresis was prepared 
by diluting one volume of the 5X stock TBE buffer with nine volumes of deionized 
water. Both of the stock and working solutions were stored at 4°C. 
2) 5X gel loading solution 
The gel loading solution (Sigma-Aldrich Co.) was a 5X solution of 0.05% (w/v) 
bromophenol blue, 40% (w/v) sucrose, 0.1 M EDTA (pH 8.0) and 0.5% (w/v) sodium 
dodecyl sulfate (SDS). The loading solution was used for non-denaturing agarose gel 
electrophoresis of nucleic acids. One volume of the solution was mixed with four 
volumes of nucleic acid sample before loading onto agarose gel. The loading solution 
was stored at 4°C. • 
3) 100 bp DNA ladder 
100 bp DNA ladder (1 |ig/|il) was purchased from Invitrogen Life Technologies. 
It was diluted with TIOEO.I buffer to a working solution of 0.1 The stock 
solution was stored at -20°C until use and the working solution was stored at 4�C. 
« 
4) Ethidium bromide (EtBr) 
Ethidium bromide (powdered form) was purchased from Sigma-Aldrich Co. 
The stock solution (10 mg/ml) was prepared by dissolving the EtBr in deionized 
water. The working solution (1 fig/ml) was prepared by 10,000-fold dilution of the 
stock solution in deionized water. Both the stock and working solutions were kept in ^ 
• - — 
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• dark at room temperature. 
5) Agarose gel 
1% (w/v) and 2% (w/v) agarose gels were prepared by dissolving 10 g and 20 g 
agarose (Sigma-Aldrich Co.) respectively in one litre 0.5X TBE buffer by heating at 
70°C with constant stirring. The solidified agarose gel was heated to melting form in 
t 
microwave oven before use. The 1% agarose gel was used for RNA gel 
electrophoresis while 2% agarose gel was used for DNA and PGR products gel 
electrophoresis. 
2.1.10 Reagents for Measuring Caspase Activity 
1) Cell lysis buffer 
The cell lysis buffer contains 1% IGEPAL-CA 630 (Sigma), 150 mM NaCl，50 
mM Tris-HCl (pH 7.5)，complete™ protease inhibitor cocktail (Roche Applied 
Science) in 50 ml deionized water. It was stored at 4 � C . 
2) 2X Reaction buffer 
The 2X reaction buffer contains 20 mM HEPES-KOH (pH 7.0), 80 mM 
P-glycerophosphate, 100 mM NaCl, 4 mM MgCb, 10 mM EGTA，0.2% CHAPS, 
200 |ig/ml BSA and 20 mM DTT. It was stored at 4°C. 
3) Dithiothreitol (DTT) 
The IM stock solution was prepared by dissolving DTT in deionized water. It 
was stored at -20°C. It was added to the 2X reaction buffer to a final concentration of 
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4) Bradford reagent 
It is a 450 ml 5X solution purchased from Bio-Rad Laboratories. When use in 
quantification of protein, one volume of Bradford reagent was added to four volumes 
of protein sample. The Bradford solution was stored at 4°C until use. 
• 
5) Caspase 3 substrate, Ac-DEVD-AMC 
Acetyl-Asp-Glu-Val-Asp-7-amido-4-methylcoumarin (Ac-DEVD-AMC) 
(Sigma-Aldrich Co.) is a caspase 3 specific fluorogenic substrate. It was dissolved in 
DMSO as a 2 mM stock solution. It was stored at -20°C. 
6) Caspase 3 inhibitor, Ac-DEVD-CHO 
Acetyl-Asp-Glu-Val-Asp-aldehyde (Ac-DEVD-CHO) (Alexis Biochemicals) is 
a specific reversible inhibitor of caspase 3. It was dissolved in sterile deionized water 
as a 10 mM stock solution. It was further diluted with RPMI medium as a 1 mM 
working solution. Both the stock and the diluted solutions were stored at -20°C. 
7) Caspase 8 substrate, Ac-IETD-AMC 
N-Acetyl-Ile-Glu-Thr-Asp-7-Amido-4-methylcoumarin (Ac-IETD-AMC) 
(Alexis Biochemicals) is a specific fluorogenic substrate for caspase 8 and granzyme � 
B. It was dissolved in DMSO as a 1 mM stock solution and stored at -20�C. 
8) Caspase 8 inhibitor, Ac-IETD-CHO 
Acetyl-Ile-Glu(OMe)-Thr-Asp(OMe)-CHO (Ac-IETD-CHO) (Alexis 
Biochemicals) is a potent, cell permeable and irreversible inhibitor of caspase 8 and 
granzyme B. It was dissolved in DMSO as a 10 mM stock solution. It was further 
diluted with RPMI medium as a 1 mM working solution. Both the stock and the . 
- ：52： “  
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diluted solutions were stored at -20°C. 
9) Caspase 9 substrate，Ac-LEHD-AFC 
N-Ace1yl-Leu-Glu-His-Asp-7-amido-4-trifluoromethylcoumarin 
(Ac-LEHD-AFC) (Alexis Biochemicals) is a caspase 9 specific fluorogenic substrate. 
It was dissolved in DMSO as a 5 mM stock solution and stored at -20°C. 
10) Caspase 9 inhibitor, Ac-LEHD-CHO 
Acetyl-Leu-Glu(OMe)-His-Asp(OMe)-aldehyde (Ac-LEHD-CHO) (Alexis 
Biochemicals) is a potent, cell permeable and irreversible inhibitor of caspase 9. It 
was dissolved in DMSO as a 10 mM stock solution. It was ftirther diluted with RPMI 
medium as a 1 mM working solution. Both the stock and the diluted solutions were 
stored at -20°C. 
11) 7-Amino-4-methyl coumarin (AMC) 
7-amino-4-methyl coumarin (AMC) was purchased from Sigma-Aldrich Co. It 
is the standard marker for the quantification of caspase 3 and caspase 8 activity. It 
was dissolved in DMSO as a 50 mM stock solution. It was further diluted with lysis 
buffer to 100 |liM. Both the stock and the diluted solutions were stored at 4°C. 
12) 7-Amino-4-trifluoromethyl coumarin (AFC) 
7-amino-4-trifluoromethyl coumarin (AFC) was purchased from Sigma-Aldrich Co. 
It is the standard marker for the quantification of caspase 9 activity. It was dissolved 
in methanol as a 20 mM stock solution. It was further diluted with lysis buffer to 80 
|xM. Both the stock and the diluted solutions were stored at 4°C. 
* 
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2.2 Methods 
2.2.1 Culture of the Cell Lines 
Both the murine and human leukemia cell lines were maintained in RPMI 
medium supplemented with 10% FBS as continuous suspension cultures. For the 
human leukemia HL-60 cells, they were maintained in RPMI medium supplemented 
with 20% FBS. All the cell lines were cultured in 25, 75 or 150 c m � tissue culture 
flasks and incubated at 37�C in a humidified incubator supplied with 5% carbon 
dioxide (CO2). The cell lines were subcultured at 2-4 day intervals depending on the 
doubling time of each cell line. Cells in exponential growth phase were used for 
experiments and long-term storage of cell lines was done by cryopreservation in 
liquid nitrogen (cryopreservation medium: 50% FBS and 10% DMSO in RPMI 
medium). 
For the subculture of particular murine and human adherent cell lines (J774A.1, 
CL.7 and WRL 68)，the growth medium was discarded and the adherent cells were ‘ 
then rinsed once with warm PBS. The cells were incubated with 2 ml (for 25 cm^ 
culture flask) or 4 ml (for 75 cm� culture flask) or 6 ml (for 150 c m � culture flask) 
warm 0.25% trypsin-1 mM EDTA solution at 37°C for 5 minutes. Complete RPMI 
medium was then added to the cells to stop the trypsiiiization process. An appropriate 
amount of cells were transferred to a new culture flask containing fresh complete 
medium. For the human cell line MEG-01, the adherent cells were detached by 
scraping and then together with the suspension cells transferred to a new culture flask 
containing fresh complete medium. � 
. * 
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2.2.2 Isolation, Preparation and Culture of Murine Peritoneal 
Macrophages 
BALB/c mice were first injected intraperitoneally (i.p.) with 1 ml 3% 
thioglycollate broth and then sacrificed 3 days later by cervical dislocation. The mice 
were placed ventral side up on a clean surface. The skin of the abdomen was 
disinfected with 70% ethanol, cut and pulled apart to expose the peritoneal 
membrane. Air was injected to inflate the peritoneal cavity. Each time 3 ml PBS was 
injected into the abdominal cavity using a 5 ml syringe fitted with a 20-gauge needle 
and the abdominal cavity was washed for 3 times. The peritoneal exudate cells (PEC) 
were then washed with cold plain RPMI medium. They were finally resuspended in 
complete RPMI medium for further use. 
To obtain the peritoneal exudate macrophages for assays, the PEC (5 x 10^ 
cells/ml) were seeded in a 96-well flat-bottomed microplate and incubated at 37°C 
for 3 hours to allow attachment of the macrophages. The wells were then washed 
once with plain RPMI medimn to remove any suspension cells. Complete RPMI 
medium was added to the wells and the peritoneal macrophages were ready for assay. 
2.2.3 Determination of Cell Proliferation by [^H]-TdR Incorporation 
Assay 
Leukemia cells (with specific cell density for different cell lines) were 
incubated with different concentrations of cytokinins in the wells of 96-well 
flat-bottomed microplates at 37°C for 48 hours (or specific periods of time) in a 
humidified 5% CO2 incubator. The cells were then pulsed with 0.5 ^iCi [^H]-TdR in 
20 |il complete medium for 6 hours (or longer time if the cell line has a longer 
doubling time). After one freeze-and-thaw cycle, the cells were harvested onto a 
glass microfiber filter (Skatron Instrument) using cell harvester (Molecular D e v i c e ) . ‘ 
— — 
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The radioactivity, in counts per minute (cpm), was measured by the low activity 
liquid scintillation Analyzer Tri-Carb® 2900TR (Packard Instrument Company). The 
results were expressed as the mean percentage inhibition of [^H]-TdR incorporation 
土 standard error (S.E.) of quadruplicate cultures, using the untreated cells as a control 
(Leung et al., 1994). The percentage inhibition of [^H]-TdR incorporation was 
calculated as follows: 
% inhibition = [(cpm of control - cpm of test sample)/ cpm of control] x 100 
2.2.4 Cytotoxicity Measurement by LDH Release Assay 
The assay was performed using the LDH-cytotoxicity assay kit purchased from 
BioVision, Inc. The assay was based on the measurement of activity of lactate 
dehydrogenase (LDH) released from the plasma membrane of damaged cells. In the 
assay, LDH activity was determined by a coupled enzymatic reaction: LDH oxidized 
lactate to pyruvate and the pyruvate then reacted with INT, a tetrazolium salt to form 
red-colored formazan. The experimental procedure was performed according to the 
manufacturer's instruction. Briefly, WEHI-3B JCS cells (5 x lO* cells/ml) were 
incubated with different concentrations of cytokinins at 37°C for different periods of 
time in 96-well flat-bottomed microplate. A high cytotoxicity positive control was 
included by incubating cells with 1% Triton X-100 in culture medium. Afterwards, 
the cells were centrifuged at 300 x g for 10 minutes. One hundred and twenty 
microlitres of supernatant were transferred to another 96-well flat-bottomed 
microplate and freeze at -70°C. After collecting all samples from various incubation 
periods, 100 jil of supernatant was transferred to another microplate and mixed with 
100 fil reaction mixture (25 fil catalyst solution and 1.125 ml dye solution). The 
samples were then incubated in dark at room temperature for 30 minutes. Absorbance 
at 490 nm was measured. The results were expressed as the mean percentage 
- 5 6 - -
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cytotoxicity 士 S.E. of triplicate cultures. The percentage cytotoxicity was calculated 
as follows: -
f 
% Cytotoxicity = (test sample 一 untreated control) X 100 
(high cytotoxicity control - untreated control) 
2.2.5 Determination of Cell Viability 
1) Trypan blue exclusion assay 
Trypan blue exclusion assay was based on the integrity of plasma membrane 
and the ability of a viable cell to exclude the trypan blue dye. It was used to 
determine the number of viable cells in cultures. The cells were incubated with 
different concentrations of cytokinins at 37�C. The viability of the cells was then 
determined at the indicated periods of time. Ten microlitres of cell suspension were 
mixed with 10 |il of 0.4% trypan blue solution. Viable cells with intact membrane 
were visible as clear cell bodies while the dead cells were stained blue. Vi-Cell™ XR 
“cell viability analyzer (Beckman Coutler) was used to perform the analysis. By 
counting the number of viable and dead cells, the cell viability was estimated and the 
results were expressed as the mean percentage of cell viability 土 S.E. of triplicate 
cultures. The percentage viability was calculated as follows: 
% viability = (no. of viable cells/ no. of total cells counted) x 100 
2) MTT colorimetric assay 
Thioglycollate-elicited murine peritoneal macrophages (5 x 10^ cells/ml) were 
incubated with different concentrations of cytokinins in the wells of 96-well 
flat-bottomed microplates at 37°C for 48 hours inside a humidified 5% CO2 incubator. 
MTT assay was also applied to the cell lines BALB/c CL.7 and WRL 68 which had 
low uptake of [^H]-TdR. The cells were then incubated with 30 \i\ MTT (5 m g / m l ) ‘ 
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for 2 hours. After centrifugation at 400 x g for 5 minutes, the medium was aspirated 
and 50 |il DMSO was added to dissolve the blue formazan deposited in the cells. The 
absorbance of the samples was measured at 540 nm in a microplate reader (Bio-Rad 
Laboratories). The results were expressed as the mean percentage cell viability 士 S.E. 
of quadruplicate cultures. The percentage viability was calculated as follows: 
% viability = [OD540 of test sample / OD540 of control] x 100 
2.2.6 Determination of Anti-leukemia Activity In Vivo 
1) In vivo tumorigenicity assay 
Leukemia WEHI-3B JCS cells (2 x lO^ cells/ml) were preincubated with 
cytokinins for 8 hours at 37°C. The treated cells were collected and washed three 
times with PBS. After viable cell counting by trypan blue exclusion, WEHI-3B JCS 
cells (1 X 106) in 0.5 ml PBS were injected intraperitoneally (i.p.) into each BALB/c 
mouse in groups of five. At day 14 post-tumor inoculation, leukemia cells were 
recovered from the peritoneal cavity of the mice and counted by the Vi-Cell™ XR 
cell viability analyzer (Beckman Coulter). 
2) In vivo anti-tumor assay 
WEHI-3B JCS cells (1 x 10^ cells) in 0.5 ml PBS were inoculated i.p. into each 
BALB/c mouse in groups of five on day 0. Starting from day 8, cytokinins of 
different doses (20 mg/ml and 10 mg/ml for kinetin; 2 mg/ml and 1 mg/ml for kinetin 
riboside) were injected i.p. into the mice on alternate days. Totally four injections of 
cytokinins were performed. At day'16 post-tumor inoculation, the WEHI-3B JCS 
cells recoverable from the peritoneal cavity of the mice were counted by the 
Vi-Cell™ XR cell viability analyzer (Beckman Coulter). 
• 
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2.2.7 Analysis of Cell Cycle Profile / DNA Content by Flow 
Cytometry 
WEHI-3B JCS cells (2 x lO* cells/ml) were incubated with different 
concentrations of cytokinins at 37°C for different periods of time. Cells were 
collected and washed once with PBS by spinning at 400 x g for 5 minutes. The cells 
were then fixed with 1 ml 70% ethanol at 4°C for 30 minutes. After that cells were 
centrifuged at 400 x g for 10 minutes to remove the ethanol and then washed once 
with PBS and centrifuged again at 400 x g for 10 minutes. The cell pellets were then 
resuspended in 1 ml freshly prepared DNA staining solution containing propidium 
iodide (40 |ig/ml) and RNase A (8 |ig/ml) and incubated in dark at 37°C for 30 
minutes. Stained cells were then subjected to FACS analysis using FACSort flow 
cytometer (Becton Dickinson). Excitation was made at 488 nm and the emission at 
590 run was used to measure the red fluorescence intensity. Ten thousands of events 
were acquired for each determination. The cell cycle distribution was calculated 
using the ModFit 3.0 program (Verity Software House). 
2.2.8 Measurements of Apoptosis 
1) Determination of the mitochondrial membrane potential 
The mitochondrial membrane potential (A\|/m) of cytokinin-treated and 
untreated WEHI-3B JCS cells was measured by JC-1 staining method (Cossarizza et 
al” 1993; Dome et al., 2001). WEHI-3B JCS cells (2 x 10^ cells) were collected by 
centrifligation. The working JC-1 solution was prepared by diluting 1.3 |il of stock 
JC-1 solution (5 mg/ml in DMSO) with 1 ml warm PBS. The cell pellets were 
resuspended and incubated in the working JC-1 solution for 15 minutes at 37°C. The 
stained cells were subjected to flow cytometric analysis. Excitation was made at 488 
nm and the emissions of red (590 nm) and green (525 nm) fluorescence were ‘ 
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measured simultaneously by FACSort Flow cytometer (Becton Dickinson). 
2) Detection of DNA fragmentation by agarose gel electrophoresis 
Apoptotic DNA fragments were isolated from the apoptotic cells according to 
the method described by Herrmann et al (1994). Briefly, WEHI-3B JCS cells (3 x 
1O^  cells/ml) were incubated with indicated concentrations of cytokinins for different 
periods of time at 37°C. After various incubation periods, the WEHI-3B JCS cells 
were harvested and washed once with cold PBS by centrifugation at 400 x g for 5 
minutes. Cell counting with 0.4% trypan blue was performed to determine the cell 
viability. WEHI-3B JCS cells (2 x 10^) were spun down and treated with 200 i^l 
IGEPAL CA-630 lysis buffer for 10 minutes at 37°C. The samples were centrifiiged 
at 6,000 X g for 5 minutes to collect the supematants containing the apoptotic DNA 
fragments. The supematants were transferred to new microcentrifuge tubes and 50 |il 
5% SDS was added to each sample. The samples were incubated with 10 |xl 
DNase-free RNase A (10 mg/ml) for 90 minutes at 56°C to remove the cellular RNA. 
Twenty microlitres proteinase K (20 mg/ml) was then added and incubated for 90 
minutes at 56°C to remove the RNase and other proteins. The DNA was then 
I 
precipitated with 0.1 volume (30 |il) of 3 M sodium acetate (pH 5.2) and 2.5 volumes . 
(750 |Lil) of ice-cold absolute ethanol. After centrifiigation at 20,000 x g for 30 
minutes at 4°C, the DNA pellets were washed with 70% ice-cold ethanol and then 
with absolute ethanol followed by vacuum aspiration to discard the supematants. The 
pellets were air-dried for about 10 minutes, then resuspended in 20 \i\ TioEo.i buffer 
and incubated for 30 minutes at 37°C. Prior to performing agarose gel electrophoresis, 
the DNA samples were incubated for 5 minutes at 65°C to denature any DNA 
secondary structures. The samples were then chilled on ice for 3 minutes and 5 |il of 
5X gel loading buffer was added to the samples. Finally the samples were loaded • 
— 
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onto the wells of 2% agarose gel and subjected to electrophoresis at 80 volts. The 
gels were stained with ethidium bromide (1 |ag/ml) for 5 minutes and then destained 
with distilled water for 25 minutes. The DNA bands were detected under UV 
illumination by Gel Doc 2000 UV transilluminator (Bio-Rad Laboratories). 
3) Detection of DNA fragmentation by ELISA method 
DNA fragmentation of apoptotic cells was also detected by ELISA, using the 
Cellular DNA Fragmentation ELISA kit purchased from Roche Applied Science. The 
principle of the kit was based on the quantitative sandwich ELISA method to detect 
DNA fragments generated during apoptosis. Briefly, thymidine analogue BrdU was 
incorporated into the genomic DNA of proliferating cells. The BrdU-labeled DNA 
fragments released from apoptotic cells were detected by DNA specific antibodies 
and peroxidase-conjugated BrdU Fab fragments. 
First, a microplate was coated with 100 jil anti-DNA antibody in incubation 
buffer overnight. Afterwards； the antibody solution was removed and 200 |il 
incubation buffer was added to the wells to block any non-specific binding site. After 
washing three times with washing buffer, the coated microplate was ready to use. 
Meanwhile, a microplate was coated with poly-D-lysine solution (0.1 mg/ml in 
sterile deionized water) for 30 minutes at room temperature and then rinsed twice 
with sterile deionized water. After air-drying for 2 hours, the poly-D-lysine coated 
microplate was ready for suspension cell culture. 
On the other hand, WEHI-3B JCS cells (2 x 10^ cells/ml) were labeled with 
BrdU-containing complete medium for 6 hours at 37�C. The labelled cells were then 
centriftiged once at 400 x g for 5 minutes and then resuspended in BrdU-free 
complete medium. BrdU-labeled WEHI-3B JCS cells (5 x cells/ml) were seeded 
in poly-D-lysine coated microplate and treated with indicated concentrations of 
-61 - """“ ‘ 
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cytokinins for specific periods of time at 37°C. WEHI-3B JCS cells without BrdU 
labeling were included as anti-DNA antibody specificity control. The cells were 
harvested by spinning at 300 x g for 10 minutes and then lysed by mixing with 200 
|al incubation buffer and incubated for 30 minutes, at room temperature. The lysates 
were centrifiiged at 300 x g for 10 minutes. Afterwards, 100 fil supernatant was 
transferred to the anti-DNA antibody coated microplate. The microplate was then 
covered with adhesive foil and incubated at 4°C overnight. The supernatant was then 
removed by tapping and the wells were washed three times with washing buffer. 
After the last wash, the washing buffer was left in the well and subjected to 
microwave irradiation ( � 5 0 0 watts) for 5 minutes in order to fix and denature the 
bound DNA, with a beaker containing 300 ml tap water to absorb excess microwave 
energy. The microplate was then cooled down for 10 minutes at -20°C. Afterwards, 
100 i^l anti-BrdU-POD conjugate solution was added to the wells and incubated for 
90 minutes at room temperature. Then 100 TMB substrate solution was added to 
the wells and incubated in ‘ dark with gentle shaking for about 20 minutes. 
Background control was made by adding TMB substrate to an empty well. Twenty 
five microlitres 4 M H2SO4 was added to the wells to stop the enzymatic reaction. 
After gentle shaking for 1 minute, the absorbance was read at 450 run with reference 
at 690 run. The results were converted to enrichment factor (by the equation shown 
as follows) to determine the extent of DNA fragmentation, which reflected the degree 
of apoptosis. 
• Enrichment factor = Absorbance of sample - absorbance of background 
Absorbance of control - absorbance of background 
To normalize the cell number among the wells, the lysed cells (mainly nuclei) were 
stained with 20 jil 0.5% crystal violet solution and incubated at room temperature for • 
- -
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1 hour with gentle shaking. The cells were then destained with tap water and allowed 
to be air-dried. The violet color of the air-dried cells was released by adding 50 
1% SDS solution with gentle shaking for 30 minutes. The absorbance was read at 
540 run. 
3) Detection of reactive oxygen species 
The reactive oxygen species (ROS) levels of cytokinin-treated and untreated 
WEHI-3B JCS cells were measured by staining the cells with dihydroethidium. 
Viable cells (2 x 10^ cells) were suspended in 0.5 ml staining solution containing 10 
|iM of dihydroethidium. The samples were incubated at 37°C for 30 minutes and 
then FACS analysis was performed. Excitation was made at 488 nm and the emission 
at 590 nm was used to measure the red fluorescence intensity by the FACSort Flow 
cytometer (Becton Dickinson). 
% 
2.2.9 Assessment of Differentiation-associated Characteristics 
1) Morphological studies 
WEHI-3B JCS cells (2,500 cells/ml) were incubated with different 
concentrations of cytokinins at 37°C for 3 days. The cells (2 x 10^) were fixed onto a 
microscopic glass slide by cytocentrifugation at 500 rpm for 5 minutes using the 
Shandon Cytospin 3 centrifuge (Shandon Scientific Ltd., U.K.). The cells were then 
air-dried, then stained with each Hemacolor staining solution in the order of Solution 
1，Solution 2 and Solution 3 for 15 seconds each and then destained under running 
tap water. The stained cells were allowed to be air-dried. Finally, the air-dried cells 
on the slides were mounted with a neutral mounting medium, Canada Balsam 
(Sigma-Aldrich Co.) and the cell morphology was examined under the Axioskop 
Plus II light microscope (Carl Zeiss, Inc). 
~ -
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2) Surface antigen immunophenotyping by flow cytometry 
WEHI-3B JCS cells (2,500 cells/ml) were incubated with different 
concentrations of cytokinins at 37°C for 3 days. The treated cells were collected and 
then the culture flasks were washed once with cold PBS and shaken vigorously to 
detach any differentiated cells attached to the culture flasks. The harvested cells were 
suspended in 2 ml PBS. Cell count was performed using hemocytometer. WEHI-3B 
JCS cells (5 X 10^) were transferred to a 15 ml centrifuge tube containing 10 ml 
ice-cold FACS medium and then centrifuged at 400 x g for 5 minutes. For the 
following procedure, ice-cold FACS medium was used in all steps. The supernatant 
was removed by aspiration and suspended in 0.2 ml FACS medium containing rat 
IgG (10 |ig/ml) and mouse IgG (10 |ig/ml) which could bound to the Fc receptors of 
the WEHI-3B JCS cells so as to block non-specific binding. The cell suspensions 
were incubated at 4°C for 30 minutes with occasional shaking. Afterwards, the cells 
were washed once with FACS medium. The cell pellets were suspended in 50 \i\ 
FACS medium and transferred to a microcentriftige tube. Fifty microlitres of FACS 
medium containing primary antibody (1 ^ig) was added to the cells. For the 
background control, 50 |xl FACS medium contained no antibody was added. After 
incubated at 4 � C for 30 minutes (with occasional shaking), the cells were washed 
( 
twice with FACS medium by spinning at 400 x g for 5 minutes at 4°C after each 
wash. Then the cells were suspended in 100 ice-cold FACS medium containing 
FITC-conjugated goat anti-rat IgG antibody (1 fig). After incubation in dark at 4 � C 
for 30 minutes (with occasional shaking), the cells were washed three times with 
FACS medium by spinning at 400 x g for 5 minutes at 4°C. The cell pellet was 
suspended in 0.6 ml 1% paraformaldehyde in a FACS tube. FACS analysis was then 
performed to measure the green fluorescence intensity, with excitation at 488 run and 
f 
emission at 525 run by the FACSort Flow cytometer (Becton Dickinson). 
— 
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3) Assay of non-specific esterase activity 
WEHI-3B JCS cells (2500 cells/ml) were incubated with different 
concentrations of cytokinins at 37°C for 3 days. The treated cells were collected and 
then the culture flasks were washed once with cold PBS and shaken vigorously to 
detach any differentiated cells attached to the culture flasks. The harvested cells were 
suspended in 2 ml HI-FBS-RPMI medium. Viable cell count was performed using 
hemocytometer. WEHI-3B JCS cells (2 x 10^) were suspended in 200 |il 10% 
HI-FBS-RPMI medium in a microcentrifuge tube. Fluorescein diacetate (4 |ig) was 
added to the tubes. The cells were then incubated at room temperature in dark for 30 
minutes with occasional shaking. Afterwards, the cells were washed twice with 
FACS medium by spinning at 400 x g for 5 minutes at 4°C. The pellet was suspended 
in 0.6 ml 1% paraformaldehyde in FACS tube and protected from light. FACS 
analysis was performed to measure the green fluorescence intensity, with excitation 
at 488 nm and emission at 525 run by the FACSort Flow cytometer (Becton 
Dickinson). • 
2.2.10 Gene Expression Study 
There were four stages in the study of gene expression and they were described in 
detail as follows: 
1) Isolation of total cellular RNA 
WEHI-3B JCS cells (3 x cells/ml) were treated with the indicated 
concentrations of cytokinins for different periods of time at 37°C. The cells were 
harvested by centrifugation at 400 x g for 5 minutes at 4°C. One ml TRIZOL reagent 
was added to lyse the cells and homogenized with repetitive pipetting. The cell lysate 
solutions were incubated at room temperature for 5 minutes to allow the complete 
dissociation of nucleoprotein complexes. Chloroform (200 |4,1) per 1 ml TRIZOL . 
• - 6 5 - — 
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reagent was added to the samples and shaken vigorously by hand for 15 seconds. The 
samples were incubated at room temperature for 3 minutes and were then centrifuged 
at 12,000 X g for 15 minutes at 4°C. After centrifugation, 500 i^l of upper aqueous 
layer containing RNA was transferred to a new microcentrifuge tube. Isopropanol 
(500 |j,l) was mixed with the aqueous portion and incubated at room temperature for 
10 minutes to precipitate the RNA. The samples were then centrifuged at 12,000 x g 
� 
for 10 minutes at 4°C. The supematants were discarded while the RNA pellets were 
washed with 1 ml 75% ethanol per ml of Trizol used in homogenization. The samples 
were mixed by vortexing and then centrifuged at 7,500 x g for 5 minutes at 4°C. The 
supematants were removed by vacuum aspiration and the RNA pellets were air-dried 
for 5 to 10 minutes. The dried RNA pellets were dissolved in 30 jil DEPC-treated 
water and incubated at 56°C for 5 min to allow complete dissolution. The RNA 
solutions were stored at -70°C until use. 
The concentration of RNA samples was estimated by a 100-fold dilution of the 
RNA samples and measuring the absorbance at 260 rnn. The purity of the RNA 
samples was estimated by measuring the ratio of A260/A280 (within the range of 1.5 
to 1.8). The integrity of RNA was checked by electrophoresis of 1 |ig RNA on a 1% 
agarose gel. Two bright bands (28S and 18S rRNA) should be observed. Small 
aliquots of RNA with a working concentration of 0.5 \igl\i\ were prepared with 
DEPC-treated water and stored at -70°C until use. 
2) Reverse transcription (RT) 
The total cellular RNA was incubated at 65°C for 5 minutes to denature the 
RNA and then chilled on ice prior to be used in the complementary DNA (cDNA) 
synthesis. Reverse transcription was performed in the GeneAmp PGR System 9700 
thermocycler (Applied Biosystems). Total RNA (1 ^g) was mixed with a reaction 
ft 
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mixture containing IX M-MLV first strand buffer, 0.5 mM of each dNTP (dATP, 
dTTP，dCTP, dGTP)，10 mM DTT，0.1 |ig oligo(dT)12-18, 40 units of RNaseOUT™ 
recombinant ribonuclease inhibitor and 200 units of M-MLV reverse transcriptase. 
The mixture was incubated at 37°C for 1 hour. Afterwards, the mixture was incubated 
at 99°C for 5 minutes to denature the reverse transcriptase and dissociate the cDNAs 
from the RNA templates and then chilling the samples on ice to inactivate the reverse 
transcriptase. The synthesized cDNA products were stored at -20°C until use. 
3) Polymerase chain reaction (PCJR) 
The cDNA samples prepared by reverse transcription were diluted to 10 |ig/ml 
with deionized water. For each sample, cDNA (equivalent to 0.05 i^g of total RNA) 
in 5 |j,l was mixed with a 20 \i\ reaction mixture containing IX reaction buffer IV, 1 
unit of Thermoprime Plus DNA polymerase, 0.2 mM of each dNTP (dATP, dTTP, 
dCTP, dGTP), 1.5 mM MgCb and 0.2 |iM of each sense and antisense 
oligonucleotide primers in a PGR tube. A negative control with no cDNA sample was 
prepared to check for any contaminations. To check if RNA samples were free from 
genomic DNA contamination, diluted RNA samples without RT were subjected to 
the amplification of house keeping gene glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH). The reactions were performed in the GeneAmp PGR System 9700 
thermocycler (Applied Biosystems). The samples were first denatured at 94°C for 5 
minutes, followed by 20 to 35 thermal cycles with denaturation at 94°C for 30 
seconds, annealing at 56°C to 61°C for 1 minute and elongation at 72°C for 1 minute. 
After the last cycle, one more step in elongation at 72°C for 5 minutes was performed 
to ensure the completeness of the reaction. The amplified PGR products were cooled 
down and stored at 4°C until performing gel electrophoresis. The annealing 
temperature and the number of cycles were optimized empirically for each primer s e t . . 
• “ — 
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Cycle titration was performed in order to find out the optimized reaction cycles that 
PGR products were in the linear range. 
4) Agarose gel electrophoresis 
The PCR products were analyzed by 2% agarose gel electrophoresis. PGR 
products (5 |al) were mixed with 1 6X gel loading buffer. The mixture was 
subjected to electrophoresis on a 2% agarose gel buffered with 0.5X TBE buffer at a 
constant voltage of 80 volts for 1 hour. 100 bp DNA ladder (0.5 |ag) (Invitrogen Life 
Technologies, Inc.) was loaded as the size marker. After electrophoresis, the gel was 
stained with ethidium bromide solution (1 |ig/ml) for 5 minutes and was destained 
with distilled water for 25 minutes. The stained gel was then analyzed under UV 
illumination by the Gel Doc 2000 UV transilluminator (Bio-Rad laboratories). The 
band intensities were estimated using ImageQuant program (Molecular Dynamics). 
House keeping gene GAPDH was used as an endogenous control to normalize the 
cDNA loading. The relative band intensities were compared with the band of 
untreated control, after normalization with the respective GAPDH. Differences of 
relative intensity of the bands larger than 100% were considered as significant 
changes whereas changes less than 50% were regarded as non-significant variations 
(Lung et al, 2005). Differences of relative intensity between 50% and 100% were 
defined as slight changes in the present study. 
2.2.11 Measurement of Caspase Activity 
I 
There were three stages in the measurement of caspase activity: 
1) Treatment of the cells and extraction of proteins 
Caspase activities of cytokinin-treated cells were measured using the method 
described by Mack et al (2000). WEHI-3B JCS cells (3 x 10^ cells/ml) were treated ‘ 
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with the indicated concentrations of cytokinins for different periods of time at 37°C. 
\ 
The cells were then harvested and washed twice with cold PBS by centrifuging at 
400 X g for 5 minutes at 4�C. Cells (2 x 10^) were mixed with 100 |il ice-cold lysis 
buffer (50 \x\ / 106 cells) and kept on ice for 10 minutes. The mixture was then 
vortexed vigorously and centrifliged at 20,000 x g for 10 minutes at 4°C. The 
supematants were collected for the next stages. 
2) Quantification of proteins 
The protein concentration of the cell lysates was determined by the Bradford 
protein assay. Briefly，bovine serum albumin (BSA) standard solutions at 2 ^g/ml, 4 
l^g/ml，6 ^ig/ml, 8 |ig/ml, and 10 ^ig/ml were prepared with deionized water in 
duplicate from the 2 mg/ml BSA stock solution. Protein samples (2 i^l each) were 
diluted with 798 \i\ deionized water. BSA standards (800 ^il) or protein samples were 
mixed with 200 |li1 Bradford reagent (Bio-Rad Laboratories). The mixtures were then 
incubated at room temperature for 5 minutes. The absorbance at 595 run was 
measured using the Bradford reagent (200 |il) in deionized water (800 |il) as the 
blank. A standard curve was constructed automatically by the BioPhotometer 
(Eppendorf) and the protein concentration of cell lysates was determined by the 
BioPhotometer. Fifty micrograms of the cell lysate protein were subjected to the 
fluorometric measurement of caspase activity. 
3) Fluorometric measurement of caspase activity 
The, correlation between caspase activities with the signal detection was 
confirmed by setting control reactions with caspase inhibitors. Briefly, 50 |il cell 
lysate (volume adjusted with cell lysis buffer) was incubated with or without 1 |il of 
the corresponding caspase inhibitor (1 |iM Ac-DEVD-CHO for caspase 3, 1 ^M 
- -
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Ac-IETD-CHO for caspase 8，1 i^M Ac-LEHD-CHO - for caspase 9) and 50 i^l 2X 
reaction buffer for 30 minutes at 37°C. Afterwards, the cell lysate (incubated with or 
without caspase inhibitor) and reaction buffer mixture were incubated with the 1 \i\ of 
the corresponding specific caspase substrate for 1 hour at 37°C. The fluorescence 
intensity of the cleaved products was measured by the Polarizon fluorescent plate 
reader (Tecan Group). Standard curves were then plotted by serial dilution of the 
AMC or AFC solution to 0.5 }aM, 1 \iM, 2 fiM and 4 jiM with the lysis buffer. The 
caspase activity was represented by the amount of fluorescence intensity of the 
cleaved products which can be quantified by comparing with the standard curve of 
free fluorescence units. The caspase activity converted from FU was calculated as 
below: 
Caspase activity = FU / slope of standard curve 
2.2.12 Statistical analysis 
Each experiment was performed at least two to three times and the results from 
one representative experiment were presented. The data were expressed as arithmetic 
mean 士 standard error. Experimental data were processed using Excel program 
(Microsoft). The Student's t-test was used for statistical analysis and calculated by 
SPSS 14.0 program (SPSS, Inc.). Normally, P-value (p) < 0.05 was regarded as 
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3.1 Introduction 
Cytokinins are abundant in plants and are important phytohormones. Recently, 
it was reported that cytokinins exhibit potent in vitro growth-inhibitory effect on the 
human promyelocytic leukemia cell line HL-60 (Ishii et al., 2002; Vermeulen et al, 
2002). Yet, the data so far available on the anti-proliferative effect of cytokinins on 
myeloid leukemia cells are inadequate for elucidation of the action mechanism of 
cytokinins, and the cellular and molecular basis by which cytokinins can exert their 
anti-tumor effects on leukemia cells remain largely unresolved." 
In the present study, the effects of various cytokinins and their riboside 
derivatives on the proliferation of a panel of murine and human leukemia cell lines 
representing different stages or lineages of abnormal hematopoietic development 
were studied. In addition, the cytotoxic effect of cytokinins on normal cell lines and 
primary cultures of macrophages was investigated. Using the murine 
myelomonocytic leukemia WEHI-3B JCS cells as a cell model, the kinetics and 
reversibility of the anti-proliferative activity of cytokinins were studied. Moreover, 
the effect of cytokinins on the cell cycle progression of WEHI-3B JCS cells was 
analyzed by flow cytometry. The expression of several cell cycle regulatory genes in 
cytokinin-treated WEHI-3B JCS cells was also examined by reverse 
transcription-polymerase chain reaction (RT-PCR). On the other hand, the effect of 
cytokinins on the in vivo growth and tumorigenicity of leukemia WEHI-3B JCS cells 
was investigated using syngeneic BALB/c mice. 
» 
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3.2 Results 
3.2.1 Effects of Various Cytokinins and Their Riboside Derivatives on the 
Proliferation of Murine Myelomonocytic Leukemia WEHI-3B JCS Cells 
In Vitro 
The effects of cytokinins and their ribosides on the proliferation of WEHI-3B 
JCS cells were initially investigated to identify the anti-tumor activity of these 
compounds. Tritiated thymidine incorporation assay was applied to study the 
proliferation of WEHI-3B JCS cells, as described in Chapter 2. Cell proliferation is 
proportional to the amount of [^H]-TdR incorporation which is measured by the 
radioactivity in scintillation counting. The murine myeloid leukemia WEHI-3B JCS 
cells were selected in the present study because this cell line has relatively short 
doubling time, well characterized in our group and the cells are sensitive to a wide 
variety of natural products and cytokines. In addition, the WEHI-3B JCS cells could 
be transplanted into syngeneic BALB/c mice without rejection and therefore allow, 
the study of anti-tumor activity in vivo. Four common cytokinins (kinetin, 
benzyladenine, isopentenyladenine and zeatin) plus the parental compound adenine, 
and their corresponding riboside derivatives (kinetin riboside, benzyladenosine, 
isopentenyladenosine, zeatin riboside and adenosine) were examined for their 
inhibitory effects on the proliferation of WEHI-3B JCS cells using the pH]-TdR 
incorporation assay. 
As shown in Fig. 3.1 to 3.10, the selected cytokinins and their riboside 
derivatives could inhibit the proliferation of WEHI-3B JCS cells in a dose-dependent 
manner. Table 3.1 summarized the estimated IC50 values of the cytokinin pairs 
selected in the present study on the proliferation of WEHI-3B JCS cells. Among the 
“ TJjT-
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compounds tested, all the riboside derivatives were found to be more potent than 
their cytokinin counterparts, the difference in their estimated IC50 values ranged from 
2-fold to 80-fold. The anti-proliferative effect of adenine was about 9-fold less potent 
than that of zeatin，the cytokinin with highest IC50 value on WEHI-3B JCS cells. On 
the other hand, the anti-proliferative effect of adenosine was 8 fold less potent than 
zeatin riboside, the cytokinin riboside with highest IC50 value on WEHI-3B JCS cells. 
Comparing the differences in IC50 values between cytokinin and its corresponding 
riboside derivative, kinetin and kinetin riboside were chosen for further studies, 
because their IC50 value difference was the largest (about 80-fold). The control 
solvent, 0.1% (v/v) DMSO, had consistently found to have no significant inhibitory 
effect on the proliferation of WEHI-3B JCS cells (Fig. 3.11). 
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Fig. 3.1: Effect of kinetin (KI) on the proliferation of the murine 
myelomonocytic leukemia WEHI-3B JCS cells. WEHI-3B JCS cells (1 x lO"^  
cells/ml) were incubated with different concentrations of kinetin (0 - 200 |iM) at 
37°C for 48 hours. Cell proliferation was measured by [^H]-TdR incorporation as 
described in Chapter 2. The cells were pulsed with 0.5 |iCi of [^H]-TdR for 6 hours 
before harvest. The results were expressed as % inhibition of [^H]-TdR incorporation 
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Fig. 3.2: Effect of benzyladenine (BA) on the proliferation of the murine 
myelomonocytic leukemia WEHI-3B JCS cells. WEHI-3B JCS cells (1 x lO* 
cells/ml) were incubated with different concentrations of benzyladenine (0 一 200 }iM) 
at 37°C for 48 hours. Cell proliferation was measured by [^H]-TdR incorporation as 
described in Chapter 2. The cells were pulsed with 0.5 [iCi of [^H]-TdR for 6 hours 
before harvest. The results were expressed as % inhibition of [^H]-TdR incorporation 
compared to the control. Each point represents the mean 土 S.E. of quadruplicate, 
cultures. 
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Fig. 3.3: Effect of isopentenyladenine (IPA) on the proliferation of the murine 
myelomonocytic leukemia WEHI-3B JCS cells. WEHI-3B JCS cells (1 x lO* 
cells/ml) were incubated with different concentrations of isopentenyladenine (0 一 200 
|iM) at 37�C for 48 hours. Cell proliferation was measured by [^H]-TdR 
incorporation as described in Chapter 2. The cells were pulsed with 0.5 fiCi of 
[^H]-TdR for 6 hours before harvest. The results were expressed as % inhibition of 
[^H]-TdR incorporation compared to the control. Each point represents the mean 士 
S.E. of quadruplicate cultures. 
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Fig. 3.4: Effect of trans-ztidm (ZE) on the proliferation of the murine 
myelomonocytic leukemia WEHI-3B JCS cells. WEHI-3B JCS cells (1 x 
cells/ml) were incubated with different concentrations of trans-ZQoSm (0 - 200 ^M) 
at 37°C for 48 hours. Cell proliferation was measured by [^H]-TdR incorporation as 
described in Chapter 2. The cells were pulsed with 0.5 |iCi of [^H]-TdR for 6 hours 
before harvest. The results were expressed as % inhibition of [^H]-TdR incorporation 
compared to the control. Each point represents the mean 土 S.E. of quadruplicate, 
cultures. 
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Fig. 3.5: Effect of adenine on the proliferation of the murine myelomonocytic 
leukemia WEHI-3B JCS cells. WEHI-3B JCS cells (1 x 10^  cells/ml) were 
incubated with different concentrations of adenine (0 - 1000 ^M) at 37°C for 48 
hours. Cell proliferation was measured by [^H]-TdR incorporation as described in 
Chapter 2. The cells were pulsed with 0.5 |aCi of [^H]-TdR for 6 hours before harvest. 
The results were expressed as % inhibition of [^H]-TdR incorporation compared to 
the control. Each point represents the mean 士 S.E. of quadruplicate cultures. 
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Fig. 3.6: Effect of kinetin riboside (KR) on the proliferation of the murine 
myelomonocytic leukemia WEHI-3B JCS cells. WEHI-3B JCS cells (1 x 10^  
cells/ml) were incubated with different concentrations of kinetin riboside ( 0 - 1 0 i^M) 
at 37�C for 48 hours. Cell proliferation was measured by [^H]-TdR incorporation as 
described in Chapter 2. The cells were pulsed with 0.5 |iCi of [^H]-TdR for 6 hours 
before harvest. The results were expressed as % inhibition of [^H]-TdR incorporation 
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Fig. 3.7: Effect of benzyladenosine (BAR) on the proliferation of the murine 
myelomonocytic leukemia WEHI-3B JCS cells. WEHI-3B JCS cells (1 x lO* 
cells/ml) were incubated with different concentrations of benzyladenosine (0 - 10 
|iM) at 37°C for 48 hours. Cell proliferation was measured by [^H]-TdR 
incorporation as described in Chapter 2. The cells were pulsed with 0.5 \iCi of 
[^H]-TdR for 6 hours before harvest. The results were expressed as % inhibition of 
[^H]-TdR incorporation compared to the control. Each point represents the mean 士 
S.E. of quadruplicate cultures. 
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Fig. 3.8: Effect of isopentenyladenosine (IPAR) on the proliferation of the 
murine myelomonocytic leukemia WEHI-3B JCS cells. WEHI-3B JCS cells (1 x 
104 cells/ml) were incubated with different concentrations of isopentenyladenosine 
( 0 - 1 0 |iM) at 37°C for 48 hours. Cell proliferation was measured by [^H]-TdR 
incorporation as described in Chapter 2. The cells were pulsed with 0.5 ^Ci of 
[^H]-TdR for 6 hours before harvest. The results were expressed as % inhibition of 
[^H]-TdR incorporation compared to the control. Each point represents the mean 士 
S.E. of quadruplicate cultures. 
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Fig. 3.9: Effect of rrans-zeatin riboside (ZR) on the proliferation of the murine 
myelomonocytic leukemia WEHI-3B JCS cells. WEHI-3B JCS cells (1 x lO^  
cells/ml) were incubated with different concentrations of trans-ztdiXm riboside (0 -
200 laM) at 37°C for 48 hours. Cell proliferation was measured by [^H]-TdR 
incorporation as described in Chapter 2. The cells were pulsed with 0.5 jiCi of 
[^H]-TdR for 6 hours before harvest. The results were expressed as % inhibition of 
[^H]-TdR incorporation compared to the control. Each point represents the mean 土 
S.E. of quadruplicate cultures. 
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Fig. 3.10: Effect of adenosine on the proliferation of the murine myelomonocytic 
leukemia WEHI-3B JCS cells. WEHI-3B JCS cells (1 x 10^  cells/ml) were 
incubated with different concentrations of adenosine (0 - 1000 |iM) at 37°C for 48 
hours. Cell proliferation was measured by [^H]-TdR incorporation as described in 
Chapter 2. The cells were pulsed with 0.5 |iCi of [^H]-TdR for 6 hours before harvest. 
The results were expressed as % inhibition of [^H]-TdR incorporation compared to 
the control. Each point represents the mean 土 S.E. of quadruplicate cultures. 
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Fig. 3.11: Effect of DMSO on the proliferation of the murine myelomonocytic 
leukemia WEHI-3B JCS cells. WEHI-3B JCS cells (1 x 10^  cells/ml) were 
incubated with different concentrations of solvent DMSO (0 - 0.1 %�v/v) at 37�C 
for 48 hours. Cell proliferation was measured by [^H]-TdR incorporation as 
described in Chapter 2. The cells were pulsed with 0.5 [iCi of [^H]-TdR for 6 hours 
before harvest. The results were expressed as % inhibition of [^H]-TdR incorporation 
compared to the control. Each point represents the mean 土 S.E. of quadruplicate 
cultures. ‘ 
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Table 3.1: The estimated IC50 values of various cytokinins and their 
corresponding riboside derivatives on the proliferation of the murine 
myelomonocytic leukemia WEHI-3B JCS cells. 
Cytokinin & cytokinin related compounds Estimated IC50 (|iM) 
Cytokinin Kinetin (KI) 一 
Benzyladenine (BA) 〜40 
Isopentenyladenine (IPA) ~ 50 
Zeatin (ZN) 〜100 
Adenine 〜900 
Cytokinin riboside Kinetin riboside (KR) 〜1 
Benzyladenosine (BR) ~ 2.5 
Isopentenyladenosine (IPAR) 〜3 
Zeatin riboside (ZR) - 5 0 
Adenosine ~ 400 
IC50 value is the estimated concentration of cytokinin or their corresponding riboside 
derivative which causes 50% inhibition on the in vitro proliferation of the murine 
myelomonocytic leukemia WEHI-3B JCS cells, as determined by the incorporation 
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3.2.2 Cytotoxicity of Kinetin and Kinetin Riboside on the WEHI-3B JCS Cells 
In Vitro 
The cytotoxicity of kinetin and kinetin riboside on the WEHI-3B JCS cells was 
analyzed by the trypan blue exclusion assay and cytotoxic lactate dehydrogenase 
(LDH) release assay. In trypan blue exclusion assay, WEHI-3B JCS cells treated with 
kinetin or its riboside for 24, 48 and 72 hours were subjected to viable cell counting. 
Results showed that the viability of WEHI-3B JCS cells were over 80% under the 
various treatment conditions (Fig. 3.12 and 3.13). 
In the cytotoxic LDH release study, lactate dehydrogenase is present 
abundantly in the plasma membrane and would be released to the culture medium � 
from damaged plasma membrane upon induction of cytotoxic agent like Triton-X 
100 (Decker and Lohmami-Matthes, 1988). By measuring the amount of LDH in 
culture medium, the cytotoxic activity of drugs could be measured. Results showed 
that neither kinetin nor kinetin riboside led to a significant release of LDH from 
WEHI-3B JCS cells (Table 3.2). These data suggest that both kinetin and its riboside 
f 
had no direct cytotoxicity on the WEHI-3B JCS cells. 
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Fig. 3.12: Effect of kinetin on the viability of murine myelomonocytic leukemia 
‘ WEHI-3B JCS cells. WEHI-3B JCS cells (1 x 10^  cells/ml) were incubated with 
different concentrations of kinetin (0 - 200 i^M) at 37�C for 24，48 and 72 hours. The 
numbers of viable and non-viable cells were counted by trypan blue exclusion assay 
using Vi -Ce lF^R cell viability analyzer (Beckman Coulter). Results were 
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Fig. 3.13: Effect of kinetin riboside on the viability of murine myelomonocytic 
leukemia WEHI-3B JCS cells. WEHI-3B JCS cells (1 x cells/ml) were 
incubated with different concentrations of kinetin riboside ( 0 - 5 p,M) at 37°C for 24， 
48 and 72 hours. The numbers of viable and non-viable cells were counted by trypan 
blue exclusion assay using Vi-Cell™XR cell viability analyzer (Beckman Coulter). 
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Table 3.2; Cytotoxic effect of kinetin and kinetin riboside on the murine 
myelomonocytic leukemia WEHI-3B JCS cells as measured by the LDH release 
assay. 
Treatment of % Cytotoxicity at 
WEHI-3B JCS cells “ “ 
4 hours 8 hours 12 hours 
with 
Medium 0.0 ±2.2 0.0 ±4.0 0.0 ±5.0 , 
Solvent control 0.0 土 3.2 0.0 土 4.1 -0.5 土 4.2 
KI (200 -1.0 士 2.1 -0.6 ±3.3 -1.3 ±4.0 
KR (4 -0.9 ±4.0 -1.3±3.1 -1.0 ±5.0 
Triton-X 100 (1%) 100 士 8.0 100 ±7.1 100 土 10.3 
WEHI-3B JCS cells (1 x 10^ cells/ml) were incubated with 0.1% (v/v) DMSO as 
solvent control, 200 \iM kinetin or 4 i^M kinetin riboside at 37°C for 4, 8 and 12 
hours. Cytotoxicity was determined by measuring the amount of cellular LDH 
released to the culture supernatant, using the cytotoxic LDH release kit (BioVision 
Inc.). Triton-X 100 (1%, v/v) was included as a control for maximum LDH release. 
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3.2.3 Effects of Kinetin and Kinetin Riboside on the Proliferation of Various 
Leukemia Cell Lines In Vitro 
In addition to the murine myelomonocytic leukemia WEHI-3B JCS cells, the 
proliferation of various leukemia cell lines of mouse or human origin, representing 
different malignant stages of hematopoiesis, following kinetin and its riboside 
treatment was examined. The murine cell lines included myeloblastic leukemia Ml 
(Fig. 3.14), macrophage-like leukemia PU5-1.8 (Fig. 3.15) and J774A.1 (Fig. 3.16)， 
T cell lymphoma MBL-2 (Fig. 3.17) and lymphocytic leukemia L1210 (Fig. 3.18). 
On the other hand, the human cell lines included promyelocytic leukemia HL-60 (Fig. 
3.19) and NB-4 (Fig. 3.20), chronic myelogenous leukemia K-562 (Fig. 3.21), acute 
eosinophilic leukemia EoL-1 (Fig. 3.22), histiocytic lymphoma U-937 (Fig. 3.23) 
and megakaryoblastic-like leukemia MEG-01 (Fig. 3.24). The IC50 values of kinetin 
* 
and kinetin riboside on the proliferation of these cell lines were summarized in Table 
3.3. The results showed that both kinetin and kinetin riboside had a broad spectrum 
of anti-proliferative activity on leukemia cell lines at different lineages of 
development and at different maturation stages. Generally, kinetin riboside was more 
potent than kinetin in terms of anti-proliferative effect on all the leukemia cell lines 
tested. 
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Fig. 3.14: Effects of kinetin (KI) and kinetin riboside (KR) on the proliferation 
of the murine myeloblastic leukemia Ml cells. Ml cells (5 x lO* cells/ml) were 
incubated with different concentrations of (A) kinetin (0 - 200 |iM) or (B) kinetin 
riboside (0 - 10 jiM) at }TC for 48 hours. Cell proliferation was measured by 
[^H]-TdR incorporation as described in Chapter 2. The cells were pulsed with 0.5 
)iCi of [^H]-TdR for 6 hours before harvest. The results were expressed as % 
inhibition of [^H]-TdR incorporation compared to the control. Each point represented 
the mean 土 S.E. of quadruplicate cultures. 
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Fig. 3.15: Effects of kinetin (KI) and kinetin riboside (KR) on the proliferation 
of the murine macrophage-like leukemia PU5-1.8 cells. PUS-1.8 cells (2.5 x 
cells/ml) were incubated with different concentrations of (A) kinetin (0 - 200 i^M) or 
(B) kinetin riboside ( 0 - 1 0 |iM) at 37°C for 48 hours. Cell proliferation was 
measured by [^H]-TdR incorporation as described in Chapter 2. The cells were 
pulsed with 0.5 }iCi of [^H]-TdR for 6 hours before harvest. The results were 
expressed as % inhibition of [^H]-TdR incorporation compared to the control. Each 
point represented the mean 土 S.E, of quadruplicate cultures. 
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Fig. 3.16: Effects of kinetin (KI) and kinetin riboside (KR) on the proliferation 
of the murine macrophage-Iike leukemia J774A.1 cells. J774A.1 cells (2.5 x lO^ 
cells/ml) were incubated with different concentrations of (A),kinetin (0 - 200 |iM) or 
(B) kinetin riboside ( 0 - 1 0 jiM) at 37°C for 48 hours. Cell proliferation was 
measured by [^H]-TdR incorporation as described in Chapter 2. The cells were 
pulsed with 0.5 ^iCi of [^H]-TdR for 6 hours before harvest. The results were 
expressed as % inhibition of [^H]-TdR' incorporation compared to the control. Each 
point represented the mean 土 S.E. of quadruplicate cultures. 
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Fig. 3.17: Effects of kinetin (Kl) and kinetin riboside (KR) on the proliferation 
of the murine T cell lymphoma MBL-2 cells. MBL-2 cells (1 x cells/ml) were 
incubated with different concentrations of (A) kinetin (0 - 200 jiM) or (B) kinetin 
riboside ( 0 - 1 0 |iM) at 37°C for 48 hours. Cell proliferation was measured by 
[^H]-TdR incorporation as described in Chapter 2. The cells were pulsed with 0.5 
jiCi of [^H]-TdR for 6 hours before harvest. The results were expressed as % 
inhibition of [^H]-TdR incorporation compared to the control. Each point represented 
« 
the mean 土 S.E. of quadruplicate cultures. 
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Fig. 3.18: Effects of kinetin (KI) and kinetin riboside (KR) on the proliferation 
of the murine lymphocytic leukemia L1210 cells. L1210 cells (1 x cells/ml) 
were incubated with different concentrations of (A) kinetin (0 - 200 piM) or (B) 
kinetin riboside ( 0 - 1 0 pM) at 37°C for 48 hours. Cell proliferation was measured 
by [^H]-TdR incorporation as described in Chapter 2. The cells were pulsed with 0.5 
)j,Ci of [^H]-TdR for 6 hours before harvest. The results were expressed as % 
inhibition of [^H]-TdR incorporation compared to the control. Each point represented 
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Fig. 3.19: Effects of kinetin (KI) and kinetin riboside (KR) on the proliferation 
of the human promyelocytic leukemia HL-60 cells. HL-60 cells (5 x cells/ml) 
were incubated with different concentrations of (A) kinetin (0 一 200 ^M) or (B) 
kinetin riboside ( 0 - 1 0 fiM) at 37°C for 48 hours. Cell proliferation was measured 
by [^H]-TdR incorporation as described in Chapter 2. The cells were pulsed with 0.5 
jiCi of [^H]-TdR for 12 hours before harvest. The results were expressed as % 
inhibition of [^H]-TdR incorporation compared to the control. Each point represented 
the mean 土 S.E. of quadruplicate cultures. 
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Fig. 3.20: Effects of kinetin (KI) and kinetin riboside (KR) on the proliferation 
of the human acute promyelocytic leukemia NB-4 cells. NB-4 cells (5 x 
cells/ml) were incubated with different concentrations of (A) kinetin (0 一 200 fxM) or 
(B) kinetin riboside (0 — 10 fiM) at 37�C for 48 hours. Cell proliferation was 
measured by [^H]-TdR incorporation as described in Chapter 2. The cells were 
pulsed with 0.5 |LiCi of [^H]-TdR for 12 hours before harvest. The results were 
expressed as % inhibition of [^H]-TdR incorporation compared to the control. Each 
point represented the mean 土 S.E. of quadruplicate cultures. 
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Fig. 3.21: Effects of kinetin (KI) and kinetin riboside (KR) on the proliferation 
of the human chronic myelogenous leukemia K-562 cells. K-562 cells (2.5 x 
cells/ml) were incubated with different concentrations of (A) kinetin (0 - 200 |a,M) or 
(B) kinetin riboside (0 - 10 i^ M) at 37�C for 48 hours. Cell proliferation was 
measured by [^H]-TdR incorporation as described in Chapter 2. The cells were 
pulsed with 0.5 jiCi of [^H]-TdR for 6 hours before harvest. The results were 
expressed as % inhibition of [ H]-TdR incorporation compared to the control. Each 
point represented the mean 士 S.E. of quadruplicate cultures. 
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Fig. 3.22: Effects of kinetin (KI) and kinetin riboside (KR) on the proliferation 
of the human acute eosinophilic leukemia EoL-1 cells. EoL-1 cells (5 x 
cells/ml) were incubated with different concentrations of (A) kinetin (0 - 200 |iM) or 
(B) kinetin riboside (0 — 10 fiM) at 37°C for 48 hours. Cell proliferation was 
measured by [^H]-TdR incorporation as described in Chapter 2. The cells were 
pulsed with 0.5 \xCi of [^H]-TdR for 12 hours before harvest. The results were 
expressed as % inhibition of [^H]-TdR incorporation compared to the control. Each 
point represented the mean 土 S.E. of quadruplicate cultures. ‘ 
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Fig. 3.23: Effects of kinetin (KI) and kinetin riboside (KR) on the proliferation 
of the human histocytic lymphoma U-937 cells. U-937 cells (5 x lO"^  cells/ml) were 
incubated with different concentrations of (A) kinetin (0 - 200 jiM) or (B) kinetin 
riboside (0—10 ^iM) at 37°C for 48 hours. Cell proliferation was measured by 
[^H]-TdR incorporation as described in Chapter 2. The cells were pulsed with 0.5 
|iCi of [^H]-TdR for 9 hours before harvest. The results were expressed as % 
inhibition of [^H]-TdR incorporation compared'to the control. Each point represented 
the mean 士 S.E. of quadruplicate cultures. ‘ 
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Fig. 3.24: Effects of kinetin (KI) and kinetin riboside (KR) on the proliferation 
of the human megakaryoblast-like leukemia MEG-01 cells. MEG-01 cells (5 x 
104 cells/ml) were incubated with different concentrations of (A) kinetin (0 - 200 jiM) 
or (B) kinetin riboside ( 0 - 1 0 |iM) at 37°C for 48 hours. Cell proliferation was 
measured by [^H]-TdR incorporation as described in Chapter 2. The cells were 
pulsed with 0.5 jiCi of [^H]-TdR for 12 hours before harvest. The results were 
expressed as % inhibition of [^H]-TdR incorporation compared to the control. Each 
point represented the mean 士 S.E. of quadruplicate cultures. 
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Table 3.3: The estimated IC50 values of kinetin and kinetin riboside on the 
proliferation of various types of leukemia or lymphoma cell lines. 
Estimated IC50 values (|iM) 
Leukemia cell line  
Kinetin (Kl) Kinetin riboside (KR) 
0 
~ Murine myelomonocytic I ^ ^ I - B B JCS �8 0 � 1 
leukemia 
Murine myeloblastic leukemia Ml ~ 90 �1 
Ayf . u 1.1 PU5-1.8 � 7 5 � 0 . 3 5 Murine macrophage-like 
leukemia . . ； 1 
J774A.1 � 5 0 � 1 
Murine T cell lymphoma MBL-2 - 8 0 � 1 . 2 
Murine lymphocytic leukemia L1210 �1 3 0 � 0 . 8 
„ , ‘. HL-60 � 1 2 0 � 0 . 4 Human promyelocytic 
leukemia NB-4 � 1 8 0 � 0 . 4 
Human chronic myelogenous 
K-562 ~ 80 � 4 
leukemia  
Human acute eosinophilic … ，^ 
^ EoL-1 � 5 0 � 0 . 2 
leukemia 
Human histiocytic lymphoma U-937 > 200 � 6 
Human megakaryoblast-like meG-01 � 1 7 0 � 5 
leukemia  
IC50 value is the estimated concentration of kinetin or kinetin riboside which can 
cause 50% inhibition on the in vitro proliferation of leukemia or lymphoma cells, as 
determined by incorporation of [^H]-TdR assay under specified experimental 
conditions. 
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3.2.4 Cytotoxicity of Kinetin and Kinetin Riboside on Non-tumor Cell Lines and 
Primary Myeloid Cells In Vitro 
In view of the broad spectrum of anti-proliferative activity demonstrated by 
kinetin and its riboside on a wide variety of tumor cell lines，it is important to study 
the cytotoxicity of kinetin and its riboside on normal cells in vitro. Murine normal 
fibroblasts BALB/c CL.7 (Fig. 3.25), human hepatocyte-like cells WRL 68 (Fig. 3.26) 
and thioglycollate-elicited murine peritoneal macrophages (Fig. 3.27) were cultured 
in vitro with different concentrations of kinetin or kinetin riboside. The viability of 
the fibroblasts, hepatocytes or macrophages was measured by the MTT assay. The 
results showed that the murine fibroblasts BALB/c CL.7 and human hepatocyte-like 
WRL 68 cells were found to be more resistant to the cytotoxic effect of kinetin and 
its riboside. Only a slight cytotoxicity on the cells was shown at higher 
concentrations of the cytokinins. On the other hand, kinetin had no cytotoxic effect 
on murine peritoneal macrophages even present at a very high concentration (200 
|iM). However, the viability of kinetin riboside-treated murine macrophages 
decreased drastically in a dose-dependent manner, and only 20% of macrophages 
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Fig. 3.25: Effects of kinetin (KI) and kinetin riboside (KR) on the viability of the 
murine normal fibroblasts BALB/c CL.7 cells. BALB/c CL.7 cells (5 x lO* 
cells/ml) were incubated with different concentrations of (A) kinetin (0 一 200 i^M) or 
(B) kinetin riboside ( 0 - 1 0 |iM) at 37°C for 48 hours. Cell viability was measured 
by the MTT assay as described in Chapter 2. The results were expressed as % cell 
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Fig. 3.26: Effects of kinetin (KI) and kinetin riboside (KR) on the viability of the 
human hepatocyte-like WRL 68 cells. WRL 68 cells (5 x lO"^  cells/ml) were 
incubated with different concentrations of (A) kinetin (0 - 200 |iM) or (B) kinetin 
riboside ( 0 - 1 0 \xM) at 37�C for 48 hours. Cell viability was measured by the MTT 
assay as described in Chapter 2. The results were expressed as % cell viability 
compared to the control. Each point represented the mean 土 S.E. of quadruplicate 
cultures. 
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Fig. 3.27: Effects of kinetin (KI) and kinetin riboside (KR) on the viability of the 
murine peritoneal macrophages in vitro. Thioglycollate-elicited BALB/c mice 
peritoneal macrophages (5 x 10^ cells/ml) were incubated with different 
concentrations of (A) kinetin (0 - 200 \iM) or (B) kinetin riboside ( 0 - 1 0 |iM) at 
37°C for 48 hours. Cell viability was measured by the MTT assay as described in 
Chapter 2. The results were expressed as % cell viability compared to the control. 
Each point represented the mean 土 S.E. of quadruplicate cultures. 
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3.2.5 Kinetic and Reversibility Studies of the Anti-proliferative Effect of Kinetin 
and Kinetin Riboside on the WEHI-3B JCS Cells In Vitro 
To study the kinetics of the anti-proliferative effect of cytokinins, WEHI-3B 
JCS cells were incubated with different concentrations of kinetin or kinetin riboside 
• 
at 37°C for different time intervals and cell proliferation was then measured by the 
[^H]-TdR incorporation assay. Results showed that kinetin inhibited the proliferation 
of WEHI-3B JCS cells in a dose- and time-dependent maimer (Fig. 3.28). The IC50 
value gradually decreased from 150 |iM (15 hours) to 120 [lM (30 hours) and finally 
80 p,M (45 hours). In the case of kinetin riboside, it inhibited the proliferation of 
WEHI-3B JCS cells in a dose- but not time-dependent manner (Fig. 3.29). The IC50 
values were roughly similar among the three different incubation times. 
In addition to the [^H]-TdR incorporation assay, the proliferation of WEHI-3B 
cells was also studied by viable cell counting, using the trypan blue exclusion assay. 
As shown in Fig. 3.30 and 3.31, both kinetin and kinetin riboside inhibited the 
proliferation of WEHI-3B JCS cells in a dose- and time-dependent manner. 
In addition to kinetic studies, reversibility studies of the anti-proliferative effect 
of cytokinins on WEHI-3B JCS cells was also investigated. The cells were incubated 
with various concentrations of kinetin or kinetin riboside for 6, 12 or 24 hours. The 
cells were washed to remove the cytokinin or riboside and then re-incubated in 
complete fresh medium up to 48 hours. Results showed that the inhibition of 
[^H]-TdR incorporation of kinetin (50，100 and 200 ^M) was only 10%, 20% and 
60% after 24 hours of incubation, as compared to the 20%, 50% and 80% 
respectively after 48 hours of incubation (Fig. 3.32). Similarly, the inhibition of 
[^H]-TdR incorporation of kinetin riboside (1,2 and 4 _ was only 20%, 22% and 
42% after 12 hours of incubation, but increased to 38%, 62% and 83% respectively 
.107- “ 
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after 48 hours of incubation (Fig. 3.33). These results suggest that a longer treatment 
time is required for the cytokinins to exert their growth-inhibitory effect on the 
WEHI-3B JCS cells. 
« 
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Fig.3.28: Kinetic study on the effect of kinetin on the proliferation of murine 
myelomonocytic leukemia WEHI-3B JCS cells. WEHI-3B JCS cells (1 x 
cells/ml) were incubated with different concentrations of kinetin (0 - 200 ^M) at 
37°C for 15, 30 and 45 hours. Cultures were then pulsed with 0.5 i^Ci of [^H]-TdR 
for 6 hours before harvest. Results were expressed as % inhibition of [^H]-TdR 
incorporation with respect to the untreated control cells. Each point represented the 
mean 土 S.E. of quadruplicate cultures. 
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Fig. 3.29: Kinetic study on the effect of kinetin riboside on the proliferation of 
murine myelomonocytic leukemia WEHI-3B JCS cells. WEHI-3B JCS cells (1 x 
104 cells/ml) were incubated with different concentrations of kinetin riboside ( 0 - 5 
^M) at 37�C for 15, 30 and 45 hours. Cultures were then pulsed with 0.5 i^Ci of 
[^H]-TdR for 6 hours before harvest. Results were expressed as % inhibition of 
[^H]-TdR incorporation with respect to the untreated control cells. Each point 
represented the mean 士 S.E. of quadruplicate cultures. 
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Fig. 3.30: Growth-inhibitory effect of kinetin on the murine myelomonocytic 
leukemia WEHI-3B JCS cells. WEHI-3B JCS cells (1 x 10^  cells/ml) were 
incubated with different concentrations of kinetin (0 - 200 i^M) at 37°C for 24, 48 
and 72 hours. The number of viable cells was counted by trypan blue exclusion assay 
using Vi-Cell™XR cell viability analyzer (Beckman Coulter). Results were 
expressed as the number of viable cells. Each point represented the mean 土 S.E. of 
triplicate cultures. 
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Fig. 3.31: Growth-inhibitory effect of kinetin riboside on the murine 
myelomonocytic leukemia WEHI-3B JCS cells. WEHI-3B JCS cells (1 x lO^  
cells/ml) were incubated with different concentrations of kinetin riboside ( 0 - 4 ^M) 
at 37�C for 24，48 and 72 hours. The number of viable cells was counted by trypan 
blue exclusion assay using Vi-Cell™XR cell viability analyzer (Beckman Coulter). 
Results were expressed as the number of viable cells. Each point represented the 
mean 士 S.E. of triplicate cultures. 
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Fig. 3.32: Reversibility study on the effect of kinetin on the proliferation of 
murine myelomonocytic leukemia WEHI-3B JCS cells. WEHI-3B JCS cells (1 x 
104 cells/ml) were incubated with different concentrations of kinetin (50 - 200 \lM) 
at 37°C for 6，12 or 24 hours. The cells were then washed at the corresponding time 
intervals indicated and cultured in kinetin-free complete medium up to 48 hours. For 
control, cells incubated with kinetin (50 一 200 i^M) for 48 hours and then washed 
before pulsing with [^H]-TdR. Cultures were then pulsed with 0.5 i^Ci of [^H]-TdR 
for 6 hours before harvest. Results were expressed as % inhibition of [^H]-TdR 
incorporation with respect to the untreated control cells. Each point represented the 
mean 土 S.E. of quadruplicate cultures. 
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Fig. 3.33: Reversibility study on the effect of kinetin riboside on the 
proliferation of murine myelomonocytic leukemia WEHI-3B JCS cells. 
WEHI-3B JCS cells (1 x cells/ml) were incubated with different concentrations 
of kinetin riboside ( 1 - 4 [iM) at 37�C for 6，12，24 and 48 hours. The cells were then 
washed at the corresponding time intervals indicated and cultured in kinetin-free 
complete medium up to 48 hours. For control, cells incubated with kinetin riboside 
( 1 - 4 |iM) for 48 hours and then washed before pulsing with [^H]-TdR. Cultures 
were then pulsed with 0.5 i^Ci of [^H]-TdR for 6 hours before harvest. Results were 
expressed as % inhibition of [^H]-TdR incorporation with respect to the untreated 
control cells. Each point represented the mean 士 S.E. of quadruplicate cultures. 
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3.2.6 Effects of Kinetin and Kinetin Riboside on the Cell Cycle Profile of 
WEHI-3B JCS Cells In Vitro 
To investigate whether cytokinins could interrupt the cell cycle progression of 
WEHI-3B JCS cells and resulting in proliferation inhibition, cell cycle analysis of 
kinetin- or kinetin riboside-treated WEHI-3B JCS cells using propidium iodide 
staining followed by flow cytometric analysis was performed. Results showed that 
after 12 hours of incubation, kinetin (200 jiM) increased the proportion of cells in 
GQ/GI phase of cell cycle significantly, with a corresponding reduction in the 
proportion of cells in S phase while the proportion of cells in G2/M phase was 
unchanged. However, after 24 and 36 hours of incubation, the effect of kinetin on 
GQ/GI arrest was less prominent (Fig. 3.34). Interestingly, kinetin riboside (4 jiM) 
caused a significant increase in the proportion of cells in GQ/GI phase of cell cycle all 
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Control KI(200 fiM)  
12 h GO/Gl 41.53 66.33 + 24.80 
S 47.27 23.02 - 24.25 
G2/M 11.18 10.65 -0.53 
Sub G1 ^ ^ +2.90 
24 h GO/Gl 33.09 45.63 + 12.54 
S 54.22 38.47 - 15.75 
G2/M 12.70 15.90 -3.20 
Sub G1 ^ +5.81 
36 h GO/Gl 36.11 41.49 +5.38 
S 53.01 45.58 -7.43 
G2/M 10.88 12.93 -2.05 
Sub G1 1.27 6.36 +5.09 
Fig. 3.34: The cell cycle profile of kinetin-treated murine myelomonocytic 
leukemia WEHI-3B JCS cells. WEHI-3B JCS cells were starved at culture medium 
containing 0.5% FBS at 3TC for 12 hours. The starved cells (1 x 10^  cells/ml) were 
then incubated in complete culture medium with 200 \M kinetin at 37°C for 12, 24 
and 36 hours. The cells (5 x 10^  cells) were fixed with ethanol and then stained with 
PI. Fluorescence intensity of the stained cells was analyzed using FACSort flow 
cytometer (Becton Dickinson). Cell cycle distribution was calculated by ModFit 
program using RFIT analysis model. (Red line: control; Black line: Kl-treated) 
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G2/M 11.18 10.32 -0.86 
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24 h GO/Gl 36.11 60.33 + 24.22 
S 53.01 30.94 - 22.07 I 
G2/M 10.88 8.53 - 2.35 
Sub G1 ^ ^ +3.19 I 
36 h GO/Gl 33.09 53.75 + 20.66 
S 54.22 34.47 - 19.75 
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Fig. 3.36: The cell cycle profile of kinetin riboside-treated murine 
myelomonocytic leukemia WEHI-3B JCS cells. WEHI-3B JCS cells were starved 
at culture medium containing 0.5% FBS at 37°C for 12 hours. The starved cells (1 x 
104 cells/ml) were then incubated in complete culture medium with 4 i^M kinetin 
riboside at 37�C for 12，24 and 36 hours. The cells (5 x 10^  cells) were fixed with 
ethanol and then stained with PI. Fluorescence intensity of the stained cells was 
analyzed using FACSort flow cytometer (Becton Dickinson). Cell cycle distribution 
was calculated by ModFit program using RFIT analysis model. (Red line: control; 
Black line: KR-treated) 
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3.2.7 Expression of Cell Cycle Related Genes in Kinetin- And Kinetin 
Riboside-treated WEHI-3B JCS Cells In Vitro 
Cyclin dependent kinase (cdk) 2/cyclin E complex and cdk2/cyclin A complex 
are responsible for the transition of Gi to S phase. Arrest of cells in GQ/GI phase of 
cell cycle is mediated by the cdk inhibitor p21 and p27. These two proteins inhibit 
the complex formation of cdk2 with cyclin E or cyclin A (Johnson and Walker, 1999). 
The Go/Gi cell cycle arrest induced by cytokinins may be related to the expression of 
cyclins and cdk inhibitors. In this section, the modulatory effects of kinetin and 
kinetin riboside on the gene expression of p21 and p27, as well as various cyclins 
including cyclin A，B，D2 and E were studied. 
Our result showed that the gene expression of p2J and p27 were unchanged in 
kinetin-treated WEHI-3B JCS cells (Fig. 3.36). In contrast, kinetin riboside-treated 
cells induce a significant upregulation of p27 but notp21 gene expression (Fig. 3.37). 
In addition, the gene expressions of cyclin A, D2 and E were downregulated in 
kinetin-treated cells (Fig. 3.38). However, only the gene expression of cyclin E was 
downregulated in kinetin riboside-treated cells (Fig. 3.39). 
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Fig. 3.36: Expression of cell cycle regulatory genes in the kinetin-treated murine 
myelomonocytic leukemia WEHI-3B JCS cells. WEHI-3B JCS cells (3 x 10^ 
cells/ml) were incubated with 200 |iM kinetin at 37°C for different time intervals (4, 
8，12 and 24 hours) or treated with 0.1% DMSO as solvent control (SC) or untreated 
(CTL). TRIZOL reagent was used to extract total RNA of the cells. Semi-quantitative 
RT-PCR was performed and the PGR products were separated on 2% agarose gel. 
Band intensity was quantified using ImageQuant program. The value at the bottom of 
each band represented the relative intensity compared to untreated control, after 
normalization with endogenous GAPDH. 
Lane 1: untreated control 
Lane 2: solvent control 
Lane 3: JCS cells treated with KI for 4 hours 
Lane 4: JCS cells treated with KI for 8 hours 
Lane 5: JCS cells treated with KI for 12 hours 
Lane 6: JCS cells treated with KI for 24 hours 
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Fig. 3.37: Expression of cell cycle regulatory genes in the kinetin 
riboside-treated murine myelomonocytic leukemia WEHI-3B JCS cells. 
WEHI-3B JCS cells (3 x lO"^  cells/ml) were incubated with 4 |iM kinetin riboside at 
37�C for different time intervals (4，8, 12 and 24 hours) or treated with 0.1% DMSO 
as solvent control (SC) or untreated (CTL). TRIZOL reagent was used to extract total 
RNA of the cells. Semi-quantitative RT-PCR was performed and the PCR products 
were separated on 2% agarose gel. Band intensity was quantified using ImageQuant 
program. The value at the bottom of each band represented the relative intensity 
compared to untreated control, after normalization with endogenous GAPDH. 
Lane 1: untreated control 
Lane 2: solvent control 
Lane 3: JCS cells treated with KR for 4 hours 
Lane 4: JCS cells treated with KR for 8 hours 
Lane 5: JCS cells treated with KR for 12 hours 
Lane 6: JCS cells treated with KR for 24 hours 
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Fig. 3.38: Expression of various cyclin genes in the kinetin-treated murine 
myelomonocytic leukemia WEHI-3B JCS cells. WEHI-3B JCS cells (3 x 10^  
cells/ml) were incubated with 200 |iM kinetin at 37°C for different time intervals (4， 
8，12 and 24 hours) or treated with 0.1% DMSO as solvent control (SC) or untreated 
(CTL). TRIZOL reagent was used to extract total RNA of the cells. Semi-quantitative 
RT-PCR was performed and the PGR products were separated on 2% agarose gel. 
Band intensity was quantified using ImageQuant program. The value at the bottom of 
each band represented the relative intensity compared to untreated control, after 
normalization with endogenous GAPDH. 
Lane 1: untreated control 
Lane 2: solvent control 
Lane 3: JCS cells treated with KI for 4 hours 
Lane 4: JCS cells treated with KI for 8 hours 
Lane 5: JCS cells treated with KI for 12 hours 
Lane 6: JCS cells treated with KI for 24 hours 
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Fig. 3.39: Expression of various cyclin genes in the kinetin riboside-treated 
murine myelomonocytic leukemia WEHI-3B JCS cells. WEHI-3B JCS cells (3 x 
104 cells/ml) were incubated with 4 [lM kinetin riboside at 37�C for different time 
intervals (4，8，12 and 24 hours) or treated with 0.1% DMSO as solvent control (SC) 
or untreated (CTL). TRIZOL reagent was used to extract total RNA of the cells. 
Semi-quantitative RT-PCR was performed and the PGR products were separated on 
2% agarose gel. Band intensity was quantified using ImageQuant program. The value 
at the bottom of each band represented the relative intensity compared to untreated 
control, after normalization with endogenous GAPDH. 
Lane 1: untreated control 
Lane 2: solvent control 
Lane 3: JCS cells treated with KR for 4 hours 
Lane 4: JCS cells treated with KR for 8 hours 
Lane 5: JCS cells treated with KR for 12 hours 
Lane 6: JCS cells treated with KR for 24 hours 
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3.2.8 Effects of Kinetin and Kinetin Riboside on the In Vivo Tumorigenicity of 
WEHI-3B JCS Cells 
Kinetin and kinetin riboside could demonstrate anti-proliferative effect on the 
myeloid leukemia WEHI-3B JCS cells in vitro. The next step would be the study of 
the growth-inhibitory activity of kinetin and its riboside on these leukemia cells in 
vivo. Kinetin or kinetin riboside pre-treated WEHI-3B JCS cells were washed with 
PBS and then injected intraperitoneally into BALB/c mice. After 14 days of 
post-inoculation, the leukemia cells harvested from the peritoneal cavity were 
measured by viable cell counting. Results showed that pre-treatment with kinetin 
(100 |iM and 150 i^M) could significantly reduce the tumorigenicity of WEHI-3B 
‘ JCS cells in syngeneic BALB/c mice in a dose-dependent manner (Fig. 3.40). On the 
other hand, pre-treatment with kinetin riboside (1 jiM and 2 |iM) could also 
significantly reduce the proliferation of WEHI-3B JCS cells in syngeneic BALB/c 
mice (Fig. 3.41). Interestingly, the tumorigenicity of WEHI-3B JCS cells pre-treated 
) with 1 )iM kinetin riboside was smaller than those pre-treated with 2 ^M kinetin 
riboside (Fig. 3.41). 
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Fig. 3.40: Effect of in vitro pre-treatment of murine myelomonocytic leukemia 
WEHI-3B JCS cells with kinetin on their tumorigenicity in syngeneic BALB/c 
mice. WEHI-3B JCS cells (3 x 10^ cells/ml) were incubated with 0.1% DMSO as 
solvent control, 100 i^M or 150 |iM kinetin at 37°C for 8 hours. The cells were then 
washed three times with PBS. Viable JCS cells (1 x 10^ cells in 0.5 ml) were injected 
i.p. into BALB/c mice in groups of five. At day-14 post-tumor inoculation, leukemia 
cells recovered from the peritoneal cavity were counted using Vi-CellT^XR cell 
viability analyzer (Beckman Coulter). Results were expressed as number of viable 
cells. Each point represented the mean 土 S.E. for groups of five mice.(* p<0.05, ** 
p<0.005, significantly different from solvent control) 
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Fig. 3.41: Effect of in vitro pre-treatment of murine myelomonocytic leukemia 
WEHI-3B JCS cells with kinetin riboside on their tumorigenicity in syngeneic 
BALB/c mice. WEHI-3B JCS cells (3 x lO* cells/ml) were incubated with 0.1% 
DMSO as solvent control, \ \M or 2 i^M kinetin riboside at 37°C for 8 hours. The 
cells were then washed three times with PBS. Viable JCS cells (1 x 10^ cells in 0.5 
ml) were injected i.p. into BALB/c mice in groups of five. At day-14 post-tumor 
inoculation, leukemia cells recovered from the peritoneal cavity were counted using 
Vi-Cell™XR cell viability analyzer (Beckman Coulter). Results were expressed as 
number of viable cells. Each point represented the mean 士 S.E. for groups of five 
mice. (* p<0.05, *** p<0.001, significantly different from solvent control) 
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3.2.9 In Vivo Anti-tumor Effect of Kinetin and Kinetin Riboside on the 
Leukemia WEHI-3B JCS Cells 
Since kinetin and kinetin riboside pre-treated WEHI-3B JCS cells demonstrated 
a reduced tumorigenicity in vivo, therefore, the in vivo anti-tumor activity of kinetin 
and kinetin riboside was also studied. WEHI-3B JCS cells were injected i.p. into 
syngeneic BALB/c mice and allowed to grow for 7 days. Two different doses of 
kinetin (10 mg/kg and 20 mg/kg) or kinetin riboside (1 mg/kg and 2 mg/kg) were 
then injected into the tumor-bearing mice on day-8 in alternate days until day-14. At 
day-16 post-tumor inoculation, the numbers of leukemia cells harvested from the 
peritoneal cavity of mice were measured by viable cell counting. Results showed that 
both kinetin and kinetin riboside could suppress the leukemia cell growth in BALB/c 
mice by 42.9% and 36.8% at 20 mg/kg and 2 mg/kg respectively (Fig. 3.42 and 
3.43). 
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Fig. 3.42: Effect of kinetin on the in vivo growth of murine myelomonocytic 
leukemia WEHI-3B JCS cells in syngeneic BALB/c mice. WEHI-3B JCS cells in 
PBS (1 X 10^ cells/ml) were injected i.p. into BALB/c mice at day 0. Starting from 
day-8 after inoculation of JCS cells，mice were divided into 3 groups with five mice 
in each group and injected i.p. with DMSO as solvent control, 10 mg/kg or 20 mg/kg 
kinetin in alternate days. At day-16 post-tumor cell inoculation, viable cells were 
recovered from the peritoneal cavity and counted. Cell number was counted by 
Vi-Cell™XR cell viability analyzer (Beckman Coulter). Results were expressed as 
number of viable cells per mouse. Each point represented the mean 土 S.E. for groups 
of five mice. 
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Fig. 3.43: Effect of kinetin riboside on the in vivo growth of murine 
myelomonocytic leukemia WEHI-3B JCS cells in syngeneic BALB/c mice. 
WEHI-3B JCS cells in PBS (1 x 10^ cells/ml) were injected i.p. into BALB/c mice at 
day 0. Starting from day-8 after inoculation of JCS cells, mice were divided into 3 
groups with five mice in each group and injected i.p. with DMSO as solvent control, 
1 mg/kg or 2 mg/kg kinetin riboside in alternate days. At day-16 post-tumor cell 
inoculation, viable cells were recovered from the peritoneal cavity and counted. Cell 
»T»\ yf 
number was counted by Vi-Cell XR cell viability analyzer (Beckman Coulter). 
Results were expressed as number of viable cells per mouse. Each point represented 
the mean 土 S.E. for groups of five mice. 
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3.3 Discussion 
In this chapter, the effects of four cytokinins and their corresponding riboside 
derivatives on the proliferation of a murine myelomonocytic leukemia cell line 
WEHI-3B JCS were investigated. This leukemia cell line has been well-characterized 
in our groups and has various advantages such as short doubling time and can 
respond to various differentiation-inducing agents such as cytokines and natural 
products (Mak et al., 1993; Leung et al, 2002; Chan et al., 2003; Leung et al, 2004; 
Lui et al.’ 2005). By comparing the anti-proliferative effect of the selected cytokinins 
and the cytokinin ribosides on the WEHI-3B JCS cells in vitro, it was found that 
benyzladenine and kinetin riboside had the most potent anti-proliferative effect in the 
cytokinin group and cytokinin riboside group respectively. Interestingly, the 
inhibitory effects of the riboside derivatives were found to be much more potent than 
the parental cytokinins ranging from 2 to 80-fold. Comparing the IC50 values of 
cytokinins and the ribosides with that of the parental compounds adenine and 
adenosine, the cytokinins were more potent than adenine ranging from 9 to 22-fold 
while the cytokinin ribosides were more potent than adenosine ranging from 8 to 
400-fold. However, there was no significant difference between the aromatic type of 
cytokinins and isoprenoid type of cytokinins in term of anti-proliferative effect. The 
result showed that the N^ side chain substitutions of the adenine ring of cytokinins 
were critical for the anti-proliferative activity of cytokinins. Moreover, the addition 
of a ribosyl group to the adenine ring could increase the potency of cytokinins. The 
present findings supported the previous studies on the comparison of 
anti-proliferative effect of cytokinins and adenine analogues (Ishii et al., 2002; 
> 
Mlejnek and Kuglik, 2000). Recent studies on structure-activity relationship of 
benzyladenine (BA) derivatives showed that the attachment of halogen, methyl or 
methoxy group to the benzyl ring could increase the growth-inhibitory activity of BA. 
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However, introduction of more substituents would decrease the activity (Dolezal et 
al.’ 2006). 
Based on the results of cell growth study, kinetin and kinetin riboside were 
selected for further studies due to the largest difference in their IC50 values. As no 
significant cytotoxic effect of kinetin and kinetin riboside on the WEHI-3B JCS cells 
was found after different time periods of incubation, the observed growth-inhibitory 
effect of kinetin and the riboside on WEHI-3B JCS cells could not be attributed 
solely or directly to their cytotoxic effect on the leukemia cells. To demonstrate 
whether the observed growth-inhibitory effect of kinetin and kinetin riboside was 
tumor cell line specific, various murine and human leukemia cell lines were used in 
our present study. These cell lines represented the cells at various stages of 
hematopoiesis. In other words, the maturity status of the cell lines was different. 
Results showed that both kinetin and kinetin riboside had anti-proliferative activity 
on these cell lines. The inhibitory effect of kinetin riboside was much more potent 
than kinetin, and the difference was more significant in some cell lines, e.g. HL-60 
and NB-4. On the other hand, the effects of kinetin and kinetin riboside on the 
viability of two normal cell lines and myeloid cells such as peritoneal macrophages 
were studied. The viability of both murine fibroblasts BALB/c CL.7 and human 
hepatocyte-like WRL 68 cells was not affected significantly. Interestingly, the 
viability of murine peritoneal macrophages was not affected by kinetin but kinetin 
riboside exhibited significant cytotoxicity on the macrophages, especially at higher 
concentrations. The reason why kinetin riboside has differential cytotoxic activity on 
murine macrophages remains unclear. Various studies showed that some agents could 
induce immunosuppression of peritoneal macrophages (Koptopoulos et al.’ 1992; 
Makker, 1978; Mellert et al, 1989). Whether kinetin riboside can exert cytotoxicity 
or immunosuppressive effect on other immune cell types is an intriguing aspect that 
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awaits further investigation. 
The kinetics of the anti-proliferative effect of kinetin and kinetin ribosides on 
WEHI-3B JCS cells was examined by ^H-TdR incorporation method. Results 
showed that kinetin inhibited the proliferation of WEHI-3B JCS cells in a 
time-dependent manner. The inhibitory effect of kinetin reached to a maximum level 
after 48 hours of incubation. In contrast, the inhibitory effect of kinetin riboside was 
similar at 20 and 40 hours of incubation and the effect was slightly weaker after 60 
hours of incubation. Therefore, the inhibitory effect of kinetin riboside may be 
reached to a maximum level within 20 hours of incubation. In terms of cell number, 
both kinetin and kinetin riboside showed a time-dependent inhibition of cell 
proliferation. The different kinetics of the growth-inhibitory effect of kinetin and its 
riboside on the leukemia WEHI-3B JCS cells may be due to structural difference. 
The addition of ribosyl group may increase the uptake efficiency of kinetin riboside. 
However, the actual reasons for the difference remain unclear and require more 
investigations. In addition to kinetic studies, the reversibility of the anti-proliferative • 
effect of kinetin and its ribosides on WEHI-3B JCS cells was also investigated. It 
was found that the growth-inhibitory effect of the cytokinins was partially reversible 
and co-incubation for more than 24 hours was required to give the maximum 
inhibitory effect. 
Cell cycle analysis was performed to elucidate the mechanisms for the 
anti-proliferative effect of cytokinins. The results showed that both kinetin and 
kinetin ribosides induced cell cycle arrest of the WEHI-3B JCS cells at the GQ/GI 
phase. The proportion of cytokinin-treated cells in GQ/GI phase was significantly 
increased compared with that of control. Interestingly, the cell cycle arresting effect 
of kinetin declined gradually after 24 hours of incubation while the effect of kinetin 
riboside was maintained even after 36 hours of incubation. Although such -a 
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difference in the cell cycle arresting effect of kinetin and kinetin riboside cannot be 
explained at the moment, the data do suggest that the anti-proliferative effect of the 
cytokinins could be, at least in parts, due to their ability to induce cell cycle arrest of 
the WEHI-3B JCS cells at the GQ/GI phase. 
Gene expression studies showed that the cyclin dependent kinase inhibitors p21 
and p27 were unchanged in kinetin-treated cells but p27 was significantly 
upregulated in kinetin riboside-treated cells. In addition, the gene expressions of 
cyclin A and E were downregulated in kinetin-treated cells. In the case of kinetin 
riboside-treated cells, only the gene expression of cyclin E was downregulated. From 
these results, the effect of kinetin on the cell cycle arrest might be mainly due to 
downregulation of cyclins A and E，which are responsible for Gi/S phase transition. 
On the other hand, kinetin riboside arrested the WEHI-3B JCS cells similar to the 
case of kinetin, by downregulating cyclins such as cyclin E responsible for Gi/S 
phase transition. In addition, the upregulation of p27 by kinetin riboside in the 
leukemia WEHI-3B JCS cells would inhibit the complex formation of cyclins with 
the cdk2 (Johnson and Walker, 1999) and further strengthen the arresting effect. It 
was reported that cytokinins were potent inhibitors of cdk2 (Vermeulen et al, 2002a; 
Vesely et al., 1994) and they inhibited several human protein kinases such as cdk 
non-specifically (Havlicek et al, 1997). Whether kinetin and kinetin riboside could 
directly inhibit the activity of cdk2 requires further investigation. 
The effects of cytokinins on the in vivo growth of transplantable leukemia 
• WEHI-3B JCS cells in syngeneic mice BALB/c were studied. Pre-treatment of 
leukemia WEHI-3B JCS cells with kinetin or kinetin riboside in vitro could 
significantly reduce the in vivo growth or tumorigenicity of the WEHI-3B JCS cells 
in syngeneic mice. Moreover, direct injection of kinetin or kinetin riboside to 
leukemia WEHI-3B JCS cells-bearing syngeneic BALB/c mice could slightly reduce 
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the growth of WEHI-3B JCS cells in vivo. The results showed that cytokinins could 
exert their anti-proliferative effect on leukemia cells both in vitro and in vivo. It had 
been previously reported that 25 mg/kg kinetin riboside impaired the health of mice 
(Griffaut et al, 2004). However, only a very low dose (1-2 mg/kg) of kinetin riboside 
was used in the present study and the toxicity of cytokinins in syngeneic mice was 
not apparent. 
Although the precise mechanisms by which cytokinins could exert their 
anti-proliferative effect on myeloid leukemia cells have not yet fully established, our 
results indicate that the effect may be related to the cell cycle arresting effect of 
cytokinins. In addition to cell cycle arrest, cytokinins may also induce apoptosis and 
differentiation of the leukemia cells and result in the growth inhibition. In the 
following two chapters, the apoptosis-inducing and differentiation-inducing activities 
of kinetin and kinetin riboside on the leukemia WEHI-3B JCS cells were studied. 
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• Chapter 4: Apoptosis-inducins effect 
4.1 Introduction 
Cell death is a vital cellular process for development and homeostasis of 
multicellular organisms. Impairment in programmed cell death mechanisms and 
signaling pathways are common in cancer cells and may result in uncontrolled cell 
proliferation. Programmed cell death in animal system includes apoptosis and 
autophagy (Edinger and Thompson, 2004). Moreover, necrosis was being considered 
I 
as a programmed cell death，yet it is still controversial (Edinger and Thompson, 
2004). However, more recent findings suggest that necrotic.cell death may also be 
genetically controlled (Zong and Thompson, 2006). Among the various cell death 
mechanisms, apoptosis is the most widely studied mode of cell death. Apoptosis is an 
active, regulated form of cell death which is a complex biochemical process 
involving multiple signaling pathways. This form of cell death has been conserved 
throughout evolution and plays pivotal roles in embryonic development, tissue 
homeostasis and remodeling, immune regulation and has been implicated in various 
pathological states (Jin and El-Deiry, 2005; Hail et al, 2006). The morphological 
changes of apoptotic cells include chromatin condensation, cytoplasmic shrinkage, 
plasma membrane blebbing, nuclear membrane disruption and formation of apoptotic 
bodies. On the other hand, the molecular changes include intemucleosomal DNA 
cleavage and distribution of phosphatidyl serine on the outer layer of plasma 
membrane. Finally, the apoptotic cells are cleared by phagocytes like macrophages 
(Jiang and Wang, 2004). Activation of apoptosis in cancer cells has been extensively 
investigated. Several chemotherapeutic drugs as well as novel small molecules used 
in clinical cancer treatment could induce apoptosis, for example 
5 ‘ -fluoro-2 ‘ -deoxyuridine and topoisomerase inhibitors (Kaufmann and Eamshaw, 
2000). In addition, a number of small molecules with specific drug targets such as 
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death receptors and caspase cascades are under preclinical and clinical studies for the 
potential application in apoptosis-based therapy (Fischer and Schulze-Osthoff, 2005; 
Reed and Pellecchia, 2005). 
There are two main pathways in apoptosis, the intrinsic or 
mitochondria-mediated pathway and the extrinsic or death receptor-mediated 
pathway (Nagata, 1999; Jiang and Wang, 2004). Bcl-2 family proteins and 
mitochondria have important roles in the intrinsic pathway. On the other hand, death 
receptors like Fas, TNF receptor and TRAIL are involved in the extrinsic pathway. 
Both pathways activate the downstream caspase cascade and nucleases to execute the 
apoptotic activity. Recently, caspase-independent apoptosis was recognized as 
another pathway of apoptosis induced by death receptor, cytotoxic drugs and 
mediated by mitochondria pro-apoptotic proteins (Kroemer and Martin, 2005). 
In the present study, the apoptosis-inducing activity of kinetin and kinetin 
riboside on the murine myeloid leukemia WEHI-3B JCS cells was studied by 
« 
examining the induction of DNA fragmentation using gel electrophoresis and 
sandwich ELISA. The kinetics and dose-dependency of the cytokinins on the DNA 
fragmentation induction were also investigated. To understand the apoptotic 
pathways triggered by cytokinins on WEHI-3B JCS cells，changes in mitochondrial 
membrane potential and the activation of caspases 3，8 and 9 were studied. In 
addition, the possible involvement of reactive oxygen species in cytokinin-induced 
apoptosis was analyzed. Finally, the expression of apoptosis-regulatory genes (Bcl-2 
family and FasL) in cytokinin-treated WEHI-3B JCS cells was examined by 
RT-PCR. 
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4.2 Results 
4.2.1 Induction of DNA Fragmentation by Cytokinins in the Murine Myeloid 
Leukemia WEHI-3B JCS Cells In Vitro 
DNA fragmentation is a widely accepted characteristic of apoptosis among the 
various morphological and biochemical features of apoptotic cell death. Different 
levels of DNA fragmentation are classified, i.e. single-strand DNA cleavage 
fragmentation, 50 - 300 kbp large fragmentation and intemucleosomal fragmentation 
(Bortner et al., 1995). In the present study, intemucleosomal DNA fragment 
extraction method described by Herrmann et al (1994) was used to investigate the 
induction of DNA fragmentation by kinetin and its riboside in the WEHI-3B JCS 
cells. 
As shown in Fig. 4.1 and 4.2，both kinetin and its riboside could induce DNA 
fragmentation in the leukemia WEHI-3B JCS cells. In the case of kinetin, 200 | jM 
kinetin could induce DNA fragmentation in WEHI-3B JCS cells in a time-dependent 
manner and the activity was obvious after 36 hours of incubation (Fig. 4.1). After 48 
hours of incubation, lower concentrations of kinetin (50 jiM and 100 jiM) also 
induced DNA fragmentation in WEHI-3B JCS cells but the induction was weaker 
than that of 200 \iM kinetin (Fig. 4.3). On the other hand, 4 i^M of kinetin riboside 
could also induce DNA fragmentation in WEHI-3B JCS cells in a time-dependent 
manner but the activity was observed after 24 hours of incubation (Fig. 4.2). Similar 
to the case of kinetin, kinetin riboside induced DNA fragmentation in WEHI-3B JCS 
cells in a dose-dependent manner after 48 hours of incubation (Fig. 4.4). Interestingly, 
the apoptosis-inducing activity of cytokinins is tumor-specific as using the murine 
embryonic fibroblasts BALB/c CL.7 cells, DNA fragmentation was not induced after. 
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kinetin (200 |iM) or kinetin riboside (4 p,M) treatment (data not shown). The DNA 
fragmentation inducing effect was quantified by the sandwich ELISA method, using 
the commercially available Cellular DNA Fragmentation ELISA Kit. Both kinetin 
(200 i^M) and its riboside (4 |iM) induced DNA fragmentation in WEHI-3B JCS cells 
in a time-dependent (Fig. 4.5) and dose-dependent manner (Fig. 4.6). The potency of 
kinetin riboside in inducing DNA fragmentation was higher than that of kinetin, as , 
shown by the ELISA assay. 
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Fig. 4.1: Kinetic study of the induction of DNA fragmentation in the 
kinetin-treated murine myelomonocytic leukemia WEHI-3B JCS cells. 
WEHI-3B JCS cells (2 x lO"^  cells/ml) were incubated with 200 |xM kinetin at 37°C 
for different time intervals (6 - 48 hours) or treated with solvent control (0.1% 
DMSO) or untreated for 48 hours. The cells (2 x 10^ cells) were lysed with lysis 
buffer and apoptotic DNA fragments were extracted as described in Chapter 2. 
Extracted DNA was analyzed by electrophoresis on 2% agarose gel and visualized 
with ethidium bromide. 
Lane 1: 100 bp DNA ladder 
Lane 2: JCS cells treated with KI for 6 hours 
Lane 3: JCS cells treated with KI for 12 hours 
Lane 4: JCS cells treated with KI for 24 hours 
Lane 5: JCS cells treated with KI for 36 hours 
Lane 6: JCS cells treated with KI for 48 hours 
Lane 7: Untreated JCS cells 
Lane 8: Solvent control-treated JCS cells 
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Fig. 4.2: Kinetic study of the induction of DNA fragmentation in the kinetin 
riboside-treated murine myelomonocytic leukemia WEHI-3B JCS cells. 
WEHI-3B JCS cells (2x 10^ cells/ml) were incubated with 4 i^M kinetin riboside for 
different time intervals (6 - 48 hours) or treated with solvent control (0.1% DMSO) 
or untreated for 48 hours. The cells (2 x 10^ cells) were lysed with lysis buffer and 
apoptotic DNA fragments were extracted as described in Chapter 2. Extracted DNA 
was analyzed by electrophoresis on 2% agarose gel and visualized with ethidium 
bromide. 
Lane 1: 100 bp DNA ladder 
Lane 2: JCS cells treated with KR for 6 hours 
Lane 3: JCS cells treated with KR for 12 hours 
Lane 4: JCS cells treated with KR for 24 hours 
Lane 5: JCS cells treated with KR for 36 hours 
Lane 6: JCS cells treated with KR for 48 hours 
Lane 7: Untreated JCS cells 
Lane 8: Solvent control-treated JCS cells 
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Fig. 4.3: Dose response study of the induction of DNA fragmentation in the 
kinetin-treated murine myelomonocytic leukemia WEHI-3B JCS cells. 
WEHI-3B JCS cells (2 x lO^ cells/ml) were either untreated, treated with solvent 
control (0.1% DMSO) or incubated with different concentrations of kinetin (50 - 200 
^M) at 37°C for 48 hours. The cells (2 x 10^ cells) were lysed with lysis buffer and 
apoptotic DNA fragments were extracted as described in Chapter 2. Extracted DNA 
was analyzed by electrophoresis on 2% agarose gel and visualized with ethidium 
bromide. 
Lane 1: 100 bp DNA ladder 
Lane 2: JCS cells treated with KI (50 ^M) 
Lane 3: JCS cells treated with KI (100 i^M) 
Lane 4: JCS cells treated with KI (200 |iM) 
Lane 5: Untreated JCS cells 
Lane 6: Solvent control-treated JCS cells 
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Fig. 4.4: Dose response study of the induction of DNA fragmentation in the 
kinetin riboside-treated murine myelomonocytic leukemia WEHI-3B JCS cells. 
WEHI-3B JCS cells (2 x cells/ml) were either untreated, treated with solvent 
control (0.1% DMSO) or incubated with different concentrations of kinetin riboside 
( 1 - 4 ^iM) at 37�C for 48 hours. The cells (2 x 10^ cells) were lysed with lysis buffer 
and apoptotic DNA fragments were extracted as described in Chapter 2. Extracted 
DNA was analyzed by electrophoresis on 2% agarose gel and visualized with 
ethidium bromide. 
Lane 1: 100 bp DNA ladder 
Lane 2: JCS cells treated with KR (1 |iM) 
Lane 3: JCS cells treated with KR (2 i^M) 
Lane 4: JCS cells treated with KR (4 |iM) 
Lane 5: Untreated JCS cells 
Lane 6: Solvent control-treated JCS cells 
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Fig. 4.5: Kinetic analysis of DNA fragmentation in the kinetin- or kinetin 
riboside-treated murine "myelomonocytic leukemia WEHI-3B JCS cells by 
ELISA. BrdU-labeled WEHI-3B JCS cells (5 x 10^ cells/ml) were solvent treated or 
treated with 200 jiM kinetin or 4 ^M kinetin riboside at 37°C for different time 
intervals (6 to 24 hours). Apoptotic DNA fragments were detected using cellular 
DNA fragmentation ELISA kit (Roche Applied Science). The degree of DNA 
fragmentation was expressed as enrichment factor as described in Chapter 2. 
(* p<0.05, ** p<0 .005，p<0 .001 , significantly different from control) 
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Fig. 4.6: Dose response analysis of DNA fragmentation in the (A) kinetin- and (B) 
kinetin riboside-treated murine myelomonocytic leukemia WEHI-3B JCS cells 
by ELISA. BrdU-labeled WEHI-3B JCS cells (5 x 10^ cells/ml) were solvent treated 
or treated with different concentrations of (A) kinetin (50，100 or 200 [iM) or (B) 
kinetin riboside (1，2 or 4 \iM) at 37°C for 24 hours. Apoptotic DNA fragments were 
detected using cellular DNA fragmentation ELISA kit (Roche Applied Science). The 
degree of DNA fragmentation was expressed as enrichment factor as described in 
Chapter 2. (* p<0.05, p<0.005, significantly different from control) 
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4.2.2 Mitochondrial Membrane Potential of Kinetin- and Kinetin 
Riboside-treated WEHI-3B JCS Cells In Vitro 
To investigate the involvement of mitochondria in kinetin and its riboside 
triggered DNA fragmentation, mitochondrial membrane potential ( A 0 m) was 
measured. In the intrinsic apoptotic pathway, mitochondrial membrane potential was 
disrupted or depolarized and the apoptotic proteins were released from the 
i 
intermembrane space of mitochondria into cytosol of the cells. A cationic dye JC-1 
was used to detect the A 0 m changes which can be measured by flow cytometry. At 
high A 0 m or in polarized mitochondrial membrane, JC-1 forms dimers that give 
red fluorescence. While at low A m or in depolarized mitochondrial membrane, 
JC-1 forms monomers that give green fluorescence (Cossarizza et al.’ 1993). During 
typical intrinsic apoptosis, a shift of red to green fluorescence of JC-1 stained cells 
reflected depolarization of A 0 m ((Dome et al.’ 2001). 
In the present study, a depolarization of A ^ m was observed in both kinetin-
and kinetin riboside-treated WEHI-3B JCS cells and the observed depolarization of 
A 0n i was only seen at 24 hours of cytokinin treatment (Fig. 4.7 and 4.8). 
I 
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Fig.4.7: Effect of kinetin on the mitochondrial membrane potential in the 
murine myelomonocytic leukemia WEHI-3B JCS cells. WEHI-3B JCS cells (2 x 
104 cells/ml) were treated with medium, solvent control (0.1% DMSO) or 200 pM 
kinetin at 37�C for (A) 6 hours, (B) 12 hours and (C) 24 hours. The WEHI-3B JCS 
cells were then stained with JC-1 dye. Top left quadrant represented cells with 
normal polarized mitochondrial membrane that emitted red fluorescence. Bottom 
right quadrant represented cells with depolarized mitochondrial membranes that 
emitted green fluorescence. (% shown indicated the percentage of cells in bottom 
right quadrant) 
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Fig.4.8: Effect of kinetin riboside on the mitochondrial membrane potential in 
the murine myelomonocytic leukemia WEHI-3B JCS cells. WEHI-3B JCS cells 
(2 X 104 cells/ml) were treated with medium, solvent control (0.1% DMSO) or 4 ^M 
kinetin riboside at 3TC for (A) 6 hours, (B) 12 hours and (C) 24 hours. The 
WEHI-3B JCS cells were then stained with JC-1 dye. Top left quadrant represented 
cells with normal polarized mitochondrial membrane that emitted red fluorescence. 
Bottom right quadrant represented cells with depolarized mitochondrial membranes 
that emitted green fluorescence. (% shown indicated the percentage of cells in 
bottom right quadrant) 
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4.2.3 Caspase Activities of Kinetin- and Kinetin Riboside-treated WEHI-3B JCS 
Cells In Vitro 
DNA fragmentation has an intimate relationship with the activation of caspase 
cascade. The caspase activated DNase (CAD) is a main DNase involved in cleaving 
genomic DNA (Widlak and Garrard, 2005). This DNase is activated by effector 
caspase 3 which in turn is mainly activated by initiator caspase 8 from the extrinsic 
apoptotic pathway, or caspase 9 from the intrinsic apoptotic pathway (Strasser et al, 
2000). There are at least 14 caspases identified in mouse and.humans until now (Fan 
et al., 2005a). Caspases 9 and 8 are known as initiator caspases while caspase 3 is a 
common effector caspase in apoptosis. Using the respective fluorogenic substrates 
specific to the caspases, the activities of caspases 3, 8 and 9 were investigated in 
kinetin- and kinetin riboside-treated WEHI-3B JCS cells by fluorescence method. 
As shown in Fig. 4.9 and 4.10，both kinetin and its riboside could trigger an 
activation of caspase 3, but the effect of kinetin riboside was much stronger (over 4.5 
fold) than that of kinetin (nearly 2 fold) at 24 hours of incubation. In the case of 
caspase 8 (Fig. 4.11 and 4.12)，kinetin triggered a very weak caspase 8 activity but 
kinetin riboside could trigger a much stronger caspase 8 activity (over 2 fold). In the 
case of caspase 9 (Fig. 4.13 and 4.15)，however, kinetin could trigger a high caspase 
9 activity which peaked at 24 hours of incubation. Again, kinetin riboside triggered a 
caspase 9 activity (nearly enhanced 6 fold) that was stronger than kinetin (enhanced 
3.5 fold) at 36 hours of incubation. The specificity of caspase activity in the method 
used was supported by the significant reduction of fluorescence unit release after 
addition of caspase specific inhibitors to the protein samples. 
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Fig. 4.9: Analysis of caspase 3 activity in the kinetin-treated murine 
myelomonocytic leukemia WEHI-3B JCS cells. WEHI-3B JCS cells (3 x 10^ 
cells/ml) were either untreated (control), incubated with solvent control (0.1% 
DMSO) or with 200 l^M kinetin at 37°C for different time intervals (12, 24 and 36 
hours). The proteins of samples were extracted and incubated with caspase 3 specific 
substrate (Ac-DEVD-AMC) with or without its specific inhibitor (Ac-DEVD-CHO). 
Samples were then excited at 360 nm and the fluorescence emitted at 465 nm was 
measured by the fluorescence plate reader Polarizon (Tecan). The AMC release unit 
was estimated by comparing sample AMC fluorescence units with the standard curve 
of free AMC molecules. The caspase 3 activity was correlated to the amount of AMC 
release. (*** p<0.001, significantly different from control) 
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Fig. 4.10: Analysis of caspase 3 activity in the kinetin riboside-treated murine 
myelomonocytic leukemia WEHI-3B JCS cells. WEHI-3B JCS cells (3 x 10^ 
cells/ml) were either untreated (control)，incubated with solvent control (0.1% 
DMSO) or with 4 |iM kinetin riboside at 37�C for different time intervals (12, 24 and 
36 hours). The proteins of samples were extracted and incubated with caspase 3 
specific substrate (Ac-DEVD-AMC) with or without its specific inhibitor 
(Ac-DEVD-CHO). Samples were then excited at 360 nm and the fluorescence • 
emitted at 465 nm was measured by the fluorescence plate reader Polarizon (Tecan). 
The AMC release unit was estimated by comparing sample AMC fluorescence units 
with the standard curve of free AMC molecules. The caspase 3 activity was 
correlated to the amount of AMC release. (** p<0.005, *** p<0.001, significantly 
different from control) 
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Fig. 4.11: Analysis of caspase 8 activity in the kinetin-treated murine 
myelomonocytic leukemia WEHI-3B JCS cells. WEHI-3B JCS cells (3 x 10^  
cells/ml) were either untreated (control), incubated with solvent control (0.1% 
DMSO) or with 200 i^M kinetin at 37°C for different time intervals (12，24 and 36 
hours). The proteins of samples were extracted and incubated with caspase 8 specific 
substrate (Ac-IETD-AMC) with or without its specific inhibitor (Ac-IETD-CHO). 
Samples were then excited at 360 nm and the fluorescence emitted at 465 run was 
measured by the fluorescence plate reader Polarizon (Tecan). The AMC release unit 
• was estimated by comparing sample AMC fluorescence units with the standard curve 
of free AMC molecules. The caspase 8 activity was correlated to the amount of AMC 
release. (*** p<0.001, significantly different from control) 
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Fig. 4.12: Analysis of caspase 8 activity in the kinetin riboside-treated murine 
myelomonocytic leukemia WEHI-3B JCS cells. WEHI-3B JCS cells (3 x lO* 
cells/ml) were either untreated (control), incubated with solvent control (0.1% 
DMSO) or with 4 |iM kinetin riboside at 37°C for different time intervals (12, 24 and 
36 hours). The proteins of samples were extracted and incubated with caspase 8 
specific substrate (Ac-IETD-AMC) with or without its specific inhibitor 
(Ac-IETD-CHO). Samples were then excited at 360 run and the fluorescence emitted 
at 465 run was measured by the fluorescence plate reader Polarizon (Tecan). The 
AMC release unit was estimated by comparing sample AMC fluorescence units with 
the standard curve of free AMC molecules. The caspase 8 activity was correlated to 
the amount of AMC release. (*** p<0.001, significantly different from control) 
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Fig. 4.13: Analysis of caspase 9 activity in the kinetin-treated murine 
myelomonocytic leukemia WEHI-3B JCS cells. WEHI-3B JCS cells (3 x 
cells/ml) were either untreated (control), incubated with solvent control (0.1% 
DMSO) or with 200 \iM kinetin at 37°C for different time intervals (12, 24 and 36 
hours). The proteins of samples were extracted and incubated with caspase 9 specific 
substrate (Ac-LEHD-AFC) with or without its specific inhibitor (Ac-LEHD-CHO). 
Samples were then excited at 400 nm and the fluorescence emitted at 505 nm was 
measured by the fluorescence plate reader Polarizon (Tecan). The AFC release unit 
was estimated by comparing sample AFC fluorescence units with the standard curve 
of free AFC molecules. The caspase 9 activity was correlated to the amount of AFC 
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Fig. 4.14: Analysis of caspase-9 activity in the kinetin ribosoide-treated murine 
myelomonocytic leukemia WEHI-3B JCS cells. WEHI-3B JCS cells (3 x lO* 
cells/ml) were either untreated (control), incubated with solvent control (0.1% 
DMSO) or with 4 )iM kinetin riboside at 37°C for different time intervals (12, 24 and 
36 hours). The proteins of samples were extracted and incubated with caspase 9 
specific substrate (Ac-LEHD-AFC) with or without its specific inhibitor 
(Ac-LEHD-CHO). Samples were then excited at 400 nm and the fluorescence 
emitted at 505 nm was measured by the fluorescence plate reader Polarizon (Tecan). 
The AFC release unit was estimated by comparing sample AFC fluorescence units 
with the standard curve of free AFC molecules. The caspase 9 activity was correlated 
to the amount of AFC release. (*** p<0.001，significantly different from control) 
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4.2.4 Induction of Reactive Oxygen Species in Kinetin- and Kinetin 
Riboside-treated WEHI-3B JCS cells In Vitro 
« 
Mitochondria are the major source of reactive oxygen species (ROS) and the 
ROS is formed mainly during the redox reaction in the respiratory chain system 
(Turrens, 2003). The respiratory chain complexes I and III in the inner mitochondrial 
membranes are the main sites of excessive ROS production. Yet mitochondria have 
various antioxidant defense mechanisms to counteract the problem of superoxides 
(Turrens, 2003). It was found that unregulated ROS produced during stress 
stimulation such as y-irradiation could damage mitochondria and trigger apoptosis 
(Droge, 2002). It was proposed that ROS could trigger the release of cytochrome c 
from mitochondria which in turn activated the caspase cascade (Simon et al, 2000). 
Some natural products such as resveratrol and conjugated linoleic acid could induce 
apoptosis of tumor cells through triggering ROS production (Tinhofer et al, 2001; 
Lui, 2005). 
Previous studies showed that isopentenyladenosine could induce apoptosis of 
the human myeloid leukemia HL-60 cells through triggering ROS production (Ishii 
et al, 2002). Therefore the effects of kinetin and kinetin riboside on ROS production 
in WEHI-3B JCS cells were investigated in the present study. It was found that O2" 
production was enhanced in kinetin-treated WEHI-3B JCS cells at 48 hours of 
incubation (Fig. 4.15). On the other hand, an increase of O2' production was seen 
both at 36 hours and 48 hours of incubation in kinetin riboside-treated WEHI-3B JCS 
cells (Fig. 4.16). 
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Fig. 4.15: Effect of kinetin on the production of superoxide anions in the murine 
myelomonocytic leukemia WEHI-3B JCS cells. WEHI-3B JCS cells (1 x 10^  
cells/ml) were incubated with solvent control 0.1% DMSO (red line) or 200 ^M 
kinetin (black line) at 37�C for 12 hours, 24 hours, 36 hours and 48 hours. The cells 
were then stained with oxygen radical sensor dye dihydroethidium. Fluorescence 
intensity was analyzed by the FACSort flow cytometer (Becton Dickinson). 
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Fig. 4.16: Effect of kinetin riboside on the production of superoxide anions in 
the murine myelomonocytic leukemia WEHI-3B JCS cells. WEHI-3B JCS cells 
(1 X 10)4 cells/ml) were incubated with solvent control 0.1% DMSO (red line) or 4 
^M kinetin riboside (black line) at 37�C for 12 hours, 24 hours, 36 hours and 48 
hours. The cells were then stained with oxygen radical sensor dye dihydroethidium. 
Fluorescence intensity was analyzed by the FACSort flow cytometer (Becton 
Dickinson). 
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4.2.5 Expression of Apoptosis Regulatory Genes in Kinetin- and Kinetin 
Riboside-treated WEHI-3B JCS Cells In Vitro 
The Bcl-2 family proteins are one of the main regulators in 
mitochondria-mediated apoptosis. There are two types of Bcl-2 family proteins, the 
pro-apoptotic and anti-apoptotic ones. Examples of mammalian pro-apoptotic Bcl-2 
members are Bax (Bcl-2-assoicated X protein) and Bad (Bcl-2-antagonist of cell 
death) while anti-apoptotic Bcl-2 members are Bcl-2 and BC1-XL (Bcl-x protein long 
isoform) (Reed, 1998). Bcl-2 family proteins consist of one to four domains, the BHl 
to B H 4 domains, a transmembrane region may be included. For Bcl-2 and BC1-XL, 
they have all 4 domains plus transmembrane region. On the other hand, the Bax 
protein has only BHl to BH3 domain plus the transmembrane region. The Bad 
protein is BH3-only and is believed to play a role in promoting Bax pro-apoptotic 
activity. The Bcl-2 family proteins worked on the outer mitochondrial membrane by 
« 
pore formation. Homo-oligomers of Bax translocate from cytosol to mitochondria 
and promote the formation of large channels on the outer mitochondrial membrane, 
resulting in the release of toxic proteins like Cyt c. Bcl-2 can bind to Bax and 
prevents its translocation to the mitochondria (Donovan and Cotter, 2004a). The 
activities of Bcl-2 family proteins can be regulated at the transcriptional level 
(Burlacu, 2003) 
Fas is an example of death receptors located on cell surface. When Fas ligands 
(FasL) bind to the Fas receptor, the death domain of Fas receptor will transduce 
signal to recruit FADD molecules. FADD molecules in turn recruit caspase 8 and 
start the activation of downstream caspase cascade (Nagata, 1999). The interplay 
between Bcl-2 family members and death receptors in apoptosis regulation is still 
controversial and unclear (Sprick and Walczak, 2004). 
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The deregulation of the Bcl-2 family plays an important role in tumorigenesis 
(Kirkin et al., 2004). The potential of Bcl-2 family proteins and Fas receptors as drug 
targets is undergoing intensive investigation (Gardner, 2004; Reed and Pellecchia, 
2005). 
Our earlier findings that both kinetin and its riboside could induce DNA 
fragmentation and activation of the initiator caspases 8 and 9 and the effector caspase 
3 in the murine myeloid leukemia WEHI-3B JCS cells suggested that these two . 
cytokinins may trigger the activation of both the intrinsic and extrinsic apoptotic 
pathways. Therefore the effects of kinetin and its riboside on modulating the 
expression of some apoptosis-related genes were examined. Our results showed that 
kinetin upregulated the gene expression of Box and Bad after 24 hours of treatment 
and had no significant effect on expression of Bcl-2 gene in WEHI-3B JCS cells (Fig. 
4.17). In contrast, kinetin riboside upregulated the gene expression of Box’ but the 
level of Bad was unchanged. Moreover, the expression level of Bcl-2 in 
kinetin-riboside treated cells had no significant change (Fig. 4.18). 
In addition, the gene expression level of FasL in cytokinin-treated WEHI-3B 
JCS cells was also investigated. As shown in Fig. 4.19, the expression of FasL gene 
was increased by 2.1-fold after 8 hours of incubation with kinetin, and up to 
13.2-fold increase was seen after 24 hours of treatment with kinetin. Similarly, 
kinetin riboside upregulated the gene expression of FasL by 2.4 fold after 8 hours of 
incubation, and a 9.3-fold increase was observed after 24 hours of treatment (Fig. 
4.20). 
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Fig. 4.17: Expression of various Bcl-2 family genes in the kinetin-treated murine 
myelomonocytic leukemia WEHI-3B JCS cells. WEHI-3B JCS cells (3 x lO* 
cells/ml) were either untreated, treated with 0.1% DMSO as solvent control or 
incubated with 200 i^M kinetin at 37°C for different time intervals (4, 8, 12 and 24 
hours). TRIZOL reagent was used to extract total RNA of the cells. Semi-quantitative 
RT-PCR was performed and the PGR products were separated on 2% agarose gel. 
Band intensity was quantified using ImageQuant program. The value at the bottom of 
each band represented the relative intensity compared to untreated control, after 
normalization with endogenous GAPDH. 
Lane 1: untreated control 
Lane 2: solvent control 
Lane 3: JCS cells treated with Kl for 4 hours 
Lane 4: JCS cells treated with Kl for 8 hours 
Lane 5: JCS cells treated with Kl for 12 hours 
Lane 6: JCS cells treated with Kl for 24 hours 
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Fig. 4.18: Expression of various Bcl-2 family genes in the kinetin 
riboside-treated murine myelomonocytic leukemia WEHI-3B JCS cells. 
WEHI-3B JCS cells (3 x cells/ml) were either untreated, treated with 0.1% 
DMSO as solvent control or incubated with 4 |iM kinetin riboside at 37°C for 
different time intervals (4，8, 12 and 24 hours). TRIZOL reagent was used to extract 
total RNA of the cells. Semi-quantitative RT-PCR was performed and the PGR 
products were separated on 2% agarose gel. Band intensity was quantified using 
ImageQuant program. The value at the bottom of each band represented the relative 
intensity compared to untreated control, after normalization with endogenous 
GAPDH. 
Lane 1: untreated control 
Lane 2: solvent control 
Lane 3: JCS cells treated with KR for 4 hours 
Lane 4: JCS cells treated with KR for 8 hours 
Lane 5: JCS cells treated with KR for 12 hours 
Lane 6: JCS cells treated with KR for 24 hours 
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Fig. 4.19: Expression of FasL gene in the kinetin-treated murine 
myelomonocytic leukemia WEHI-3B JCS cells. WEHI-3B JCS cells (3 x 10^ 
cells/ml) were either untreated, treated with 0.1% DMSO as solvent control or 
incubated with 200 [iM kinetin at 37°C for different time intervals (4, 8，12 and 24 
hours). TRIZOL reagent was used to extract total RNA of the cells. Semi-quantitative 
RT-PCR was performed and the PGR products were separated on 2% agarose gel. 
Band intensity was quantified using ImageQuant program. The value at the bottom of 
each band represented the relative intensity compared to untreated control, after 
normalization with endogenous GAPDH. 
Lane 1: untreated control 
Lane 2: solvent control 
Lane 3: JCS cells treated with KI for 4 hours 
Lane 4: JCS cells treated with KI for 8 hours 
Lane 5: JCS cells treated with KI for 12 hours 
Lane 6: JCS cells treated with KI for 24 hours 
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Fig. 4.20: Expression of FasL gene in the kinetin riboside-treated murine 
myelomonocytic leukemia WEHI-3B JCS cells. WEHI-3B JCS cells (3 x lO* 
cells/ml) were either untreated, treated with 0.1% DMSO as solvent control or 
incubated with 4 kinetin riboside at 37°C for different time intervals (4, 8，12 and 
24 hours). TRIZOL reagent was used to extract total RNA of the cells. 
Semi-quantitative RT-PCR was performed and the PGR products were separated on 
2% agarose gel. Band intensity was quantified using ImageQuant program. The value 
at the bottom of each band represented the relative intensity compared to untreated 
control, after normalization with endogenous GAPDH. 
Lane 1: untreated control 
Lane 2: solvent control 
Lane 3: JCS cells treated with KR for 4 hours 
Lane 4: JCS cells treated with KR for 8 hours 
Lane 5: JCS cells treated with KR for 12 hours 
Lane 6: JCS cells treated with KR for 24 hours 
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4.3 Discussion 
In this chapter, the apoptosis-inducing effect of cytokinins on myeloid leukemia 
cells was investigated. One of the hallmarks of apoptosis is induction of DNA 
fragmentation (Zhang and Xu, 2000). Gel electrophoresis showed that both kinetin 
and. kinetin riboside induced DNA fragmentation of WEHI-3B JCS cells in a time-
and dose-dependent manner. The results indicated that the cytokinins could induce 
apoptosis of WEHI-3B JCS cells. To quantitate the induction of DNA fragmentation 
by the cytokinins on WEHI-3B JCS cells, sandwich ELISA detecting BrdU-labeled 
DNA fragments was employed (Ito et al, 1996). The results agreed with the results 
from gel electrophoresis. In addition, the potency of kinetin riboside was higher than 
that of kinetin. Moreover, both kinetin and its riboside failed to induce DNA 
fragmentation in the murine normal fibroblasts BALB/c CL.7 cells (data not shown). 
Previous work had shown that isopentenyladenosine but not isopenetnyladenine 
could induce DNA fragmentation in the leukemia HL-60 cells (Ishii et al” 2003). In 
addition, benzyladenosine was also found to be capable of inducing DNA 
fragmentation in HL-60 cells (Mlejnek and Kuglik, 2000). Our present finding 
indicated that not only cytokinin riboside (kinetin riboside) but also cytokinin 
(kinetin) were capable of inducing DNA fragmentation, although their potency 
differed markedly. The reasons for the discrepancy in our results with others remain 
unclear, it is possible that the difference in structure between kinetin and 
isopentenyladenine may result in their different ability in inducing DNA 
fragmentation. 
Mitochondria have vital roles in the regulation of apoptosis (Chandra et al, 
2002; Kuwana and Newmeyer, 2003). Changes in mitochondrial membrane potential 
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(A\|/m) is one of the parameters indicating the possible involvement of mitochondria 
in apoptosis (Ly et al., 2003). Our results showed that both kinetin and kinetin 
riboside induced a small depolarization of A\|/m in WEHI-3B JCS cells. Yet it was 
reported that A\|/m depolarization might not be detected under some certain 
conditions (Waterhouse et al., 2001). In spite of the small depolarization, the results 
suggested that mitochondria may also be involved in the cytokinin-induced apoptosis 
of WEHI-3B JCS cells. 
Caspase cascade is closely related to the execution of apoptosis (Fan et al, 
2005). Analysis of caspase activity showed that kinetin could trigger the activation of 
caspases 3 and 9 significantly but only trigger caspase 8 slightly. In contrast, kinetin 
riboside could trigger the activation of caspases 3，8 and 9 significantly. In case of 
caspase 3, the triggering effect of kinetin riboside was much stronger than that of 
kinetin. Caspase 8 is involved in extrinsic pathway of apoptosis while caspase 9 is 
involved in intrinsic pathway. Caspase 3 is the downstream target of caspases 8 and 9 
and is one of the executors of apoptosis. Our results suggested kinetin 
riboside-induced apoptosis may involve both extrinsic pathway and intrinsic 
pathways, while that of kinetin may rely mainly on the intrinsic pathway. 
Reactive oxygen species (ROS) elevation is a newly recognized inducing signal 
of apoptosis and it mainly targets the mitochondria (Droge, 2002). It was reported 
that conjugated linoleic acid could trigger the generation of ROS which may be 
involved in the apoptosis of WEHI-3B JCS cells (Lui, 2005). In kinetin-treated 
WEHI-3B JCS cells, ROS was detected after 48 hours of incubation. On the other � 
hand, in kinetin riboside-treated WEHI-3B JCS cells, ROS was detected after 36 • 
hours of incubation. The results suggested that ROS generation in the 
cytokinin-treated WEHI-3B JCS cells was a rather late event after the induction of 
apoptosis. Since kinetin is a well-known antioxidant and is a secondary product of 
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DNA oxidation (Barciszewski et al, 1997)，the mechanism for the generation of 
ROS in kinetin-treated WEHI-3B JCS cells is unclear. The ROS might be a 
secondary product after disruption of mitochondria (Kroemer et al” 1997) and the 
amount of ROS may overcome the antioxidizing effect of kinetin. On the other hand, 
isopentenyladenosine was reported to trigger the generation of ROS in the human 
myeloid leukemia HL-60 cells and this might play a role in the induction of 
apoptosis (Ishii et al.’ 2002). This group also demonstrated that inhibiting ROS 
production could prevent isopentenyladenosine-induced DNA fragmentation. 
Bcl-2 family proteins are involved in the regulation of mitochondria-mediated 
apoptosis by pore formation on the mitochondrial outer membrane (Donovan and 
Cotter, 2004). On the other hand, FasL is one of the ligands of death 
receptor-mediated apoptosis through the death signal from the Fas receptors (Nagata, 
1999). The Bcl-2 family consists of anti-apoptotic (e.g. Bax and Bad) and 
pro-apoptotic members (e.g. Bcl-2 and BC1-XL). Analysis of the gene expression of 
Bcl-2 family revealed that kinetin induced upregulation of Bax and Bad genes with 
no significant effect on the Bcl-2 gene expression. In contrast, kinetin riboside had no 
obvious effect in Bcl-2 and Bad gene expression but upregulated the Bax gene only. 
On the other hand, both kinetin and kinetin riboside could upregulate the expression 
of FasL gene in WEHI-3B JCS cells. This indicated that extrinsic pathway of 
apoptosis be triggered by the cytokinins. 
The results suggested that kinetin-induced intrinsic pathway of apoptosis 
involved the upregulation of Bax and Bad whereas only Bax was involved in the 
kinetin riboside-induced apoptosis. This resulted in more pore formation in the 
outermembrane of mitochondria and accompanied by the release of apoptotic 
proteins from the mitochondria, such as AIF, cytochrome c and Smac. AIF is 
responsible in caspase-independent DNA fragmentation resulting in chromatin 
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condensation and production of 50 kbp fragments of DNA (Lorenzo et a/., 1999). 
Cytochrome c will complex with Apaf-1 and form Apaf-1 xytochrome c complex. 
This complex is responsible for the activation of caspase 9，which in turn activates 
the inactive procaspase 3 into active caspase 3 and then activates the CAD to cleave 
the chromatins (Jiang and Wang, 2004). Smac is responsible for the activation of 
caspase 3 and procaspase 9 by binding to the inhibitor of apoptotic protein (lAP), 
which binds and inactivates caspases (Verhagen et al.’ 2000). However, AIF and 
Smac may not be released together with cytochrome c due to the large molecular size 
( � 5 2 kDa and �2 5 kDa) (Donovan and Cotter, 2004). Although the exact mechanism 
for the release of these toxic proteins from the mitochondria is unclear, it was 
proposed that the pore size of mitochondria formed by Bcl-2 pro-apoptotic proteins 
is an important influencing factor. In addition, the sequence for the release of the 
proteins from mitochondria is also controversial (Donovan and Cotter, 2004). 
On the other hand, the upregulation of FasL gene expression may indicate the 
involvement of Fas receptor mediated apoptosis in the extrinsic pathway. The 
binding of FasL-Fas receptor recruits the FADD protein and this in turn activates 
caspase 8, followed by the activation of caspase 3 (Nagata, 1999). Considering the 
results of caspase 8 activation analysis and the gene expression of FasL, we can 
speculate that kinetin riboside induced the expression of FasL which in turn trigger 
the activation of caspase 8. In the case of kinetin, although the FasL gene expression 
was also increased, the activation of caspase 8 was found to be much weaker as 
compared to that of kinetin riboside. The differential ability of kinetin riboside and 
kinetin in the activation of caspase 8 remains obscure, whether this is due to 
preferential upregulation of Fas receptor is certainly an intriguing aspect that awaits 
further investigation. 
Recent studies on HL-60 cells showed that cytokinins may enter the leukemia 
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cells through intracellular adenosine transporter (Ishii et al” 2002). Cytokinin 
ribosides were phosphorylated into monophosphates by adenosine kinase while 
cytokinins were phosphorylated by phosphoribosyl transferase. The cytokinin 
riboside monophosphates or mononucleotides may deplete the ATP content of cells 
I 
and trigger apoptosis (Mlejnek and Dolezel, 2005). Therefore, it would be of interest 
to examine whether kinetin and kinetin riboside treatment would affect the ATP 
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5.1 Introduction 
Induction of tumor cell differentiation has been intensively investigated and a 
number of clinical studies were conducted for the therapy of hematologic 
malignancies (Miller and Waxman, 2002; Leung et al, 2005). One clinically useful 
differentiation-inducing drug is all-/ra«5-retinoic acid (ATRA) which has been used 
for the treatment of acute promyelocytic leukemia or AML3 type leukemia (Awisati 
and Tallman, 2003). Myeloid leukemia stem cells lose their ability to differentiate 
and continue to proliferate. Differentiation inducers such as ATRA may induce the 
leukemia cells to undergo maturation or terminal differentiation, followed by 
cessation of cell proliferation (Tsiftsoglou et al.，2003). 
The WEHI-3B JCS murine myeloid leukemia cell model was intensively 
studied in our groups and previous reports showed that the leukemia WEHI-3B JCS 
cells were able to undergo monocytic differentiation upon induction by various 
agents. Examples of these agents are cytokines such as tumor necrosis factor-a 
(TNF-a) (Mak et al., 1993), interleukin-1 (IL-1) (Chan et al.，1997)，natural products 
like conjugated linoleic acid (CLA) (Lui et al, 2005), major constituents of licorice 
such as glycyrrhizin and 18-p glycyrrhetinic acid (Leung et al, 2004), coumarins 
(Leung et al, 2002), and also DNA topoisomerase II inhibitor etoposide (Chan et al., 
2003). Therefore, WEHI-3B JCS cells provide a well-characterized model for 
elucidation of the differentiation-inducing effect of cytokinins. 
In the present study, the differentiation-inducing activity of kinetin and kinetin 
riboside on WEHI-3B JCS cells was studied in terms of morphological, 
immunophenotypic and biochemical changes. To study the morphology, WEHI-3B 
JCS cells were treated with kinetin or kinetin riboside for 72 hours and then 
cytocentrifuged on slides for cytoplasm and nucleus staining. Moreover, the cell size 
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and granularity changes of the treated cells were analyzed by flow cytometry. On the 
other hand, immunophenotypic changes of kinetin- or kinetin riboside-treated 
WEHI-3B JCS cells were studied by staining of lineage-specific differentiation 
markers on the cell surface. In addition, the biochemical change of cytokinin-treated 
WEHI-3B JCS cells was assessed by flow cytometric analysis of the monocytic 
serine esterase activity in the leukemia cells. 
« 
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5.2 Results 
5.2.1 Morphology of Kinetin- and Kinetin Riboside-treated WEHI-3B JCS cells 
To investigate whether kinetin and kinetin riboside could mediate 
differentiation of the murine myelomonocytic leukemia WEHI-3B JCS cells, the 
morphological changes of WEHI-3B JCS cells after cytokinin treatment in vitro were 
studied on cytospin preparations. Briefly, WEHI-3B JCS cells were treated with 
various concentrations of either kinetin or kinetin riboside at 37°C for 72 hours. The 
cells were then fixed onto microscopic glass slides by cytocentrifugation and 
Hemacolor solutions were used to stain the cytoplasm and nucleus of the cells. 
In the case of kinetin treatment (50 |iM and 100 |iM)，a small population of the 
WEHI-3B JCS cells were found to have increased cytoplasmic vacuolation when 
compared with the control cells (Fig. 5.1 A to C，as indicated by the arrows). The 
cells treated with 150 ^M kinetin did not have increased vacuolation, however, some 
of the cells had blebbing of their plasma membrane and displayed irregular cell shape 
(Fig. 5.1 D, as indicated by the arrows). On the other hand, the kinetin 
riboside-treated WEHI-3B JCS cells did not have any obvious increase in 
vacuolation at the 3 different concentrations tested (0.5 |LLM, 1 |XM and 2 |IM). Plasma 
membrane blebbing and shrinkage of cells were observed in the kinetin 
riboside-treated WEHI-3B JCS cells (Fig. 5.2, as indicated by the arrows). In 
contrast, the DNA topoisomerase II inhibitor etoposide， a well-known 
differentiation-inducing agent，could cause significant morphological alterations of 
WEHI-3B JCS cells. The etoposide-treated (0.5 ^iM) cells demonstrated various 
characteristics of monocytic cell differentiation. The cells had increased in cell size, 
cytoplasm to nucleus ratio and increased vacuolation (Fig. 5.1 E and Fig. 5.2 E, as 
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indicated by the arrows). Compared with the morphology of the control cells, lower 
concentrations of kinetin treatment could induce weak differentiation of WEHI-3B 
JCS cells. However, kinetin riboside treatment and higher concentrations (e.g. 150 
|iM) of kinetin treatment failed to induce obvious morphological differentiation of 
the WEHI-3B JCS cells, and some of the cells displayed morphological 
characteristics of apoptotic cell death. Differential counting of the cytokinin-treated 
WEHI-3B JCS cells showed that cytokinin treatment failed to trigger terminal 
differentiation of the leukemia cells (Table 5.1). 
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Fig. 5.1: Morphology of the kinetin-treated murine myelomonocytic leukemia 
WEHI-3B JCS cells. WEHI-3B JCS cells (2,500 cells/ml) were treated with (A) 
solvent control (0.1% DMSO), (B) 50 \ M kinetin, (C) 100 nM kinetin, (D) 150 ^M 
kinetin or (E) 0.5 [ M etoposide as positive control at 37®C for 72 hours. The cells (5 
X 10)4 cells) were cytocentrifuged onto microscopic glass slides and stained with 
Hemacolor solutions. (Magnification: 400 X; scale bars shown represent 50 i^m) 
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Fig. 5.2: Morphology of the kinetin-riboside treated murine myelomonocytic 
leukemia WEHI-3B JCS cells. WEHI-3B JCS cells (2,500 cells/ml) were treated 
with (A) solvent control (0.1% DMSO), (B) 0.5 pM kinetin riboside, (C) 1 [M 
kinetin riboside, (D) 2 \ M kinetin riboside or (E) 0.5 \ M etoposide as positive 
control at 3TC for 72 hours. The cells (5 x cells) were cytocentrifuged onto 
microscopic glass slides and stained with Hemacolor solutions. (Magnification: 400 
X; scale bars shown represent 50 i^m) 
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Table 5.1: Morphological identification of kinetin- or kinetin riboside-treated 
WEHI-3B JCS cells at various stages of differentiation types. 
Treatment of cells Percentage of different cell types (mean 士 S.D.) 
with Immature blast cells Intermediate stage Macrophage-like 
cells cells 
Solvent control 91.5 ±3.2 8.5 ±2.5 0 
(0.1%, v/v DMSO) 
Etoposide 0 . 5 2 0 . 7 土2.8 68.9±4.2 10.4±1.9 
(positive control) 
Kinetin (KI) 
KI 50 i^M 82.2 ±2.5 17.8 ±3.4 0 
KI 100 i^M 80.4 ±3.4 19.6 ±2.9 0 
KI 150 [iU 90.4 士 2.9 9.6 ±1.5 ‘ 0 
Kinetin riboside (KR) 
KR 0.5 i^M 90.3 土 1.5 9.7 ±1.8 0 
K R l ^M • 92.8 ±2.5 7.2 土 1.9 0 
K R 2 ^ M 91.4 土 3.1 8.6 土 1.5 0 
WEHI-3B JCS cells (2,500 cells/ml) were treated with either solvent control, kinetin 
or kinetin riboside as described in the legends of Fig. 5.1 and Fig. 5.2. The 
morphology of the cells was identified by staining the cells with Hemacolor staining 
solution set. The stained cells were scored as the immature blast cells (myeloblasts), 
intermediate stage cells (myelocytes and promonocyte-like cells) and 
macrophage-like cells as described by Chan et al (1997). At least 300 cells were 
counted for each determination and expressed in percentage of different cell types. 
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5.2.2 Cell Size and Granularity of Kinetin- and Kinetin Riboside-treated 
WEHI-3B JCS cells 
Increases in both cell size and granularity or internal complexity of the cells are 
always observed during the differentiation process, and these physical parameters of 
the cells could be studied by flow cytometry. In flow cytometric analysis, cell size is 
reflected by forward scatter (FSC) while cell granularity is reflected by side scatter 
(SSC). Whether the morphological changes of kinetin- and kinetin riboside-treated 
WEHI-3B JCS cells indicated a differentiation-inducing effect was unclear. 
Therefore, the cell size and granularity of the cytokinin-treated JCS cells were also 
analyzed. 
Increased cell granularity (SSC) of kinetin-treated WEHI-3B JCS cells was 
observed in a dose-dependent manner and the increase was comparable with the 
etoposide-treated WEHI-3B JCS cells (Fig. 5.3). In the case of kinetin riboside 
treatment, dose-dependent increase of cell granularity was also observed but the 
increase was less prominent when compared with kinetin and etopsoide treatment 
(Fig. 5.4). The results showed that cytokinin treatment could induce an increase in 
cellular granularity but not in cell size on the leukemia WEHI-3B JCS cells. 
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Fig. 5.3: Cell size and granularity of the kinetin-treated murine myelomonocytic 
leukemia WEHI-3B JCS cells. WEHI-3B JCS cells (2,500 cells/ml) were treated 
with (A) solvent control (0.1% DMSO), (B) 50 pM kinetin, (C) 100 [M kinetin, (D) 
150 pM kinetin or (E) 0.5 \M etoposide as positive control at 37X for 72 hours. The 
cells were fixed with paraformaldehyde and analyzed for FSC and SSC using the 
FACSort flow cytometer (Becton Dickinson). (The % shown indicated proportion of 
cells in the top left quadrant) 
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Fig. 5.4: Cell size and granularity of the kinetin riboside-treated murine 
myelomonocytic leukemia WEHI-3B JCS cells. WEHI-3B JCS cells (2,500 
cells/ml) were treated with (A) solvent control (0.1% DMSO), (B) 0.5 \ M kinetin 
riboside, (C) 1 \ M kinetin riboside, (D) 2 pM kinetin riboside or (E) 0.5 ^M 
etoposide as positive control at 37^0 for 72 hours. The cells were fixed with 
paraformaldehyde and analyzed for FSC and SSC using the FACSort flow cytometer 
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5.2.3 Changes in Surface Antigen Expression of Kinetin- and Kinetin 
Riboside-treated WEHI-3B JCS Cells 
Differentiated cells would have different surface antigen expression profiles 
compared with undifferentiated cells. By analyzing the expression of specific surface 
antigens on WEHI-3B JCS cells, the differentiation-inducing effect of kinetin and its 
riboside could be examined. Previous studies in our laboratory had shown that the 
expressions of the two monocytic lineage-specific surface markers Mac-1 (CDlib) 
and F4/80 in WEHI-3B JCS cells were up-regulated upon cytokine treatments (Mak 
et al., 1993; Leung et al., 1994). On the other hand, the surface marker Gr-l was 
reported to be granulocytic lineage-specific in other cell lines underwent 
differentiation (Fleming et al., 1993). 
As shown in Fig. 5.5 to 5.7, the expression of Mac-1 was increased only in 50 
\lM kinetin-treated WEHI-3B JCS cells. In contrast, no significant changes in the 
expression of the F4/80 and Gr-l antigens were observed in kinetin-treated 
WEHI-3B JCS cells. On other hand, an increase in expression of Mac-1 was 
observed in 0.5 \iM kinetin riboside-treated WEHI-3B JCS cells. Similar to the case 
of kinetin, no significant increases in the expression of F4/80 and Gr-l antigens were 
observed, but instead there was a slight down-regulation of these two markers after 
kinetin riboside treatment. The results suggested both kinetin and its riboside failed 
to induce terminal differentiation of the WEHI-3B JCS cells. 
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Fig. 5.5: Analysis of the expression of surface antigen Mac-1 in the 
kinetin-treated murine myelomonocytic leukemia WEHI-3B JCS cells. 
WEHI-3B JCS cells (2,500 cells/ml) were treated with solvent control (0.1% DMSO), 
kinetin (50 i^M, 100 i^M or 200 \M) or 0.5 pM etoposide as positive control at 37�C 
for 72 hours. WEHI-3B JCS cells were then stained with rat monoclonal antibodies 
to Mac-1 antigen. Fluorescence intensity was analyzed using the FACSort flow 
cytometer (Becton Dickinson). (Red line: solvent control; black line: kinetin-treated 
or etoposide-treated) 
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Fig. 5.6: Analysis of the expression of surface antigen F4/80 in the 
kinetin-treated murine myelomonocytic leukemia WEHI-3B JCS cells. 
WEHI-3B JCS cells (2,500 cells/ml) were treated with solvent control (0.1% DMSO), 
kinetin (50 100 pM or 200 ^M) or 0.5 l^M etoposide as positive control at 3TC 
for 72 hours. WEHI-3B JCS cells were then stained with rat monoclonal antibodies 
to F4/80 antigen. Fluorescence intensity was analyzed using the FACSort flow 
cytometer (Becton Dickinson). (Red line: solvent control; black line: kinetin-treated 
or etoposide-treated) 
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Fig. 5.7: Analysis of expression of surface antigen Gi^l in the kinetin-treated 
murine myelomonocytic leukemia WEHI-3B JCS cells. WEHI-3B JCS cells 
(2,500 cells/ml) were treated with solvent control (0.1% DMSO), kinetin (50 ^M, 
100 i^M or 200 ^M) or 0.5 ^M etoposide as positive control at 37�C for 72 hours. 
WEHI-3B JCS cells were then stained with rat monoclonal antibodies to Gr-l 
antigen. Fluorescence intensity was analyzed using the FACSort flow cytometer 
(Becton Dickinson). (Red line: solvent control; black line: kinetin-treated or 
etoposide-treated) 
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Fig. 5.8: Analysis of expression of surface antigen Mac-1 in the kinetin 
riboside-treated murine myelomonocytic leukemia WEHI-3B JCS cells. 
\VEHI-3B JCS cells (2,500 cells/ml) were treated with solvent control (0.1% DMSO), 
kinetin (0.5 \M, \ \M or 2 pM) or 0.5 [M etoposide as positive control at 37�C for 
72 hours. WEHI-3B JCS cells were then stained with rat monoclonal antibodies to 
Mac-1 antigen. Fluorescence intensity was analyzed using the FACSort flow 
cytometer (Becton Dickinson). (Red line: solvent control; black line: kinetin 
riboside-treated or etoposide-treated) 
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Fig. 5.9: Analysis of expression of surface antigen F4/80 in the kinetin 
riboside-treated murine myelomonocytic leukemia WEHI-3B JCS cells. 
WEHI-3B JCS cells (2,500 cells/ml) were treated with medium, solvent control 
(0.1% DMSO), kinetin (0.5 ^M, 1 ^M or 2 pM) or 0.5 pM etoposide as positive 
control at 3TC for 72 hours. WEHI-3B JCS cells were then stained with rat 
monoclonal antibodies to F4/80 antigen. Fluorescence intensity was analyzed using 
the FACSort flow cytometer (Becton Dickinson). (Red line: solvent control; black 
line: kinetin riboside-treated or etoposide-treated) 
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Fig. 5.10: Analysis of expression of surface antigen Gr-1 in the kinetin 
riboside-treated murine myelomonocytic leukemia WEHI-3B JCS cells. 
WEHI-3B JCS cells (2,500 cells/ml) were treated with solvent control (0.1% DMSO), 
kinetin (0.5 \iM, \ \M or 2 pM) or 0.5 pM etoposide as positive control at 3TC for 
72 hours. WEHI-3B JCS cells were then stained with rat monoclonal antibodies to 
Gr-1 antigen. Fluorescence intensity was analyzed using the FACSort flow cytometer 
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5.2.4 Monocytic Serine Esterase Activity in Kinetin- and Kinetin 
Riboside-treated WEHI-3B JCS Cells 
In addition to surface phenotypic alterations, differentiated cells would have 
different biochemical properties compared with undifferentiated cells. Monocytic 
r-
serine esterase (MSE) is a kind of non-specific esterase in monocytic lineage cells 
(Yam et al.^ 1971). The esterase activity could be measured indirectly by using the 
substrate fluorescein diacetate. A fluorescent product would be formed which could 
be detected by flow cytometry. Previous studies in our laboratory had shown that 
WEHI-3B JCS cells induced to undergo monocytic differentiation by CLA showed 
an increase in MSE activity (Lui et a!” 2005). Interestingly, our results showed that 
kinetin and its riboside triggered a reduction of MSE activity in WEHI-3B JCS cells, 
in contrast to the significant increase in MSE activity in etoposide-treated JCS cells 
(Fig. 5.11 and Fig. 5.12). , 
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Fig. 5.11: Analysis of monocytic serine esterase activity of the kinetin-treated 
murine myelomonocytic leukemia WEHI-3B JCS cells. WEHI-3B JCS cells 
(2,500 cells/ml) were treated with (A) 50 \ M kinetin, (B) 100 i^M kinetin or (C) 150 
HM kinetin or (D) 0.5 (jM etoposide as positive control at 37�C for 72 hours. 
WEHI-3B JCS cells were then incubated with fluorescein diacetate. The fluorescence 
intensity was analyzed by the FACSort flow cytometer. (red line: solvent control; 
black line: Kl-treated or etoposide-treated) 
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Fig. 5.12: Analysis of monocytic serine esterase activity of the kinetin 
riboside-treated murine myelomonocytic leukemia WEHI-3B JCS cells. 
WEHI-3B JCS cells (2,500 cells/ml) were treated with (A) 0.5 i^M kinetin riboside, 
(B) 1 pM kinetin riboside or (C) 2 \ M kinetin riboside or (D) 0.5 pM etoposide as 
positive control at 37�C for 72 hours. WEHI-3B JCS cells were then incubated with 
fluorescein diacetate. The fluorescence intensity was analyzed by the FACSort flow 
cytometer. (red line: solvent control; black line: KR-treated or etoposide-treated) 
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5.3 Discussion 
Differentiation-inducing activity of natural products such as retinoids 
(Breitman et al, 1980; Awisati and Tallman, 2003) and cytokines such as GM-CSF 
appears to be a therapeutic strategy in cancer treatment (Leung et al., 2005) and it is 
usually used in combination with chemotherapy (Recchia et a/” 1997; Raffoux et al.’ 
2003). Previous work in our laboratory had shown that the murine myeloid leukemia 
WEHI-3B JCS cells could undergo monocytic differentiation upon induction by 
various agents, including TNF-a (Mak et al,, 1993)，midazolam (Mak et al, 1997)， 
biochanin A (Fung et al, 1997), coumarin (Leung et al, 2002), etoposide (Chan et 
al., 2003) and conjugated linoleic acid (Lui et al., 2005). 
It was reported that isopentenyladenine could induce granulocytic 
differentiation of the human promyelocytic leukemia HL-60 cells and NB-4 cells in 
vitro, in terms of morphological changes and NBT reducing activities (Ishii et al., 
2003). In the present study, it was found that kinetin and kinetin riboside exhibited 
weak, if any, differentiation-inducing ability on the murine myeloid leukemia 
WEHI-3B JCS cells. Morphological examination showed that there were little 
differentiation-associated morphological changes in kinetin- and kinetin 
riboside-treated WEHI-3B JCS cells, except at lower concentrations of kinetin. The 
• 
vacuole formation of the treated cells was not obvious and nucleus to cytoplasm ratio 
was similar. Interestingly, the forward scatter and side scatter analysis of the 
cytokinin-treated WEHI-3B JCS cells showed a dose-dependent increase in side 
scatter or granularity of the treated cells. The results indicated the granularity but not 
the cell size was increased by cytokinin treatment. However, the significance of such 
a finding remains obscure. Phenotypic examination showed that the expression of 
monocytic surface marker Mac-1 was increased slightly in cells treated with a low 
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concentration of kinetin or kinetin riboside. In contrast, higher concentrations of 
kinetin riboside induced a down-regulation of Mac-1 expression in the WEHI-3B 
JCS cells. On the other hand, the expression of the monocytic differentiation antigen 
F4/80 and granulocytic marker Gr-l was almost unchanged in cytokinin-treated cells. 
Biochemical examination showed that the monocytic serine esterase activity of 
kinetin- or kinetin riboside-treated WEHI-3B JCS cells was reduced significantly. 
The reasons for the decrease in esterase activity are unclear. Collectively, our 
findings indicate that under the prescribed experimental conditions, both kinetin and 
its riboside failed to induce terminal differentiation or maturation of the murine 
myeloid leukemia WEHI-3B JCS cells. 
The differentiation inducing activity of cytokinins on myeloid leukemia cells 
were at variance with the findings reported by Ishii et al. (2003). This may be due to 
structure-activity difference between kinetin used in our study and 
isopentenyladenine used by Ishii and co-workers. The N^ side chain of kinetin is an 
oxygenated benzene ring while the N^ side chain of isopentenyladenine is a 
non-substituted benzene ring. Alternatively, the difference of our findings with the 
literature may be due to the intrinsic differences in the leukemia cell lines being used 
for investigation. The human myeloid leukemia HL-60 cells used by Ishii's group are 
sensitive to retinoids and undergo granulocytic differentiation (Breitman et al, 1980). 
However, the murine myeloid leukemia WEHI-3B JCS cells are insensitive to 
retinoid-induced differentiation (Mak et al, 1993). Interestingly, recent findings on 
the differentiation-inducing ability of isopentenyladenine on HL-60 cells showed that 
a Ca2+ binding gene SPlOO was up-regulated significantly (Ishii et al., 2005). This 
result suggested that cytokinin-induced differentiation of HL-60 cells may involve 
intracellular Ca^ "^  mobilization. 
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In this M.Phil, study, various common cytokinins (kinetin, benzyladenine, 
isopentenyladenine and zeatin) and their riboside derivatives were demonstrated to 
display differential anti-proliferative activity on the murine myeloid leukemia 
WEHI-3B JCS cells in a dose-dependent manner. The activity of cytokinin ribosides 
was found to be much more potent than their cytokinin counterparts, indicating that 
the chemical structure of cytokinins can significantly influence their in vitro 
anti-tumor activity. Comparing the structures of the cytokinins with that of the 
parental adenine, N^ side chain substitution enhanced the anti-proliferative activity of 
cytokinin significantly. Cytokinins with aromatic side chain (kinetin and 
benzyladenine) had similar anti-proliferative activity as compared to the cytokinins 
with isoprenoid side chain (isopentenyladenine and trans-zQatin). Addition of a 
riboside group to the adenine ring enhanced the anti-proliferative effect of cytokinin 
dramatically. The direct cytotoxic effect of kinetin or its riboside on WEHI-3B JCS 
cells was very little over a wide range of concentrations being tested. This strongly 
indicated that the observed growth-inhibitory activity of cytokinins on WEHI-3B 
JCS cells could not be attributed solely to the direct cytotoxicity of kinetin or its 
riboside on WEHI-3B JCS cells. The anti-proliferative activity of kinetin and kinetin 
riboside was partially reversible and co-incubation of the leukemia WEHI-3B JCS 
cells with the cytokinins was required in order to achieve an optimal 
growth-inhibitory effect. In addition to WEHI-3B JCS cells, kinetin and kinetin 
riboside inhibited the growth of various human and mouse leukemia cell lines in a 
dose-dependent manner. The inhibitory effect of kinetin riboside was more potent 
than kinetin in all the cell lines being investigated. On the other hand, the viability of 
the murine fibroblasts BALB/c CL.7 cells and human hepatocyte-like WRL 68 cells 
was not suppressed significantly by kinetin or kinetin riboside treatment. However, 
the viability of the murine peritoneal macrophages was significantly decreased by 
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kinetin riboside treatment but not by kinetin. Whether other cytokinin ribosides can 
exert similar cytotoxic effect on murine macrophages requires further investigations. 
In addition, the potential immunosuppressive activity of kinetin riboside on other 
immune cell types is also worthy of further elucidation. Our data further showed that 
in vitro pretreatment with cytokinins could suppress the in vivo tumorigenicity of the 
leukemia WEHI-3B JCS cells in syngeneic BALB/c mice. Moreover, in vivo 
administration of cytokinins could inhibit the growth of leukemia WEHI-3B JCS 
cells in the tumor-bearing mice. Nevertheless, future in vivo studies should focus on 
the toxicity and side effects of cytokinins in the mouse model in order to explore the 
potential of the cytokinins in leukemia treatment. 
Besides growth-inhibitory effect, both kinetin and kinetin riboside could 
significantly arrest the WEHI-3B JCS at the GQ/GI phase of the cell cycle. Gene 
expression study showed that kinetin could downregulate the expression of cyclin A 
and E genes, while the expression levels of cdk inhibitors p21 and p27 were 
unchanged. On the other hand, the gene expression of the cyclin E was decreased in 
the kinetin riboside-treated WEHI-3B JCS cells. However, the expression of p27 was 
upregulated in the kinetin riboside-treated WEHI-3B JCS cells. These results suggest 
that the modulation of gene expression of cyclins and Cdk inhibitors (p21 and p27) is 
one of the mechanisms for the cytokinin-induced cell cycle arrest. Further 
investigation on the expression of cyclins at the protein level and the activity of 
cellular CDKs of cytokinin-treated myeloid leukemia cells should be conducted in 
the future. 
In addition, the cytokinins could induce significant DNA fragmentation, which 
is an indicator of apoptosis, of the WEHI-3B JCS cells in a time- and dose-dependent 
manner. As other studies showed that isopentenyladenine did not induce DNA 
fragmentation (Ishii et al., 2002), therefore, whether the observed apoptosis-inducing 
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effect was cell type-specific or cytokinin-specific still awaits further investigation. 
In the study of caspase activities, kinetin caused the pronounced activation of 
caspases 3 and 9 but only triggered activation of caspase 8 to a lesser extent. In 
contrast, kinetin riboside induced significant activation of caspases 3, 8 and 9 when 
compared to that of kinetin. These results suggested that kinetin might mainly induce 
the complex of Apaf-1:cytochrome c and then activated caspase 9, which in turn 
activated caspase 3 to execute apoptosis of the WEHI-3B JCS cells, and the role of 
Fas-mediated apoptosis may be a minor one. In the case of kinetin riboside, both 
intrinsic and extrinsic apoptotic pathways may be triggered, with the resulting 
activation of the common effector caspase 3. Our preliminary results also showed 
that pretreatment of the WEHI-3B JCS cells with pan caspase inhibitor z-VAD-FMK 
before incubation with cytokinins did not impair the DNA fragmentation induced by 
kinetin or its riboside in WEHI-3B JCS cells. This implied that the cytokinin-induced 
DNA fragmentation in WEHI-3B JCS cells may also be caspase-independent. Our 
observation is in line with an earlier report of Mlejnek et al. (2001) who had 
demonstrated that benzyladenosine was able to induce caspase-independent DNA 
fragmentation in the human myeloid leukemia HL-60 cells. Caspase-independent 
apoptosis could be induced by various agents, including staurosporine (Belmokhtar 
et al., 2001) and TNF-a (Maianski et al, 2003). To elucidate the dependence of 
caspases and the mechanism of cytokinin-induced apoptosis, the role of mitochondria 
and the release of mitochondrial apoptotic proteins (AIF, Smac and cytochrome c) 
should be studied as it had been reported that AIF could mediate apoptosis without 
the activation of caspase cascade (Cregan et al” 2004). 
In addition to caspase activation, the generation of reactive oxygen species 
(ROS) was enhanced in cytokinin-treated WEHI-3B JCS cells. Although the ROS 
enhancing effect of kinetin riboside was stronger than that of kinetin, the effect in 
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both cases was a rather late event compared with the kinetics of DNA fragmentation 
induction, suggesting that ROS may not play an important role in triggering 
apoptosis of the WEHI-3B JCS cells. 
By studying the modulatory effects of cytokinins on apoptosis-related gene 
expression, it was found that both kinetin and kinetin riboside could upregulate the 
expression of pro-apoptotic Bax gene while no significant effect was observed on 
Bcl-2 gene expression. In addition, the FasL gene expression was significantly 
enhanced in the cytokinin-treated WEHI-3B JCS cells. These results suggested that 
cytokinins could induce the apoptosis of WEHI-3B JCS cells through modulation of 
the Bcl-2 family member and FasL gene expressions. 
Attempts had been made to study the differentiation-inducing activity of 
cytokinins on WEHI-3B JCS cells. Neither kinetin nor kinetin riboside demonstrated 
significant differentiation-inducing effect on the WEHI-3B JCS cells, in terms of 
morphological, phenotypic and functional changes. Interestingly, the granularity of 
the kinetin- or kinetin riboside-treated WEHI-3B JCS cells was increased in a 
dose-dependent manner without significant changes in the cell size. In addition, the 
monocytic serine esterase activity of the cytokinin-treated WEHI-3B JCS cells was 
also downregulated. The reason why cytokinins can cause a downregulation effect on 
the monocytic serine esterase activity remains obscure. Whether the effect is cell line 
specific is unknown and await further investigation. 
To conclude, our findings showed that cytokinins exhibited anti-proliferative 
effect on various human and murine leukemia cell lines and exerted 
apoptosis-inducing but not differentiation-inducing activity on the murine myeloid 
leukemia WEHI-3B JCS cells. However, there are still many questions on the 
anti-tumor mechanisms of cytokinins that remain unanswered. For example, the 
mechanism of cytokinin uptake, the cellular interacting partners and the signal 
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transduction pathways of cytokinins in leukemia cells have not yet been investigated. 
In the future, more researches should be conducted in understanding the action 
mechanisms of cytokinins, their structure-activity relationship and their spectrum of 
pharmacological activities etc. before they can be exploited for the therapeutic 
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